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SUMMARY
Osteoarthritis (OA) affects 26 million Americans, or approximately 14% of the adult
population. The incidence of OA is predicted to dramatically increase in the next 20 years
as the US grows older and the rate of obesity continues to increase. There are currently
no clinical interventions that cure OA. Current biomaterial delivery systems exhibit several
limitations. First, most drug-delivery particles are hydrophobic, which is not optimal for
hydrophilic protein encapsulation. Second, hydrophobic particles, such as PLGA, could
cause wear damage to the already-fragile OA cartilage structure. Additionally, these parti-
cles usually suffer from non-specific protein adsorption, which causes increased phagocytosis
and can lead to increased inflammation. New therapies that increase the effectiveness of
OA treatments or reverse OA disease progression will greatly decrease the economic costs
and individual pain associated with this disease.
The goal of this thesis was to develop a new drug-delivering material to deliver anti-
inflammatory protein for treating OA. Our central hypothesis for this work is that a con-
trolled release/presentation system will more effectively deliver anti-inflammatory protein
therapies to the OA joint.
The primary goal of this work was to synthesize a block copolymer that could self-
assemble into injectable, sub-micron-scale particles and would allow an anti-inflammatory
protein, IL-1ra, to be tethered to its surface for efficient protein delivery. The block copoly-
mer incorporated an oligo-ethylene monomer for tissue compatibility and non-fouling be-
havior, a 4-nitrophenol group for efficient protein tethering, and cyclohexyl methacrylate,
a hydrophobic monomer, for particle stability. We engineered the copolymer and tested it
in both in vitro culture experiments and an in vivo model to evaluate protein retention in
the knee joint. The rationale for this project was that the rational design and synthesis of a
new drug- and protein-delivering material can create a modular polymer particle that can
xxi
deliver multi-faceted therapies to treat OA.
This work characterizes the in vitro and in vivo behavior of our polymer particle system.
The protein tethering strategy allows IL-1ra protein to be tethered to the surface of these
particles. Once tethered, IL-1ra maintains its bioactivity and actively targets synoviocytes,
cells crucial to the OA pathology. This binding happens in an IL-1-dependent manner.
Furthermore, IL-1ra-tethered particles are able to inhibit IL-1β-induced NF-κB activation.
These studies show that this particle system has the potential to deliver IL-1ra to arthritic
joints and that it has potential for localizing/targeting drugs to inflammatory cells of interest






Osteoarthritis (OA) affects 26 million Americans, or approximately 14% of the adult
population[68]. The incidence of OA is expected to dramatically increase in the next 20
years as the US grows older and the rate of obesity continues to increase. By 2030, 25% of
adults in the US, or about 67 million people, will be affected by OA[202], with the obesity
pandemic disproportionately adding to that population. According to the well-respected
Framingham study on osteoarthritis, obesity and old age both increase the risk of developing
OA, as do previous joint trauma and occupational physical loading[172]. The US economy
will also spend a lot of money treating both the symptoms and the resulting quality-of-life
losses from this disease. One estimate puts the current total economic cost of OA at $185.5
billion: $149.4 billion of that is paid by insurance companies, and $36.1 billion comes from
out-of-pocket expenses.
There are currently no clinical interventions that cure OA. Patients can only treat the
disease symptoms with palliative measures, such as non-steroidal anti-inflammatory drugs
(NSAIDs), steroid injections, and administration of drugs or proteins directly to the joint.
These measures are chronic treatments that require ongoing visits to the doctor, which can
reduce patient compliance. The eventual outcome of this disease is total joint replacement,
which is major surgery and significantly affects quality of life[61]. New therapies that
increase the effectiveness of OA treatments or reverse OA disease progression will greatly
decrease the economic costs and individual pain associated with this disease.
Osteoarthritis is a complex pathology that involves the immune/inflammatory system.
There is mounting evidence that the cytokine interleukin-1 (IL-1) plays a prominent role in
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OA. This pro-inflammatory cytokine stimulates the expression and upregulation of a myr-
iad of destructive immune molecules, including IL-6, IL-8 and MMP-13[169][13][44][278].
Researchers have examined the role of IL-1 in OA disease progression by creating IL-1
knock-out mice and by using interleukin-1 receptor antagonist (IL-1ra), the natural protein
inhibitor of IL-1, either through gene therapy or bolus protein injections[191][74][118][139].
In general, modulating IL-1levels or activity has improved OA progression in the short
term[350][124]. These results are promising, but a more robust therapeutic strategy is
needed to deliver therapeutically relevant IL-1ra to treat OA because the current treat-
ments either have serious safety concerns (gene therapy), require repeated dosing (protein
injections), and/or suffer from high cost, systemic side effects, and low patient compliance.
Retaining and controlling the delivery of small molecule drugs and anti-inflammatory
proteins in the joint has proved very difficult. By using a carrier, such as polymer particles
or PEGylation, researchers have increased the residence time of drug-eluting particles from
a few hours to a few days. The size and material of the carrier vehicle influence how long the
material resides in the joint. Adhesive moieties, such as RGD and phage-panned peptides,
have been used to increase the particle retention rate as well. In animal studies, only a
few adhesive particle types had improved retention over non-adhesive particles[112][292].
Additionally, combining targeting moieties with immunomodulatory molecules like drugs
or proteins has not been explored in a particle system in OA, although there has been
significant interest in these combination therapies for cancer treatment[112][226].
1.1.2 Project Significance
This project is significant because it develops a modular material that self-assembles into
nanoparticles of the appropriate size for controlled IL-1ra protein delivery to treat OA-
related inflammation.
1.1.3 Objective
This thesis seeks to create a novel polymer drug delivery platform for sustained delivery of
anti-inflammatory proteins to the joint.
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1.1.4 Central Hypothesis
Our central hypothesis is that a controlled release/presentation system will more effectively
deliver anti-inflammatory protein therapies to the joint.
1.1.5 Rationale
The rational design and synthesis of a new drug- and protein-delivering material can create
a modular polymer particle that can deliver multi-faceted therapies to the joint to treat
OA.
1.1.6 Specific Aim 1
The goal of this aim is to engineer a new block copolymer via RAFT polymerization methods
from tetraethylene glycol methacrylate and cyclohexyl methacrylate monomers to create a
particle system that presents moieties on its surface for covalent protein tethering.
The hypothesis for this aim is that we can design a reverse addition-fragmentation chain
transfer (RAFT)-based amphiphilic block copolymer that incorporates the 4-nitro-phenol
(pNP) leaving group. This copolymer will form particles that covalently tether IL-1ra to
the particle surface in mild aqueous conditions while maintaining the protein bioactivity.
We will first verify that all components of this new polymer can be synthesized and show
that our synthetic strategy is able to form a block copolymer. We will then determine the
conditions necessary to yield particles in our desired size range. Finally, we will optimize
conditions for tethering IL-1ra to the particles.
The expected outcomes for this aim are the creation of a block copolymer by RAFT
polymerization that will self-assemble under aqueous conditions to form particles in our
desired size range. Additionally, we expect that this polymer particle will allow protein to
be tethered to its surface in controlled densities.
1.1.7 Specific Aim 2
The goal of this aim is to evaluate our RAFT-based amphiphilic copolymer for IL-1ra
protein presentation in vitro.
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We will tether our particles with IL-1ra, show that the protein maintains its bioactivity,
and then test the specificity, cytocompatibility, and bioactivity of our protein-decorated
particles in a cell culture model.
The expected outcomes of this aim are that our block copolymer particles will allow
protein tethering and will maintain the proteins bioactivity. We also expect that our protein-
tethered particles will target our cells of interest and will modulate the IL-1β-induced
inflammatory cascade in vitro.
1.1.8 Specific Aim 3
The goal of this aim is to evaluate the effect of surface-bound IL-1ra on particle retention
and cellular targeting in the healthy rat knee joint.
The working hypothesis for this aim is that our IL-1ra-tethered polymer particles will
have longer residence time in the rat knee joint compared to a single bolus dose of IL-1ra
protein. We will inject IL-1ra tethered particles and soluble IL-1ra into the knee joints of
rats. We will use a near-infrared dye to to track the residence time of our IL-1ra-tethered
particles and soluble protein in vivo. We will look for particle localization in the knee joints
post-mortem by histological sectioning. We will also evaluate whether the particles have
any negative effect on the cartilage morphology using EPIC-µCT imaging.
The expected outcomes for this aim are that our IL-1ra-tethered particles will be retained
for a longer time than bolus protein and will also localize to inflammatory cells within the
synovial joint space in a healthy rat knee.
1.1.9 Broader Impacts
This work provides a new, modular polymer particle system for drug delivery for intra-
articular delivery to treat OA. Our use of IL-1ra for targeting particles to inflammatory cells
is unique and shows promise for use in osteoarthritis treatments. The polymer itself adds
to an expanding library of RAFT polymerization-based polymers. The polymer particles
are appropriately sized for retention in the articular joint space and show no adverse effects
on the native joint tissue. The modular nature of our protein tethering moiety will allow
for stoichiometric variation of tethered proteins of both targeting and therapeutic benefit.
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A host of disease states that show upregulated IL-1 could benefit from this therapeutic
strategy. Because the particle core can encapsulate hydrophobic drugs for a multi-therapy
treatment, IL-1ra-targeted particles could be loaded with a broad range of drugs for treating




2.1 Significance and Prevalence of Osteoarthritis
Osteoarthritis (OA) affects 26 million Americans, or approximately 14% of the adult
population[68]. The incidence of OA is predicted to dramatically increase in the next 20
years as the US grows older and the rate of obesity continues to increase. By 2030, OA
will affect 25% of adults in the US, or about 67 million people[202][42], with the obesity
pandemic disproportionately adding to that population. According to the well-respected
Framingham study on osteoarthritis, obesity and old age both increase the risk of developing
OA, as do previous joint trauma and occupational physical loading[172]. The US economy
will also spend a lot of money treating both the symptoms and the resulting quality-of-life
and productivity losses from this disease[203]. One estimate puts the current total economic
cost of OA at $185.5 billion: $149.4 billion of that is paid by insurance companies, and $36.1
billion comes from out of pocket expenses[202].
There are currently no clinical interventions that cure OA. Patients can only treat
the disease symptoms with palliative measures such as non-steroidal anti-inflammatory
drugs (NSAIDs), steroid injections, and administration of drugs or proteins directly to
the joint[361]. These measures are chronic treatments that require ongoing visits to the
doctor, which can reduce patient compliance. The eventual outcome of this disease is total
joint replacement, which is major surgery and significantly affects quality of life[61]. New
therapies that treat OA symptoms or reverse OA disease progression will greatly decrease
the economic costs and individual pain associated with this disease[34][361].
2.2 Pathology of OA
Osteoarthritis is a disease that involves the breakdown of cartilage tissue and the underlying
bone structure in a joint. It also involves other joint tissues and the synovial membrane
around the joint[68]. For example, a normal knee joint is comprised of the interface between
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the femoral head and the tibial plateau. This joint is classified as a synovial joint because
the bony surfaces are covered in articular cartilage and are surrounded by a fibrous capsule
and a synovial membrane[129].
In the healthy knee, each bony surface is covered by a stratified layer of articular cartilage
to allow easy articulating movement. Wedges of fibrocartilage called menisci on either side
of the femoral heads help protect the joint further during mechanical loading. Synovial fluid,
a filtered version of blood plasma, lubricates and feeds the joint tissue. Chondrocytes resist
compressive forces by secreting extracellular biomolecules like aggrecan, collagen II, and
hyaluronic acid, creating a complex hydrophilic extracellular environment[152]. OA causes
drastic changes to all of these joint components and involves the cartilage, synovium, and
the bone[296].
During OA, cytokines, aggrecanases and matrix metalloproteinases (MMPs) secreted by
disregulated chondrocytes and synovial fibroblasts degrade the cartilage tissues extracellular
matrix (ECM), damaging the cartilage mechanical properties and function by reducing the
tissue hydration and structural integrity[276][289]. Synovial fluid (SF) constituents also get
degraded by these inflammatory enzymes, reducing its lubricating action. These enzymatic
changes, paired with changes in the mechanical loading environment, cause the articular
cartilage to differentiate into a more bone-like state and also to damage the supporting
menisci. Scientists still debate what initially causes OA, but ultimately, the mechanical




Figure 2.1: Diagram of healthy and osteoarthritic (OA) knees (Gerwin+ 2006). OA causes
fibrillation and loss of cartilage, inflammation of the synovial membrane, and changes to
subchondral bone.
Osteoarthritis is a disease that causes cartilage thinning and fibrillation, subchondral
bone hardening and bone spurs, known as osteophytes, within a joint (Fig. 2.1)[169][146][208].
The literature still debates whether cartilage damage initiates these changes, or whether the
initial inflammation from an injury or tissue damage propagates the disease[289][290][228].
However, what is known is that a set of diverse initiating events all result in the same
clinical symptoms[169] that doctors diagnose as either primary or secondary OA, based
on the cause of arthritis. Primary OA degenerates the joint tissue over time without an
acute cause, although there are several well-known risk factors, such as age, obesity and
hereditary predisposition[154]. Secondary OA stems from an initiating event, usually joint
trauma, that creates a cartilage defect, inflammatory environment and structural
abnormalities in the joint loading[218][154].
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2.3 Inflammation in the OA joint
Osteoarthritis is characterized by localized inflammation in one or a few joints and does not
cause systemic joint inflammation the way rheumatoid arthritis does. However, during OA,
large quantities of immune cells infiltrate into the affected joint space, thus localizing large
quantities of inflammatory cytokines to the area[33][278][290][316]. Researchers have sought
to identify soluble markers of OA to allow for minimally invasive, early diagnosis of this
disease to facilitate preventative treatment rather than end-stage palliative measures[243].
However, early diagnosis of OA is extremely difficult because early-stage OA is usually
asymptomatic and people are unaware they are developing the disease.
Inflammatory cells play a large role in OA progression. Joints affected by primary
OA have pervasive inflammatory cell infiltration that includes T helper cells, T suppressor
cells, B lymphocytes, macrophages, and granulocytes[287][306]. Ishii and colleagues have
shown that both Th1 and Th2 cells are present in OA infiltrates[186]. T lymphocytes are
detectable in OA synovial cultures and comprise about 22% of total cells. Macrophage
levels in OA and RA cultures were similar[58]. CD14+ synovial macrophages have been
implicated in osteoclast formation and bone resorption[2][51]. Selectedly removing these
synovial macrophages from human OA-derived cultures using CD14+ beads reduced the
levels of pro-inflammatory cytokines such as IL-6, IL-8, and proteinases such as MMP-1
and MMP-3[51].
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Figure 2.2: Interconnection of cell types and cytokines in OA signaling (Bondeson+ 2010).
The joint synovium, specifically synovial macrophages, are directly implicated in OA
disease pathology, rather than acting as a bystander (Fig. 2.2)[43][289][50][49][341]. In
the synovial joint there are two distinct cell types within the synovial lining: type A
macrophage-derived synoviocytes, and type B fibroblast-like synoviocytes (FLS). Type A
cells are defined by the following surface molecules: CD11b, CD68, CD14, CD163, and Fcγ
RIIIa. The FLS, or type B, cells differ from type A by expressing prolyl hydroxylase and
synthesizing fibronectin, fibrillin-1, and tenascin. The common markers for both types of
synoviocytes are CD44 (HA receptor), VCAM-1 and ICAM-1. Disregulated Type B syn-
oviocytes have been specifically linked to the OA pathology because they are the primary
source of HA, an important lubricating component of synovial fluid[146].
2.3.1 Cytokines in OA
The two main cytokines in OA are IL-1 and TNF-alpha[50][4][14][35][64][51][151][299][155][153]
[231][266][265][125][122][234][232][233][359][72][199][347][322]. IL-1 upregulates a host of
pro-inflammatory cytokines, like IL-6, and matrix metalloproteinases, such as MMP-3,
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which indicate joint inflammation[169][13]; however, IL-1 also controls cartilage homeostasis[77][121][340].
TNF-α acts synergistically with IL-1 during OA to incite inflammation and tissue destruc-
tion. However, while TNF-α is the dominant cytokine in RA and directly drives IL-1
production, IL-1 and TNF-α share responsibility for the destructive environment as inde-
pendently functioning members of the OA cytokine team[64][50][88][87][267][352]. TGF-β
also plays a complicated homeostatic role in OA. On the one hand, it maintains the chondro-
cytic anabolic pathway by driving the repair response through Smads[18], but TGF-β gene
therapy in mice resulted in osteophyte formation and joint fibrosis[18][342]. Interestingly,
loss of the TGF-β receptor caused chondrocyte differentiation and an OA-like phenotype in
a mouse model[303][225]. IL-1 downregulates expression of the TGF-β Receptor II, which
reduces cell responsiveness to TGF-β and disrupts cartilage homeostasis[280]. The exact
regulation of these cytokines plays a crucial role in OA disease progression and provides
powerful targets for future OA therapies. In addition to higher expression of these cytokines,
synovial joint cells upregulate the associated cytokine receptors and become highly sensi-
tive to changes in protein levels[184]. Arthritic chondrocytes express twice as many IL-1
receptors (IL-1RI) as normal, healthy chondrocytes and act as the dominant cell type in
OA[235][309]. This upregulation, together with lower expression levels of the non-signaling
receptor (IL-1RII)[12], increases the probability that IL-1β binds to a signaling IL-1R on
OA chondrocytes and transduces inflammatory signals than if it were exposed to healthy
chondrocytes. OA cells only need 1% of IL-1Rs to be occupied in order to stimulate MMP
production, whereas healthy cells require 4% receptor occupancy to produce the same MMP
levels[235].
2.3.2 MMPs in OA
In addition to cytokines, matrix metalloproteinases (MMPs) also participate in OA joint
destruction. MMPs play a destructive role in OA by cleaving structural ECM proteins.
Current literature has shown that OA synovial fluid contains aggrecan fragments generated
by MMP and aggrecanase cleavage[328]. High levels of MMP-1, -3, -8, -9 and -13 are found
in OA SF, while they are not detectable in healthy SF[44][278][333]. MMP-13 specifically
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is expressed in OA joints but not adult healthy joints[239][40][285][357][138].
By administering MMP inhibitors (both specific and non-specific) to IL-1-stimulated
bovine cartilage explants, Wilson et al. were able to delay the IL-1-induced loss of compres-
sion modulus but did not reduce its magnitude, which suggests that non-MMP-dependent
mechanisms also play a role in matrix degradation[365].
A family of “a disintegrin and metalloproteinase with thrombospondin motifs”, or
ADAMTS, are also involved in OA. ADAMTS-4 and -5 have been shown to play a role in
destruction in the OA joint. In fact, IL-1 upregulates ADAMTS-4 expression in bovine carti-
lage and chondrocytes[278]. However, in mice, ADAMTS-5 is the controlling ADAMTS de-
tected in OA studies, whereas ADAMTS-4 is implicated as the major factor in humans[150]
[149][133][134][181][230][318][323][345].
2.4 Osteoarthritis and IL-1
IL-1 has been used to induce an osteoarthritic phenotype in animal models. When IL-
1 is injected into the knee joint of rabbits, infiltrating cells invade the tissue and cause
a significant loss of proteoglycans in the cartilage tissue. After 24 h, IL-1 causes carti-
lage destruction that looks like 7-14 days of arthritis progression in other arthritis animal
models[272][6]. In culture models of OA, the removal of exogenous IL-1 allows cartilage
explants to recover their expression of glycosaminoglycans (GAGs) and to reestablish nor-
mal mechanical properties[262]. Additionally, IL-1 inhibits the synthesis of collagen II, the
main structural ECM molecule in cartilage, which contributes to the decline of the cartilage
tissue structure during OA[194]. Hyaluronic acid, a normal component of the joint SF, can
modulate this IL-1-induced collagen inhibition to maintain tissue homeostasis, but because
HA production is also significantly reduced during OA, HA cannot exert as much influence
over the cartilage environment.
IL-1 directly causes the osteoarthritic phenotype by upregulating itself and other pro-
inflammatory cytokines, such as IL-6, IL-8, and other proteins that destroy matrix, such
as matrix metalloproteinases and ADAMTS proteins. These proteins in turn cleave crucial
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ECM components, such as collagen II and aggrecan, and inhibit the production of lubricat-
ing synovial fluid components like hyaluronic acid. Collagen cleavage, for example, affects
the integrity of the cartilage tissue and thus also affects its macro ability to resist compres-
sive loads and cyclical stress and eventually exposing the underlying bone to more severe
forces.
During osteoarthritis, IL-1 expression increases in the synovial fluid, the superficial syn-
ovial lining cells, as well as in the superficial and middle layers of the cartilage[25][266].
MMP-3 also localizes to the same tissues during OA, which is expected because IL-1 upreg-
ulates MMP-3, as well as nitric oxide (NO), MMP-1, and MMP-13[373]. Both prostaglandin
D2 and IFN-γ can reverse this IL-1-mediated cartilage destruction, in part by stimulating
IL-1ra production[263]. However, OA chondrocytes coordinate inflammatory cytokine and
NO expression[238]. They also have lower levels of IFN-γ receptors which makes them
less responsive to any increase in IFN-γ and interferes with IFN-γ’s ability to offset the
destructive forces of IL-1[3].
One of the consequences of increased NO levels in arthritic tissue is a NO-dependent
downregulation of IL-1ra expression[269]. Conversely, higher levels of the IL-1 decoy re-
ceptor (sIL-1RII) inhibit IL-1-induced NO synthesis in multiple cell types, such as chon-
drocytes, synovial cells, and epithelial cells[14]. The presence of sIL-1RII benefits the joint
environment by reducing the amount of IL-1 mRNA that accumulates in cells while also
stimulating PG synthesis. The relationship between NO and IL-1ra synthesis in OA is
specifically IL-1-mediated. Reduced TNF-R levels did not affect NO production in OA
tissue[14].
The severity and progression of osteoarthritis can be attenuated by modulating different
parts of the IL-1 pathway, specifically by affecting the levels of IL-1, IL-1ra, or the IL-1
receptors present in the joint[82][64][72][91][125][156][293][298].
The IL-1 pathway can be modulated by directly affecting the levels of IL-1β or IL-1ra
in the affected joint space. For example, pro-IL-1β must be cleaved by caspase-1 (aka ICE)
in order to form mature, active IL-1β. Inhibiting caspase-1 could reduce the amount of
active IL-1 present and could attenuate IL-1-induced destruction[82]. Adding more IL-1ra
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can shift the balance between inflammatory and anti-inflammatory pathways during OA as
well[128][6][66][177]. Exogenous protein, gene therapy and stimulation of IL-1ra production
by native cells can all contribute to modulating the IL-1 signal cascade[1][21][135][354].
Another way to interfere with the IL-1 pathway is to shift the type of IL-1 receptors
and/or the amount of receptors present. There are only about 200 IL-1R in primary cells,
but a cell only needs about 10 occupied receptors to transduce a signal[308][329][92]. Re-
ducing the number of IL-1 receptors on OA inflammatory cells could modulate the severity
of cartilage destruction and joint damage. IFN-γ, IL-10, IL-13, IGF-1, and TGF-β all
modulate the levels of IL-1R. IL-1 receptors can be used to modulate the IL-1 cascade
either by increasing the levels of soluble and/or non-signaling receptors present or by re-
ducing the amount of membrane-bound signaling IL-1RI. TGF-β reduces overall IL-1R
expression[103], IL-10 and IFN-γ reduce both IL-1RI and IL-1RII[90], and IL-13 and IGF-1
increase the amount of IL-1RII present in the OA joint[80][168][351]. Each of these proteins
has functions beyond merely regulating IL-1 expression, and those alternate actions have to
be taken into account when deciding how to employ them for OA treatment. For example,
TGF-β reduces IL-1R levels, but when delivered to the joint by gene therapy, it also induces
osteophyte formation and joint fibrosis[18][342].
Exogenous IL-1R can also have positive effects on OA disease progression[108][85]. A
small molecule NSAID drug, Tenidap, reduced the levels of IL-1R in a time-dependent
fashion, while other common OA drugs like naproxen and dexamethasone did not produce as
great an effect[268]. Tenidap also reduced the amount of collagenase and MMP-3 produced
by IL-1-stimulated osteoarthritic chondrocytes. However, clinical trials of this drug were
halted after the FDA blocked its full commercialization due to unacceptable benefit/risk
ratios. Some patients in this trial experienced loss of bone mineralization and increased
protein in their urine[123][335].
2.5 IL-1/IL-1ra
The interleukin-1 signaling pathway plays an important role in processes ranging from
inflammatory events to angiogenesis. IL-1 is involved in pro-inflammatory events, but also
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acts in cell homeostasis, angiogenesis, and other processes. The IL-1 family includes 3 major
IL-1 proteins (IL-1α, IL-1β, IL-1ra), as well as two receptors that are differentially expressed
throughout the body. IL-1β, IL-1α, and IL-1ra are all 17 kDa proteins expressed throughout
development. IL-1ra was originally characterized and sequenced in seminal Nature papers in
1990[67][111][166][301][348][325][167][245][216][110]. IL-1ra shares 26% homology with IL-
1β, while IL-1α and IL-1β share 22% homology, and IL-1ra and IL-1α share 18% homology.
Human IL-1ra shares 76% homology with the murine and rat forms of the molecule, IL-1β
is 78% homologous, and IL-1α only shares 55% similarity between human and murine/rat
genes[94][187].
There are two receptors that bind all three of these IL-1 family proteins[100][99][95][102]
[47][237][312][136][291]. These receptors are structurally related to the TLR family of innate
receptors[257][310]. The first one is the active, or signaling, IL-1R, called IL-1RI. It was
originally discovered on T cells as an 80 kDa, membrane-bound receptor[100]. After IL-1
binding, the receptor can signal in two ways: one, the cytoplasmic tail undergoes serine-
threonine phosphorylation and induces downstream signaling, and two, the receptor-protein
complex gets internalized and translocates to the nucleus to affect signal cascades and gene
expression. These two pathways activate at least 4 different downstream pathways: p38
MAPK, ERK 1/2, JNK 1/2/3, and NF-κB (Fig. 2.3)[204].
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
Figure 2.3: The IL-1 signalling cascade (Science Signalling Database, Kracht+ 2010).
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Signaling by IL-1β and IL-1α only occurs through this IL-1RI receptor[206][84][311]. A
second IL-1-binding receptor was found on macrophages and was designated IL-1RII
[237][320][321]. This second receptor is only 63 kDa and is unique because it does not
transduce signal, due to its short, 29-AA-long cytoplasmic tail. IL-1RI, on the other hand,
has a 213-AA-long cytoplasmic domain, which allows for easy cytoplasmic phosphorylation
and downstream signaling[79][101][258][284][314][320]. This pair of receptors thus acts to
regulate the cellular response to IL-1β and IL-1α by providing decoy and active binding
molecules[89][331]. Both of these receptors also exist in soluble form, adding to the regu-
lation of IL-1β signaling. The relative levels of each of the four receptors (soluble IL-1RI,
membrane-bound IL-1RI, soluble IL-1RII, and membrane-bound IL-1RII) determine the




Figure 2.4: Representations of the IL-1R binding IL-1β (Schreuder+ 1997). A: Ribbon
diagram of the IL-1R with IL-1β bound; B: Space-filling model of the IL-1R with IL-1β
bound
All three proteins occur naturally in both secreted and intracellular forms and bind with
varying affinities to the IL-1 receptors[81]. However, IL-1ra is the only IL-1 family protein
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Table 2.1: Avidity of IL-1 protein binding to the IL-1 receptors
Avidity of IL-1 protein binding to the IL-1 receptors[92][93][313][259][330]
mIL-1RI IL-1β = IL-1ra = IL-1α
sIL-1RI IL-1ra >IL-1α >IL-1β
mIL-1RII IL-1β >IL-1ra >IL-1α
sIL-1RII IL-1β >IL-1α >IL-1ra
that binds to the IL-1R without causing any signaling[16][119][300]. IL-1ra fails to recruit
the IL-1RAcP to form the active signaling complex. IL-1ra only contacts 2 of the 3 binding
sites in the IL-IR binding pocket that are necessary to recruit the IL-1RAcP and to cause
activation of the receptor (Fig. 2.4 and Fig. 2.5)[101][209][358]. When the IL-1β domain
was added back to IL-1ra, IL-1ra activated the IL-1R[160].

Figure 2.5: The IL-1 receptor binding sites (indicated in red) on IL-1α, IL-1β, and IL-1ra
(Evans+ 1995).
The balance between IL-1 and IL-1ra is essential to regulating IL-1-related catabolic
pathways and seems to determine the severity of a disease state such as OA[11][17][147].
Therapeutic strategies could be designed to interfere at crucial points within these signaling
cascades, such as inhibiting the conversion of pro-IL-1β to mature IL-1β by ICE[82], adding
more IL-1ra to influence the cytokine balance in the joint[6], and injecting soluble IL-1Rs
to act as IL-1β sinks in the joint space[15][108], among others[4].
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2.6 IL-1ra delivery for OA (human, animal models)
Because of IL-1’s prominence in arthritis pathogenesis, researchers have used the antagonist
molecule IL-1ra to treat both osteoarthritis and rheumatoid arthritis. Clinical trials have
explored the safety of soluble IL-1ra[74] and have found that humans can tolerate up to 150
mg of IL-1ra with no adverse symptoms. Patients even showed reduced macrophage infiltra-
tion, and improved pain and function scores for up to 3 months after IL-1ra injection, even
though the proteins half-life was only 4 h[74][83]. Other clinical trials tested RA patients’
tolerance to frequent, high doses of IL-1ra, and found that they tolerated injections up to 7
times a week for 3 weeks, with the only major complaint being injection site irritation[65].
RA patients showed some improvement when they received IL-1ra (anakinra); however, the
differences were not significant[78]. Soluble IL-1ra has also been tested in animal models
of arthritis. Mice who were given continuous infusion of IL-1ra (1 mg/day) had better in-
hibition of CIA in both early and late-stage disease, while mice given PEGylated sTNF-RI
only showed reduced early disease[191]. Another mouse study investigated the effect of IL-
1RAcP versus IL-1ra in inhibiting CIA[315]. While both molecules blocked some of the CIA
progression, the IL-1RAcP group did not adversely affect T cell function, while the IL-1ra
group showed some negative impact. In the canine ACL transection OA model, soluble
doses of IL-1ra reduced the severity and total area of degradation on the tibial plateau over
4 weeks[66]. As diseases, RA and OA behave differently on a molecular level, which might
explain why IL-1ra has less success when used in RA versus OA. Most recombinant IL-1ra
used in these trials is produced in E. coli[59][41][132], which may affect the proteins potency
because E. coli does not glycosylate proteins like mammalian cells do. However, the cost
of producing IL-1ra in a mammalian cell system is significantly higher than producing it in
bacteria. Alternatively, producing IL-1ra in situ via gene therapy allows IL-1ra to receive
proper glycosylation, which in turn may also improve its potency and subsequent patient
outcomes[159].
Increasing the retention time of soluble IL-1ra may help make it more effective. By
fusing IL-1ra to an antibody to human serum albumin, a ubiquitous protein in the body,
researchers showed a significant decrease in the pain/functional impairment in mice with
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collagen-induced arthritis compared with soluble IL-1ra[173].
IL-1ra has wide potential to be a powerful therapeutic for treating OA. Currently, large
doses of soluble IL-1ra are necessary to achieve therapeutic results because IL-1ra has a
slow receptor “on” rate, is rapidly excreted, suffers from poor tissue penetration, and can
be thwarted by increased levels of membrane-bound IL-1RI and the decoy soluble IL-1RI[91].
2.7 Drug and Anti-Cytokine Therapies for OA
Steroids are commonly used for OA treatment in the clinic. Drugs such as dexamethasone
(Dex) can alleviate swelling and pain in arthritic joints through direct intra-articular injec-
tion. However, these drugs are small molecules and are cleared from the joint in a matter
of hours[91][146]. To increase the efficacy of steroidal drug treatment and to avoid side
effects, researchers have encapsulated Dex into liposomes for controlled delivery. The only
marketed liposomal Dex complex, named LipotalonTM, is available in the EU but is not ap-
proved by the FDA[39]. Other liposomal Dex formulations have been evaluated in a mouse
model of collagen-induced arthritis. Dex was encapsulated by rehydrating cholesterol-based
liposomes in a concentrated solution of Dex-phosphate[283]. Administering these particles
in a one-time dose to collagen-induced arthritic (CIA) mice slowed their arthritis progres-
sion for 7 days post-administration, while higher daily doses of free Dex were required to
achieve the same amount of inflammatory suppression.
OrthokineTMis a commercially available anti-cytokine OA therapy that uses chromium
sulfate-modified glass beads to stimulate IL-1ra production from patient-harvested blood
and then reinjects the preconditioned serum back into the patients[135][354][295]. The au-
tologous conditioned serum (ACS) groups in the trials had statistically significant reductions
in pain and clinical scores that were greater than the control groups’ scores and persisted
past the treatment window[20][368][242][295].
A novel class of small molecule MMP-13 inhibitors showed moderate chondroprotective
effects and improved bone and osteophyte scores in rats with MIA-induced OA as compared
to the vehicle controls[22][304]. These MMP-13 inhibiting drugs showed promise for use as
a disease-modifying OA drug (DMOAD) because they reduced cartilage destruction and
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Table 2.2: Current Drugs for Osteoarthritis Treatment
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Cytokine traps have been created as sinks for disease-inducing cytokines. The cytokine
traps work by providing a soluble cytokine receptor, such as IL-1R, complexed with its
accessory receptor protein, such as the IL-1RAcP, via recombinant Fc tails. This complex
exhibited a 100-fold increase in cytokine affinity over the affinity from the soluble receptor
alone[108].
Selectively removing cytokine-inducing cells from the OA joint space could also mod-
ify the disease progression. In an explanted OA synovial fibroblast cell culture model,
CD14+ OA synovial macrophages were removed from primary OA-derived cell cultures
using targeted beads. Cultures that lacked these CD14+ cells showed “significant inhi-
bition” of synovial fibroblast-produced cytokines, leading to the hypothesis that synovial
macrophages incite synovial fibroblasts to stay activated[51]. The ability to selectively re-
move these synovial macrophages in an in vivo setting could be technically complicated,
which would limit the effectiveness of this technology. However, targeting CD14+ cells may
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provide an alternative strategy for modifying the OA pathology.
Current drug and anti-cytokine strategies have shown moderate success in ameliorating
OA inflammation and pain in the short-term. However, these therapies have not shown
long-term benefit without chronic injections or oral dosing. OA activates a broad spec-
trum of cells, cytokines, and metabolites that are not easily or permanently altered by
a single protein or drug. Anti-cytokine therapies must embrace multi-valent, controlled
delivery approaches, like incorporating multiple cytokines and/or drugs paired with long-
release/long-retention delivery vehicles to effectively alter the OA environment to affect
disease progression in a permanent manner.
2.8 IL-1ra Gene therapy for OA
Researchers have looked to gene therapy to administer continuous high levels of IL-1ra for
arthritis treatment to address the problem of fast protein clearance from the joint. They
have explored retroviral[21][46][118][115][355][117], lentiviral[158][159][157] and
adenoviral[139][249][350][241] vectors to induce IL-1ra expression in different animal models
and human patients.
In a mouse model of IL-1ra gene therapy, mouse HSCs were transduced with an IL-
1ra-containing retrovirus and then were transferred into irradiated mice. The primary
transduced animals produced IL-1ra within a range of 50-1000 ng/mL. To then prove the
stability of the transduction, cells from the primary animals were transferred into secondary
lethally irradiated animals, where they produced 40-140 ng/mL IL-1ra for up to 7 months
post-transfer[46].
In rats, a lentivirus that expressed IL-1ra efficiently transduced synovial cells in vivo
without significant extraneous transduction of other cells. Expression of IL-1ra in immuno-
compromised rats lasted up to 6 weeks, whereas immunocompetent rats only expressed the
protein for 20 days[158].
In rabbits, retroviral expression of IL-1ra ex vivo was evaluated in both allograft and
autograft models. The allografted cells expressed protein for 12 days, while autografted
cells expressed at least 100 pg IL-1ra/knee for up to 5 weeks[21]. In another study, arthritis
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was induced by MCL transection combined with menisectomy, and adenoviral expression
vectors containing IL-1ra and/or soluble TNF-RI were directly injected into rabbit knees.
The joints were evaluated for protein expression and reduction of synovitis. Rabbits that
received IL-1ra showed reduced cartilage degradation, but adding sTNF-RI vector reduced
the synovitis as well as some of the degradation[350]. Fernandes et al. used canine cells
to deliver IL-1ra to MMT-induced arthritic rabbits using a plasmid-lipid conjugate[124].
The amount of IL-1ra vector injected positively correlated with a decrease in lesion size.
Finally, researchers induced arthritis by medial collateral ligament transection together with
a medial meniscal transection (MCLT/MMT) and then injected retrovirally transduced
allograft cells containing IL-1ra, IL-10, or both IL-1ra and IL-10. Rabbits receiving IL-
1ra-transduced cells showed less cartilage breakdown than those receiving IL-10-transduced
cells, but animals receiving both genes showed superior chondroprotection over animals who
received either single protein[378].
Dogs were given arthritis using the anterior cruciate ligament transection (ACLT) model.
Synovial cells were harvested from the left knee, were transfected with IL-1ra, and were
then reinjected into the joint space. IL-1ra-transduced cells reduced the appearance of
macroscopic lesions on the tibial plateau and femoral condyles, and also decreased the
average histologic lesion scores[264].
In horses, synoviocytes were adenovirally transduced with IL-1ra, alone or in tandem
with IGF-1, and the effects of these synoviocyte cells were assessed on explanted horse car-
tilage cultures. Explants cultured with IL-1 or media only were exposed to the transduced
synoviocytes. Non-arthritic explants with IL-1ra/IGF had higher PG content than any of
the other groups. IL-1-degraded cultures recovered some PG content when exposed to IL-
1ra-expressing synoviocytes, but IL-1-degraded cultures fully recovered their PG content
when exposed to both IL-1ra and IGF-expressing synoviocytes[249]. The same combination
of proteins expressed in Adenoviral-Associated Vectors (AAV) was used to repair chondral
defects in horses. There were no significant changes among the groups, however, the IL-
1ra/IGF treated group had higher collagen II and PG content[241]. A final equine study
showed that an adenoviral vector could express detectable levels of IL-1ra for 28 days and
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improved the overall cartilage erosion scores. However, IL-1ra did not affect the joint
effusion[139].
A limited number of clinical gene therapy trials have evaluated IL-1ra in humans. Two
females with RA in their finger joints had their synovial fibroblasts harvested, retrovirally
transduced with IL-1ra, and then reinjected into the affected MCP joints. One patient
saw extreme reduction in her joint swelling, while the other showed moderate reduction
in her symptoms[355][117]. Evans et al. also delivered transduced autologous synovial
fibroblasts to the MCP joints of 9 female RA patients. The joints from patients receiving
intermediate or high doses of transduced cells had detectable IL-1ra expression at 1 week
post-injection[118]. In a related study, intervertebral disc explants were transduced with a
vector expressing IL-1ra. IL-1ra expression reversed matrix degradation in the IVD cultures
and also inhibited metal-dependent protease activity[214].
The practical application of gene therapy for OA suffers from concerns about gene vector
safety, low transduction efficiency in situ, loss of gene expression over time, cell alterations
during ex vivo manipulations, and public perception[264][139][158][355][195][118][116]. Al-
though in the long-term, gene therapy technologies will hopefully overcome these hurdles,
the current therapies still lack the combination of efficacy and safety that would override
the public and the FDAs reluctance to embrace these therapeutic approaches.
2.9 Animal models for OA
2.9.1 Induced Arthritis
Researchers can induce arthritis in the lab in two main ways: mechanical instability and
chemical damage[98][185][279]. The most common mechanical instability OA models in-
volve either transecting the ACL, MCL, or cutting the medial meniscus to destabilize the
joint and cause arthritis. These methods have been evaluated in rabbits, dogs, rats, and
sheep[9][55][210][349][341]. The canine ‘groove’ model is a less common OA model that
involves inducing mechanical damage to the articular cartilage and then forcing the dogs to
load the damaged joint in a transient fashion. This model recapitulates human OA in 10
wks[236].
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Monosodium iodoacetate (MIA) is a chemical OA model that causes chondrocyte death,
leading to an extreme inflammatory environment[54][76][163][162][364][343]. MIA recapitu-
lates an OA-like phenotype with cartilage lesions visible both macroscopically and histolog-
ically. It also induces nociceptors and stimulates pain during OA[255]. The synovial mem-
brane shows signs of hyperplasia and fibrosis. MIA also alters proteoglycan metabolism,
reducing the amount of sulfated GAGs present in the cartilage[105][327]. Animals show
reduced spontaneous mobility, which indicates pain and joint stiffness (catwalk)[127]. Af-
ter OA induction by MIA, rats exhibit changes to articular cartilage in tibial plateaus
and femoral condyles by 7 days and large-scale bone changes at 28 days. This method
does not fully recapitulate osteoarthritis because it causes extreme cartilage damage in a
short period of time, but it is used as a model of cartilage degradation and pain during
osteoarthritis[114][302][126].
2.9.2 Spontaneous Arthritis
Researchers have created knock-out mice that lack various proteins thought to be criti-
cal in osteoarthritis development. Although k.o. models can be powerful research tools,
spontaneous arthritis is highly strain-specific. For example, IL-1ra-k.o. mice developed
rheumatoid-like arthritis spontaneously when crossed on a Balb/C background, while C57/Bl6
mice showed RA protection[177]. Most of the other IL-1-related gene-knockout mice (IL-1,
ICE, iNOS, stromeolysin-1) showed faster cartilage degradation after knock-out[77]. This
result was surprising because the literature assumes IL-1 plays a primarily destructive role in
OA. The Dunkin-Hartley guinea pig strain shows susceptibility for spontaneous arthritis. At
24 weeks of age, the DH guinea pigs had twice the radiographic score of their age-matched,
non-arthritic strain counterparts (Bristol Strain 2) and maintained high IL-1β expression
into adulthood, implying a role for IL-1β in spontaneous OA development[281][297][10]. Al-
though spontaneous arthritis animal models can recapitulate the osteoarthritis progression
that is seen in humans, disease progression takes time to develop, making drug testing and
therapeutic evaluations slow[28][30][31][32][317][251].
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2.10 Biomaterials for OA drug/protein delivery
There has been no shortage of biomaterial-based efforts to deliver drugs and protein for
OA treatment[211]. The most common approach involves the creation of either solid or
liposomal particles that encapsulate a small molecule drug[178][223]. Methotrexate (MTX)
(antimetabolite/antifolate agent), dexamethasone (Dex) (glucocorticoid), and indomethacin
(Ind) (NSAID) are the current standard drugs for treating OA and show up most frequently
as model drugs for encapsulation. These small molecule drugs easily retain their bioac-
tivity when encapsulated. Liposome-encapsulated Dex has been used for IA delivery in
healthy and AIA-arthritic rabbits[48]. Dex has also been encapsulated in magnetic PLGA
particles[63]. In fact, liposomal Dex is available in Europe for intraarticular delivery for
OA[39]. Liposomal Dex reduced arthritis scores and inflammation in a mouse model of
arthritis at 8 days post-injection compared with control animals that received daily bolus
doses of Dex[283]. Localized or conjugated forms of MTX avoid or minimize its detrimental
side effects, such as bone marrow and gastrointestinal toxicities[165]. MTX has been con-
jugated to hyaluronic acid for controlled delivery in antigen-induced arthritic rats and sig-
nificantly reduced joint swelling for up to 20 days post-injection[174][175]. Liposomal MTX
decreased IL-1 and IL-6 gene expression (as measured by mRNA levels) in AIA-induced
rats for 7 days after the initial particle injection[363][362]. MTX was encapsulated in PLA
particles for delivery to the rabbit joint. Loading the drug into particles increased the local
concentration of MTX while also decreasing the circulating levels of MTX[220][219]. Zhang
et al. delivered NIPAAm-ethyl aminobenzoate amphiphilic particles containing Ind to CFA-
induced arthritic Sprague-Dawley rats[374]. The Ind-loaded particles reduced paw edema in
a more pronounced fashion than a dose of soluble Ind, while also eliminating the gastric ul-
ceration that occurs with free Indomethacin. Clodronate liposomes have been administered
intraarticularly to humans with RA[24]. Clodronate eliminates synovial lining macrophages
and osteoclasts by inducing apoptosis. Patients receiving clodronate liposomes had reduced
CD68 staining, which correlated with reduced cartilage destruction. However, this drug did
not affect the FLS, possibly limiting the overall effectiveness of this treatment for OA. The
inherent properties of micellar particles make them attractive for targeted drug therapies,
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but they have not been investigated for OA applications[196].
Particle systems have been evaluated by themselves for retention and size appropri-
ateness in the intra-articular joint space[179]. Liposomal chelators made of a cholesterol
derivative (less than 1 µm) had retention of up to 41% at 21 days[23]. However, these
contained no therapeutic payload. Other research investigated albumin microspheres for
intraarticular drug delivery to rabbits. The albumin particles were 3.5 µm in size and
were loaded with rose bengal dye. They showed 50% retention in the knee for 4 days[282].
Chitosan microparticles have been synthesized for intraarticular delivery of celecoxib to
CFA-induced rats. Celecoxib-loaded particles (8 µm diameter) released 50% of their pay-
load by 1 h, and unloaded 80% in 96 h in vitro[334]. Finally, researchers have created
hyaluronic acid-coated PLGA particles to increase their adhesiveness and retention in the
intra-articular space. The particles were evaluated only for biosafety indicators, but showed
no signs of wear and no inflammation[382].
Although small molecule drugs show promise in treating many symptoms of arthritis,
the use of biomolecules as therapeutics may have more targeted, biologically-relevant ef-
fects on the disease. However, most biomolecules are smaller than the retention threshold
of the synovial joint and require a carrier or other mechanism to retain these therapeutics
in the target area. One recent approach created a fusion protein from Elastin-Like Pep-
tides and IL-1ra. When injected at physiological temperature, this construct self-assembles
into submicron scale “drug depots” that act as reservoirs for the presentation of IL-1ra to
macrophages and other inflammatory cells in the arthritic joint space[7][197][305]. Both
soluble and aggregated IL-1ra-ELPs reduced IL-1β levels up to 72 h post-stimulation in
in vitro cultures[197]. Previous work with just the ELP showed retention in the joint of
4 days, compared with 3.37 h for non-assembling ELPs[36]. However, the fusion protein
reduced the native bioactivity of IL-1ra by almost 90% by interfering with its ability to bind
to the receptor[305]. In IL-1β-induced arthritic rats, IL-1ra-ELP depots improved the joint
phenotype over bolus IL-1ra. The authors noted a less severe pathology in the IL-1ra-ELP-
treated femoral condyles and in the histological sections compared with both untreated
and bolus IL-1ra-treated tissue[7]. Chondroitin sulfate-coated Gelatin microspheres were
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evaluated for retention and delivery of catalase and albumin to mice knee joints[62]. The
particles efficiently encapsulated catalase (75% efficient) and released their payload only in
the presence of collagenase. A chondroitin sulfate particle coating may help increase the
residence time and targeting of particles within the joint space.
Attaching a PEG oligomer or polymer chain to a protein referred to as PEGylation - has
been evaluated for increasing the circulation time of various proteins, including IL-1ra[142].
Gaertner et al. took advantage of N-terminal serine/threonines to attach a PEG oligomer
to IL-1ra, IL-8, and G-CSF. However, there was only minor improvement to the protein
half-life by this strategy[141]. Other groups have also attempted PEGylation using a mono-
PEGylated IL-1ra with either a 5k or 10k PEG chain attached to the terminus. PEGylated
IL-1ra retained 40% of its original binding activity through thiol-directed conjugation, while
randomly conjugated protein only maintained 9.8% activity[371][372].
Microencapsulation techniques have been attempted to deliver therapeutic quantities of
protein using particles[360]. A double emulsion process was used for a multi-block copolymer
system to encapsulate albumin in vitro[37]. However, this process suffers from low protein
encapsulation efficiency (only a few weight % of total formulation) or exposure of the protein
to organic solvent. Alternatives include using reverse dialysis of a protein solution against
precipitating agents, making protein crystals for encapsulation, and cooling a pre-heated
supersaturated solution before dialyzing against pre-formed particles[188][26][326][379].
Other research has attempted to attach proteins to particles (liposomes, micelles, solid
particles) for therapeutic delivery or tissue targeting[229][250]. A variety of tethering moi-
eties have been incorporated into biomaterials to allow protein conjugation and delivery.
The most common chemical handles are: acetylation[366][253][198][193][106], biotinylation
[189][176][71]/Streptavidin[53], maleimide[221][247][270][307][344][171] or thiol-termination
[286][252][246][224][205][200][104], hydroxyl termination[201][180], click chemistry (azido
functionality)[260][170][86][377], and the ubiquitous EDC-NHS chemistry for carboxylic
acid-primary amine linkages[369][277][222][70][56]. The 4-nitrophenol moiety has been used
only in a limited fashion and specifically by one research group that employs this function-
ality for tethering antibodies to liposomal particles[5][97][113][192][217][226][227][244][332]
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[338][337][339]. For example, a PEG-PE micelle modified with pNP showed 10-20 antibodies
attached to a single particle by fluorescence and SDS-PAGE. The PEG-PE micelles carry
a net negative charge that could inhibit non-specific cellular uptake of the micelles[336].
For this thesis research, pNP became a good alternative to EDC-NHS protein tethering,
based on the mild reaction conditions for pNP-primary amine displacement and the overall
stability of the pNP leaving group. IL-1ra has been encapsulated in PLGA particles for
cancer delivery[213]. The particles released significant amounts of IL-1ra for up to 14 days
and significantly increased the survival of tumor-bearing mice. Current biomaterial deliv-
ery systems exhibit several limitations. First, most drug-delivery particles are hydrophobic,
which is not optimal for hydrophilic protein encapsulation. Second, hydrophobic particles,
such as PLGA, could cause wear damage to the already-fragile OA cartilage structure. Ad-
ditionally, these particles usually suffer from non-specific protein adsorption, which causes
increased phagocytosis and can lead to increased inflammation. Liposomal particles have
limitations as well. Because of their spontaneous, self-assembling structure, they have
lower stability in serum than solid polymer particles, and are subject to hydrolysis and
oxidation[294][212]. They also tend to leak out encapsulated drugs and can be expensive
to manufacture[182][52][353][19][140]. Solid polymer particle systems, such as PLGA, are
good at small molecule drug delivery, while liposomes are usually better for protein deliv-
ery because they have hydrophilic cores for protein encapsulation. Our amphiphilic system
has both drug and protein delivery capabilities in the same particle system. The design of
these particles allows for protein immobilization on the surface, as well as hydrophobic drug
encapsulation in the particles core. Finally, the literature is short on examples of particles
for OA treatment that employ both a targeting moiety and a therapeutic drug in the same
particle[27][38][56][71][69][86][112][144][176][256][254][292][346]. Targeted therapies that are
delivered intra-articularly will increase the effectiveness of current OA treatments and will
serve as the next generation of drug delivery technologies[73][109].
Our IL-1ra-based system has distinct advantages over current particle-based technolo-
gies. First, IL-1ra acts as both a targeting ligand and a therapeutic molecule simultaneously,
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abrogating the need for multiple ligands. However, our tethering scheme is highly modu-
lar because it uses primary amines to conjugate proteins/peptides to the particle surface.
For instance, this system could allow the delivery of TGF-β, IL-1ra, and IGF-1 simulta-
neously. Secondly, the pNP protein tethering moiety has a high conversion efficiency that
allows for concentrated protein tethering to the particle surface. RAFT polymerization
makes a low polydispersity polymer that will form particles in a narrow size range. The
RAFT polymer also allows us to easily form a block copolymer with the monomers of our
choice. We incorporate a hydrophilic TEGM segment with a hydrophobic CHM segment,
both with predictable size based on stoichiometry, to allow the formation of a “core-shell”
or“micellar-like” particle structure when exposed to aqueous solvent (hydrophilic on the
outside, hydrophobic on the inside). The polymer chain length can be easily modified by
varying the ratio of monomers during polymerization. Finally, although not addressed in
the scope of this thesis work, this polymer system can easily incorporate hydrophobic small
molecule drugs in its core, allowing us to form dual-action therapeutic particles.
2.10.1 RAFT polymers
Reversible Addition Fragmentation chain Transfer (RAFT) is a recent polymerization strat-
egy whose advantages include a wide range of monomers that can be used and the “non-
demanding” reaction conditions. RAFT polymerization uses some of the same principles
as classical free radical polymerization, like initiation by UV, thermal activation or gamma
initiation, but the chain transfer in RAFT is reversible and leads to simultaneous chain
growth without affecting polymerization rates (Fig. 2.6). This growth mechanism creates
polymers in a one-step process with a pre-determined MW and low polydispersity index
(PDI). The original RAFT paper from Chiefari et al. demonstrated the ability of RAFT
transfer agents to build polymers with a narrow MW distribution using styrene and acry-
lonitrile monomers over 18 h. These polymers had low PDI, especially compared to the
same monomers polymerized via standard methods[75].
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Figure 2.6: Schematic of the general RAFT polymerization strategy (Chiefari+ 1998). A
radical initiator (e.g., A radical initiator, such as AIBN (R), reacts with the monomer to
make a radical monomer (R-Mn) that then interacts with the dithioester (RAFT agent)
(A-X), displacing a radicalized leaving group (A) that further activates monomer units and
allows for chain propagation.
RAFT has been broadly used for making monomeric polymer chains as well as block
copolymers (di, tri, etc.). Methacrylate polymers were synthesized by RAFT using a 4-
nitrophenol (pNP) functional moiety on the chain transfer agent. These polymers had
polydispersity indexes of less than 1.3, which is a major improvement over traditional
methods that have PDI values closer to 2.0[120]. The polymer chains also showed up
to 86% pNP substitution rates when exposed to a modified glycine amino acid in solvent
(TEA/DMSO)[183]. RAFT polymerization is able to create a wide range of narrow PDI
polymers in a one-step process without protecting/deprotecting steps. It is also compatible
with a wide range of monomers and has predictable MW characteristics that make it a
modular synthetic process with desirable polymer fidelity[75]. RAFT polymers have great
promise for drug and protein delivery applications[240][248][288][324][370].
Other functional handles for protein/peptide tethering have also been employed in
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RAFT polymers. A biotin-functionalized RAFT agent was used to form pNIPAAm and
pHPMA, as well as a diblock copolymer from NIPAAm/HPMA (PDI<1.3). The diblock
polymer formed a “core-shell” structure when exposed to temps above NIPAAms LCST,
and left the biotin groups on the surface to allow decoration of the particles with avidin-
functionalized molecules[176]. RAFT polymers with protected aldehydes have also been
synthesized to allow for post-particle modification with peptides. A p(OEGMA)-block-
p(STY-co-TMI) polymer had a PDI of less than 1.2 and formed micelles when exposed to
aqueous solvent. Deprotecting the aldehyde functionality allowed for “decoration” of the
particles with the RGD peptide. The particles also used the isocyanate groups from the
block copolymer to create a cross-linked core to stabilize particles[106].
Diblock RAFT polymers have been formed into micellar particles by dialysis of the
polymer solution against water or buffer[375]. Garnier et al. synthesized RAFT copoly-
mers with a poly(butyl acrylate) hydrophobic segment and various hydrophilic segments
(poly(dimethyl acrylamide) (pDMA), poly(acryloyloxyethyl methylsulfoxide) (p(M4)), and
poly(N-acryloylpyrrolidine) (pAPR). These polymers all formed micelles around 20-100 nm
that had rod or worm-like shapes[143].
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CHAPTER III
ENGINEERING A RAFT-BASED BLOCK COPOLYMER TO MAKE
PROTEIN-DELIVERING PARTICLES
3.1 Summary
Polymer microparticles have been used in a limited fashion to deliver proteins to arthritic
joints. Encapsulating proteins within particles can affect their bioactivity due to exposure
to solvents and other non-physiologic environments. Solid microparticles are usually hy-
drophobic in nature, which can cause nonspecific protein adsorption, particle phagocytosis,
and can drive inflammation. Developing a particle system that can preserve the protein
bioactivity while also exhibiting the stability characteristics of a solid microparticle would
increase the effectiveness of a microparticle drug-delivery system. We report here the syn-
thesis and characterization of an amphiphilic RAFT block copolymer that self-assembles
into particles in our target size range of 300 nm. The monomer components of the polymer
incorporate a “stealth” tetraethylene glycol methacrylate to form a hydrophilic particle
corona and a hydrophobic cyclohexyl methacrylate group to form a highly stable particle
core. We also report the successful modification of a commercial microRAFT agent with
the 4-nitrophenyl moiety, which acts as the protein tethering handle on the particles.
3.2 Introduction
Creating tailored technologies for protein and drug delivery in a disease model is crucial to
the ultimate success of that technology. An attractive application is delivery of biological
molecules like disease-specific proteins in relevant quantities to the appropriate cells/tissue.
Bolus injections of proteins, such as IL-1ra, can be effective therapeutics in the short-term,
but require repeat injections and can become quite costly[65]. Current delivery strategies
can efficiently encapsulate hydrophobic, non-biological drugs without losing their effective-
ness or bioactivity[211][39][178]. However, these polymers have limited application to pro-
tein delivery because of their hydrophobicity and solvent use, which both can detrimentally
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affect protein bioactivity and encapsulation rate.
PEGylation of the protein itself is one strategy that addresses this limitation. This
modification forms pseudo-particles with the protein and increases the effective protein
size. However, this addition can affect the protein’s bioactivity, even though it may increase
body residence time[142][371][372]. Other research has attempted to form “drug depots”
with the protein conjugated to a self-assembling recombinant protein[305]. This strategy
also severely decreased the bioactivity of the protein by almost 90% in vitro. Therefore,
more effective strategies for delivering protein are needed.
Targeted delivery of these therapies is a primary design criterion for current drug/protein
delivery technologies. Targeting strategies include RGD (a non-specific integrin binding
motif)[383], biotin-streptavidin interactions, which have a strong Kon, but can be strongly
immunogenic[57], phage-derived peptides[292], folate (ovary, breast, kidney, myeloid cell,
and lung cancers), and even antibodies (i.e., breast cancer targeting)[226][112]. Our use
of a full protein for synoviocyte targeting has much higher affinity (IC50IL−1ra = 0.4 nM
vs. IC50RGD >100 nM) [137][273] and specificity than peptides like RGD. Our targeting
protein, IL-1ra, concomitantly acts as an anti-inflammatory therapeutic, giving it strong
multi-use potential.
We present a new block copolymer that efficiently and covalently tethers protein by
harnessing the power of an aqueous protein tethering chemistry that acts with high efficiency
in mild reaction conditions (pH>7.4). This polymer technology can be tailored to make a
range of particle sizes while maintaining the same protein tethering chemistry. We harness
this technology to create sub-micron-scale particles with a surface-bound anti-inflammatory
protein for simultaneous synoviocyte cell targeting and therapeutic functions. This system
has wide potential for making modular, multi-functional particles by simply varying the
protein mixture during tethering.
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3.3 Materials and Methods
3.3.1 µRAFT agent modification
The µRAFT agent was designed and synthesized by Dr. D. Scott Wilson (Murthy Lab,
Georgia Institute of Technology) for use in this project and was referenced from [380]. All
reagents were obtained from Sigma-Aldrich and used as-is, unless otherwise specified.
3.3.1.1 Synthesis of 17-hydroxy-3,6,9,12,15-pentaoxaheptadecyl
2-((phenylcarbonothioyl)thio)acetate (1)
A solution of N,N’-dicyclohexylcarbodiimide (DCC) (619.0 mg, 3.0 mmol) in 5 mL dichloro-
methane (DCM) was added drop-wise to a stirred solution of (benzothioylsulfanyl)acetic
acid (500 mg, 2.36 mmol), hexaethylene glycol (1.41 g, 5.0 mmol), and a catalytic amount
of 4-dimethylaminopyridine (DMAP) in 50 mL DCM at 0◦C. After adding the DCC, the
solution was allowed to come to room temperature. After 2 additional hours of stirring, the
solutions were filtered, and the organic solution was concentrated via rotary evaporation,
resuspended in ethyl acetate, and finally evaporated onto silica gel. The desired product
was isolated by flash silica gel chromatography on silica gel, using a mixture of ethyl acetate
and hexanes (6:4).
3.3.1.2 Synthesis of 1-(4-nitrophenoxy)-1-oxo-2,5,8,11,14,17-hexaoxanonadecan-19-yl
2-((phenylcarbonothioyl)thio)acetate (µRAFT agent)
A solution of 4-nitrophenyl chloroformate (201 mg, 1.0 mmol) in 1 mL of DCM was added
drop-wise to a stirred solution of (1) (476 mg) and pyridine (95 mg, 1.5 mmol) maintained
at 0◦C. After 1 h of stirring, the solutions were filtered, and the organic solution was concen-
trated via rotary evaporation, was resuspended in ethyl acetate, and finally was evaporated
onto silica gel. The desired product was isolated via flash silica gel chromatography on silica
gel using a mixture of ethyl acetate and hexanes (4:6).
3.3.2 Tetraethylene Glycol Methacrylate (TEGM) synthesis
Tetraethylene glycol (5.0 g, 25.7 mmol) (#110175, Aldrich, St. Louis, MO, USA), and
pyridine (2.0 g, 25.3 mmol) (#PX20202-5, EMD, Gibbstown, NJ, USA) were added to
anhydrous dichloromethane (DCM) (100 ml) in a 250 ml flask and stirred for 30 min at
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0◦C. Methacryloyl chloride (2.6 g, 25 mmol) (#64120, Fluka, Sigma-Aldrich, St. Louis,
MO, USA) was added drop-wise to the stirred solution. The reaction was allowed to stir at
0◦C for 2 h, and then at room temperature for an additional 2 h. The reaction was then
concentrated via rotary evaporation, resuspended in ethyl acetate, and then evaporated
onto silica gel. The monomethacrylate product was separated from the di-methacrylate
byproduct and any remaining starting materials via flash silica gel chromatography on
silica gel, using a mixture of ethyl acetate and hexanes (7:3).
3.3.3 Copolymer synthesis
3.3.3.1 Hydrophilic block synthesis
TEGM (0.9 g, 3.43 mmol), µRAFT agent (22.0 mg, 0.034 mmol), and AIBN (0.5 mg,
0.003 mmol)(#441090, Aldrich, St. Louis, MO) were combined in DMF (1.5 ml). The
reaction flask was degassed by five freeze-pump-thaw cycles, and was then immersed in an
oil bath and stirred at 65◦C. After 20 h, the reaction was terminated by flash freezing in
liquid nitrogen. The reaction product was added to DCM (5 ml) and then was precipitated
from methanol (25 mL). The supernatant was decanted and the precipitated polymer was
subjected to three more rounds of resuspension (DCM) and precipitation (MeOH) before
being concentrated under reduced pressure. The purified polymer was analyzed for weight
by gel permutation chromatography (THF) and the structure and purity of the resulting
polymer were verified by 1H-NMR (DCM).
3.3.3.2 Hydrophobic block synthesis
pTEGM (0.5 g, 1.90 mmol), cyclohexyl methacrylate (213.65 mg, 1.27 mmol) (Tokyo Chem-
ical Industry Co, Ltd., Tokyo, Japan) and AIBN (0.25 mg, 0.0015 mmol) were combined
in DMF (1.5 mL). The reaction flask was degassed by five freeze-pump-thaw cycles and
was then immersed in an oil bath and was stirred at 65◦C. After 20 h, the reaction was
terminated by flash freezing in liquid nitrogen. The reaction product was added to DCM (5
mL) and was precipitated using methanol (25 mL). The supernatant was decanted and the
precipitated polymer was subjected to three more rounds of resuspension (DCM) and pre-
cipitation (MeOH) before being concentrated under reduced pressure. The purified polymer
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Table 3.1: Synthesis of hydrophilic polymer chain (Block A): Example Calculations
Block A µRAFT TEGM AIBN
Molar Ratios [1] [100] [1/10]
60◦C,
8 h
Example Calculation 22 mg 900 mg 0.5 mg
[0.034 mmols] [3.43 mmols] [0.003 mmols]
(664.15 mg/mmol) (263.1 mg/mmol) (164.21 mg/mmol)
Table 3.2: Synthesis of block copolymer (Block A+B): Example Calculations
Block A+B Block A CHM AIBN
Molar Ratios [3] [2] [1/4] 60◦C, 20 h
Example Calculation 500 mg 214 mg 0.25 mg
[1.90 mmols] [1.27 mmols] [0.0015 mmols]
263.1 mg/mmol 168.23 mg/mmol 164.21 mg/mmol
was analyzed for weight by gel permutation chromatography (THF) and the structure and
purity were verified by 1H-NMR (DCM).
3.3.4 1H-NMR and 13C-NMR Analysis
Samples of the modified components (µRAFT, TEGM) and the copolymer were dried under
vacuum to remove excess solvent. The samples were resuspended in CDCl3 for NMR analy-
sis. All analyses were run on a 400 MHz low-field NMR (Oxford Instruments, Oxfordshire,
England).
3.3.5 MALDI-TOF Mass Spectroscopy
MALDI-TOF mass spectroscopy analysis was done by the Georgia Tech Core Facilities
laboratory.
3.3.6 Particle Formation and Protein Tethering
Copolymer was dissolved in THF at a concentration of 40 mg/mL. 50 mL of 0.01 M PBS
was added to a 100 mL beaker and was set on a stir plate at 400 rpm. 20 mg polymer,
dissolved in 2.5 mL THF/DMF (9:1), was added to the aqueous phase at 20 mL/h using a
syringe pump (10 mL syringe, 18 gauge needle). Once the polymer was added, the solution
was transferred to a 250 mL round-bottom flask and the solvent was evaporated under
reduced pressure for 30 min to remove THF. The particle solution was concentrated by
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centrifugation using 100 kDa centrifugal filters (#UFC810096, Amicon Ultra-4 Centrifugal
Filters with Ultracel-100 kDa membranes, Millipore, Billerica, MA) (2,750 x rpm, 3 min),
and was then sonicated for 30 sec to resuspend any clumped particles.
IL-1ra or heat-denatured Bovine Serum Albumin (HD-BSA) protein was added to the
particle solution and the pH was raised to 8.0 using 0.01 M NaOH. The particle+protein
solution was allowed to react overnight. Ten mg glycine in PBS was added to quench any
remaining reactive groups and was allowed to react for 30 min. The particle solutions were
put in 10 kDa dialysis tubing and were dialyzed overnight against PBS with at least 3 buffer
changes. The particles were transferred to sterile microcentrifuge tubes and were stored at
4◦C until further use.
3.3.7 Cytotoxicity Assay
RAW 264.7 macrophage cells (From the Murthy lab (Georgia Tech); TIB-71, ATCC, Manas-
sas, VA) were cultured using Dulbeccos Minimum Essential Media (DMEM) supplemented
with 10% FBS at 37◦C, 5% CO2. At confluency, cells were scraped to remove them from
the culture plates. The cell suspension was centrifuged, and the pellet was resuspended in 1
mL media. Cells were counted using a hemacytometer, and diluted to a final concentration
of 300,000 cells/mL. One mL was added to each 12-well. Cells were allowed to adhere for 4
h. Supernatant was removed and replaced with pure DMEM overnight to quiesce cells. The
next morning, 0.5 mL of phenol-red-free DMEM + particles was added at concentrations of
0.1, 1, and 10 mg/mL. The cells were incubated with the particles in serum-free media for 6
h before analyzing using MTT (Sigma-Aldrich, St. Louis, MO). The MTT assay measures
the oxidation of MTT dye by cellular reductase enzymes. It measures cellular metabolic
activity and is used as an indirect measure of cell viability and proliferation. MTT sub-
strate (50 µL) was added to each well and was incubated for 2 h at 37◦C. 0.5 mL 0.1 M
HCl was added to each well to develop the substrate. Each well was pipetted to mix and
then transferred to a 96-well plate for colorimetric detection using a plate reader at 570 nm
(HTS 7000 Plus, Perkin Elmer, Waltham, MA).
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3.3.8 Particle Characterization: Dynamic Light Scattering (DLS)
50 µL of particle solution was resuspended in 3 mL PBS in a cuvette. The DLS instrument
(90 Plus Particle Size Analyzer, Brookhaven Instruments Corporation, Holtsville, NY) was
allowed to warm up for 10 min and the cuvette was agitated by inverting multiple times
quickly before placing in the DLS for analysis. The particles were analyzed 3 times at 1
min each (refractive index: 1.33). The DLS has a scattering angle of 90◦, a 35 mW solid
state standard laser (660 nm), and a Brookhaven BI-9000AT correlator board. It uses a
MAS-OPTION integration system.
3.3.9 Particle Characterization: Fourier Transform Infrared Spectroscopy (FTIR)
Michael Bayless (Soper group, Georgia Tech) helped run the FTIR analysis for the modified
components in this work. Infrared (IR) spectra were obtained on a Bruker Alpha-p Fourier
transform infrared spectrophotometer.
3.3.10 Particle Characterization: Quantification of 4-nitrophenol (pNP) re-
lease
pNP release was quantified by high pressure liquid chromatography (HPLC) using a reverse-
phase C18 column (#WAT044375, Nova-Pak C18 column, 4 µm, 4.6 x 150 mm, Waters
Corp., Milford, MA) and an isocratic flow profile with 50% methanol in nanopure H2O,
supplemented with 0.01 M tetrabutylammonium bromide (TBAB)[8]. Samples were run at
1 mL/min for 15 min each. A spectrum from 190 nm to 500 nm was collected. The UV-vis
spectrum of pNP (λ = 254 nm) has peaks around 405-410 nm, 310-315 nm, and 225 nm
(0.1 mM pNP at pH 7.0)[381]. We chose to focus on the peak at 405 nm to avoid any
interference at 310 nm that may occur due to proteins in the solution.
3.3.11 Protein Tethering Analysis via Dot Blot
Nitrocellulose membrane was cut to the size of a 96-well plate and placed in a 96-tube PCR
tube holder. Ten µL of particles or protein standard was pipetted into each well space and
was allowed to dry completely (approx. 1 h). The membrane was blocked in ELISA wash
buffer (WB) (25 mL 1% HD-BSA, 200 µL 0.5 M EDTA, 50 µL Tween-20, fill to 100 mL with
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PBS) for 1 h at RT on a shaker table. Wash buffer was removed and 1:400 dilution of rabbit
anti-IL-1ra antibody (#NB110-4797, Novus Biologicals, Littleton, CO) in ELISA WB was
added to the membrane. The membrane was incubated for 1 h at room temperatureon a
shaker table. The membrane was washed three times for 5 min each in fresh ELISA WB,
then a 1:10,000 dilution of goat anti-rabbit nearIR 800 antibody (IRDye 800CW, Odyssey,
LI-COR Biosciences, Lincoln, NE) in ELISA WB was added to the membrane. The blot
was covered in foil and was incubated at RT for 1 h on a shaker table. The membrane was
washed twice for 5 min in fresh ELISA WB and the blot was imaged using a LICOR nearIR
scanner (Odyssey Infrared Imager, LI-COR Biosciences, Lincoln, NE). The intensity of each
spot was measured using the LICOR ODYSSEY 2.1 software.
3.4 Results
Our strategy for this aim was to engineer an amphiphilic block copolymer with a stable
protein tethering moiety that formed submicron scale particles and allowed protein tethering
to the particle surface. Figure 3.1 shows the schematic for the proposed block copolymer.
After modifying the commercial RAFT agent and tetraethylene glycol (Fig. 3.2, Fig. 3.3),
we performed 1H-NMR, 13C-NMR, MALDI-TOF mass spectrometry, and Fourier Transform
Infrared Spectroscopy (FTIR) to verify the synthesized products (µRAFT, Figs. 3.4-3.7,
TEGM, Figs. 3.8-3.11). We then used this modified compound, referred herein as the
µRAFT agent, as the foundation for our block copolymer. RAFT agents make up a large
library of block copolymers [324]. We show that the modified µRAFT agent successfully
acts as the base for the polymerization of tetraethylene glycol into our hydrophilic block A
polymer (Fig. 3.12). We then added cyclohexyl methacrylate to the block A and reinitiated
polymerization to add the hydrophobic block B onto the existing block A’ polymer to create
our amphiphilic block copolymer. We confirmed this polymerization by 1H-NMR (Figs.
3.13). By GPC analysis, the molecular weight of block A was 2734, and block B was 13029,
for a total estimated MW of 15,763 Da (Fig. 3.14).
Example Copolymer Reaction Yields
1134.2 mg monomer –>468.6 mg Block A
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468.6 mg Block A + 1,808 mg CHM –>722 mg Copolymer
Figure 3.1: Block copolymer synthesis strategy. A modified commercial RAFT agent
(µRAFT) was used to facilitate the polymerization. Tetraethylene glycol and µRAFT were
mixed and polymerization was initiated using AIBN. Monomeric cyclohexyl methacrylate
was added to the product of the first reaction (Block A) and polymerization was re-initiated




Figure 3.2: Modification Schematic of microRAFT agent. (Benzothioylsulfanyl)acetic acid





Figure 3.3: Modification Schematic of Tetraethylene Glycol. Tetraethylene glycol was
modified in a 1-step reaction to create tetraethylene glycol methacrylate. The resulting












Figure 3.4: Verification of µRAFT modification by 1H-NMR. Peaks were observed at 3.7
ppm (22H, int. value: 20.75+1.64) (c, d), 4.2 (2H, 1.75) (b), and 7.4 (4H, 3.79), 7.5 (1H,










Figure 3.5: Verification of microRAFT modification by 13C-NMR. Peaks were observed at
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Figure 3.6: Verification of microRAFT modification by mass spectroscopy. MALDI-TOF
spectrum of modified µRAFT agent with a theoretical mass-to-charge ratio (M/Z) of 664.15.





























































































































































































































































Figure 3.8: Verification of TEGM modification by 1H-NMR. Peaks were observed at 1.9
ppm (3H, 3.55) (a), 3.0 ppm (1H, 1.1) (f), 3.6 ppm (14H, 14.92) (e), 4.2 ppm (2H, 2.94)
(d), 5.6 ppm and 6.0 ppm (1H, 1.0; 1H, 1.0) (b,c).

 
Figure 3.9: Verification of TEGM modification by 13C-NMR. Peaks were observed at 70
ppm (a), and 77 ppm (CDCl3).
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Figure 3.10: Verification of TEGM modification by mass spectroscopy. The theoretical
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Figure 3.12: Verification of Block A synthesis by 1H-NMR. Peaks were observed at 3.7
ppm (14H, 13.98) (c, f), 4.2 ppm (2H, 2.0) (b, e), 1.9 ppm (2H, 1.49) (g), and 0.9-1.1 ppm




















Figure 3.13: Verification of copolymer synthesis by 1H-NMR. Peaks were observed at 3.6
ppm (m*14H) (a), 4.1 ppm (m*2H) (d), 1.3 ppm (n*10H) (b), 0.9 ppm (m*3H, n*3H) (e),
1.9 ppm (6H) (f), and 7.0 ppm (9H)(c). m = number of TEGM monomers; n = number of
CHM monomers.
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Figure 3.14: Verification of copolymer synthesis by gel permeation chromatography. The
molecular weight of the hydrophilic Block A was found to be 2743 Da; The hydrophobic
section, Block B, was 13029 Da (15763 Da (Block A+B) - 2734 Da (Block A only) = 13029
Da (Block B)) . Green, Block A+B; Blue, Block A.
To make particles, we added 50 mL 0.01 M PBS, pH 6.0, to a 150 mL beaker with a
stir bar. We added 20 mg polymer in a total volume of 2.5 mL THF/DMF (9:1) to the
aqueous phase while stirring at 400 rpm (Fig. 3.15). The polymer solubilizes fully in THF,
supplemented with up to 10% v/v DMF, but requires at least 48 h to fully resolubilize after
vacuum drying. The polymer spontaneously assembled into particles of approximately 280
nm in diameter and maintained their original size over 24 h, even after the addition of
protein (Figs. 3.16, 3.17).
The polymer chain is approximately 17 nm long if you assume that the polymer backbone
is fully extended. From the GPC data, there are an estimated 10 TEGM monomers per
chain (2734 Da/262 g/mol monomer weight) and 77 CHM monomers per chain (13029
Da/168 g/mol monomer weight). Multiplying the number of monomers by their effective
volume gives an overall volume of the polymer chain as 15.675 nm3 (101 cm3/mol CHM*77
molecules = 12.914 nm3; 166.25 cm3/mol TEG*10 molecules = 2.7607 nm3). The particles’
diameter of 280 nm implies that the polymer chains are aggregating in a semi-random
manner rather than assembling into a well-defined micellar structure. The volume of a
single particle is 11,494,040 nm3, so there are approximately 733,272 chains per particle.
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If there are 1,600,000 particles per mg polymer, that would predict an average molecular
weight of each particle to be 0.625 ng/particle. Taking 733,272 chains*15,763 Da/chain
= 1.156*1010 Da per particle, or 1.9196*105 ng per particle. These numbers differ by 4
orders of magnitude. Factors that may explain these differences are a loss of polymer in the
process between the initial particle formation step and the measurement of the particles by
flow, the polymer chain packing may be smaller than the assumed linear conformation and
would increase the actual number of polymer chains per particle, and the assumed values































Figure 3.16: DLS sizing of particles. Particles were measured by dynamic light scattering
using a refractive index of 1.33 (water). Samples were measured 3 times for 1 min each.
Particles were measured after rotoevaporation of solvent (rotovap), after raising the pH to
initiate protein tethering (pH), and at 15, 30, 45, 60, 120 min, and overnight after adding
protein to the particles. The average of all the measurements was also calculated (Average).
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
Figure 3.17: SEM images of particles. Particle size was confirmed by scanning electron
microscopy.
Figure 3.18: Schematic of protein tethering to polymer particle surface. Primary amines
on the protein attack the carbonyl group, displacing the pNP and creating a stable peptide
bond with the polymer chain.
The schematic of the protein tethering chemistry is shown in Fig. 3.18. To calculate
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the theoretical maximum protein tethering on these particles, we determined the quantity
of pNP groups per mg of particles (Fig. 3.19). We added ethanolamine to a 1 mg/ml
particle solution and stirred for 30 min to fully remove all pNP groups from the particles.
Ethanolamine is ideal because it has a free primary amine and dramatically increases the pH
of a solution, which helps drive this spontaneous reaction. We then measured UV absorption
of the particle solution as compared to known amounts of pNP as well as unreacted polymer
solution. 150 µL (1 mg) of particles, with average diameter of 280 nm, released 0.88 nmol
pNP. Since each pNP represents a possible site for protein tethering, we can say that the
theoretical maximum protein per mg particles is 30,730 g/mol*0.88 nmol pNP, or 27 µg
protein/mg particles. The same amount of particles incubated with IL-1ra released only
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Figure 3.19: HPLC quantification of 4-nitrophenol (pNP) release from particles.
Ethanolamine released 0.88 nmol of pNP, while IL-1ra released only 0.788 nmol of pNP.
pNP standards were run at the same time for quantification purposes.
A macrophage cell line was incubated with polymer particles at a range of concentrations
(0, 0.1, 1, 10 mg/mL) to determine the cytotoxicity of these particles. The metabolic activity
of the cells was assayed by the MTT assay. Cells incubated up to 1 mg/mL polymer particles
maintained their metabolic activity; however, at 10 mg/mL, the cells had severely reduced































Figure 3.20: Copolymer particles have no significant effect on macrophage metabolic ac-
tivity at concentrations up to 1 mg/mL in vitro. Particles were incubated with RAW 264.7
macrophage cells at various concentrations to determine their effect on cellular metabolic
activity. The cells were serum-starved overnight prior to addition of particles. Cells were
incubated with particles for 6 h before assessing the metabolic activity by the colorimetric
MTT assay.
We then determined whether the particles could allow protein tethering to their sur-
face. Our polymer design incorporates a 4-nitrophenol group (pNP), which is displaced by
primary amines to form a peptide bond at slightly basic pH (>pH 7.4). To demonstrate
that protein is tethered to the nanoparticles, we made particles as described above, raised
the pH using sterile NaOH and added 1 mg of IL-1ra. The solution reacted for three hours,
and any unreacted pNP was quenched by adding 10 mg glycine and reacting for another
30 min. The remaining free protein was dialyzed away using 100 kDa dialysis membranes.
We lyophilyzed the particles and analyzed protein attachment by dot blot. Our particles
show strong IL-1ra antibody staining, indicating that IL-1ra was successfully tethered to
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the particles (Fig. 3.21).

Figure 3.21: Dot Blot for IL-1ra. IL-1ra-tethered particles, glycine-tethered particles, or
soluble IL-1ra were dried on nitrocellulose membranes and were probed with anti-IL-1ra





















Figure 3.22: Quantification of IL-1ra on particles by dot blot. IL-1ra-tethered par-
ticles showed significantly more protein binding than particles quenched with glycine
(Quenched) or particles quenched with glycine and exposed to IL-1ra (Quenched+IL-1ra).
* = p<0.0001.
We found that our BSA-tethered particles showed only background levels of fluorescence
(-5.27, s.e.m. = 0.620), while the IL-1ra-tethered particles bound approximately 500 ng IL-
1ra per mg of particles (487.46, s.e.m. = 2.098, p<0.0001) (Fig. 3.22).
3.5 Discussion
The amphiphilic block copolymer created in this work forms particles and allows protein
to be tethered to its surface. Compared to solid polymeric particles, such as PLGA, these
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particles provide a hydrophilic, “stealth” environment for the presentation of our anti-
inflammatory protein, IL-1ra. Additionally, most current polymer particles do not incorpo-
rate a protein tethering handle on the surface and would require reengineering the material
to allow for addition of a surface-bound targeting ligand. The release of pNP indicates
covalent tethering has occurred between the protein and the particle. This tethering moi-
ety is stable at neutral to slightly acidic pH and has a relatively slow decay rate (around
2 h) compared with that of the highly unstable EDC/NHS intermediate. The increased
reaction time is beneficial because it can increase the efficiency of reaction. These parti-
cles are non-cytotoxic up to 1 mg/mL concentration in cell culture, which is a generally
accepted phenomenon[130][131]. Many polymer systems show significant cytotoxic effects
at 10 mg/mL concentrations, as we saw for this system. Our particles showed excellent
tethering of IL-1ra (250 ng/mg particles) and had only background levels of signal on
albumin-tethered particles. This polymer particle system is easily modified to create larger
or smaller particles, based on the molecular weight of the block segments. This system
design could incorporate a hydrophobic small molecule drug in the particle’s core to cre-
ate a dual therapeutic strategy. We believe that this copolymer has wide applicability for
targeted therapeutic delivery in a wide range of disease states. This particle system could
use any protein or peptide of choice because the tethering moiety uses primary amines to
anchor the protein to the particle surface. However, our use of IL-1ra in this system has
broad application to diseases involving inflammation and/or inflammatory cells, such as
cancer and heart disease, because of the ubiquity of IL-1 in these systems.
Additionally, our particle technology has several advantages over the current state-of-
the-art polymer particles. First, the stability of the protein tethering moiety on our particles
allows for a higher efficiency tethering process compared to standard EDC-NHS tethering
chemistry (2 h vs. 10 min. half-life). Secondly, the submicron scale of our particles could
allow for better diffusion and retention within the joint space. The size also increased
the surface area-to-mass ratio, which increases the potential protein payload per mass of
polymer. Finally, our use of an anti-inflammatory protein as the targeting ligand increases
the specific targeting of our particles to synoviocytes and other inflammatory cells like
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macrophages. Current technologies for intra-articular drug delivery have focused on using
sulfate groups to localize particles within the cartilage ECM or phage-panned peptides that
bind to collagen II[292]. The ability to tether proteins to a polymer particle and maintain its
bioactivity represents a technological advance for protein-polymer therapeutics. Currently,
it is possible to encapsulate proteins within polymer particles, but the encapsulation process
or the material itself detrimentally affect the protein’s bioactivity. Attaching proteins to a
polymer particle can be as simple as activating existing carboxylic acid groups on the poly-
mer chain using the EDC-NHS ester reaction; however, this reaction requires there to be
carboxylic acids within the polymer chain, which is not always the case. The intermediate
ester complex is also highly unstable, resulting in relatively inefficient protein tethering in
aqueous solutions. Researchers have also synthesized polymer chains with biotin or strep-
tavidin pendant or terminal groups, but biotin-streptavidin can be immunogenic and is not
an ideal tethering solution for therapeutic use. Our technology incorporates a stable pNP
group on the end of the polymer chain that is significantly more stable than the EDC-NHS
tethering method and does not have the immunogenic concerns of the Biotin-Streptavidin
system. Both EDC-NHS and pNP technologies use primary amines located on the pro-
tein/peptide as the reactive handle; this reaction scheme is ubiquitous and has a varied
effect on the protein’s bioactivity. Although we did not measure total protein versus active
protein on our particles, we observed a significant amount of binding of our IL-1ra-tethered
particles by the IL-1 receptor, as well as the ability of IL-1ra-tethered particles to abrogate
IL-1β-induced signaling cascades (see Chapter 4). We expect that some of the protein ac-
tivity was affected by the tethering process, but we also assert that a significant enough
proportion of the activity was maintained to make this a therapeutically relevant technol-
ogy. Our technology varies from traditional protein-delivering particle systems because it
covalently tethers protein to the surface rather than encapsulating it for controlled solu-
ble release. Many therapeutic proteins act by binding to receptors and transducing signal
through the receptor’s cytoplasmic domains and do not need to be solubly released in order
to exert their effect; only proteins that must be internalized to affect their target should be
candidates for encapsulation. Finally, using IL-1ra to target these particles to inflammatory
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cells in addition to its inherent therapeutic effects should increase the effectiveness of thera-
peutic drugs that could be encapsulated within the particle core. By localizing particles to
the cells that help mediate osteoarthritis, drugs and proteins can be more directly delivered
to the appropriate target to increase the benefit of each protein molecule delivered.
3.6 Conclusion
These results establish a new amphiphilic block copolymer made by RAFT polymerization
methods that self-assembles into sub-micron scale particles. The polymer particles allow
efficient tethering of proteins to their surface via the 4-nitrophenol moiety. This polymer
system allows for modular protein attachment, variability in particle size, and potential




IN VITRO BIOLOGICAL CHARACTERIZATION OF
IL-1RA-TETHERED POLYMER PARTICLES
4.1 Summary
This work focused on characterizing the bioactivity of the IL-1ra-tethered particles in vitro.
We found that the IL-1 receptor binds to IL-1ra on the surface of our particles. Addition-
ally, IL-1ra-tethered particles are bound by synoviocytes in an IL-1-dependent manner. The
IL-1ra-tethered particles inhibit NF-κB activation in IL-1-responsive cells after IL-1 stim-
ulation. These experiments establish IL-1ra-tethered particles as a new way to target key
OA mediating cells and show that the IL-1ra-tethered particles have added benefit because
they also inhibit IL-1β-mediated signaling. This technology is useful because it establishes
a new way to target drug-delivering particles to inflammatory cells while simultaneously
acting as a therapeutic molecule. It has broader applicability due to its modular protein
tethering ability and its potential to deliver proteins to inflammatory cells of interest.
4.2 Introduction
An important goal of drug delivery strategies is to deliver proteins in a controlled manner
to the site or cells of interest[146]. Current polymer drug delivery particles have criti-
cal disadvantages. The hydrophobicity of many drug-delivering polymers (e.g., PLGA)
severely reduces or destroys the bioactivity of encapsulated proteins[148][190][215]. Lipo-
somal particles have a more protein-friendly environment, but are limited by their in vivo
instability[294][212]. Methods for delivering and retaining immunomodulatory proteins are
critical for improving current OA treatments, as well as other disease pathologies[73][109].
Researchers are actively looking for ways to increase protein retention and control its
release in the body. Current in vitro investigations include PEGylating native proteins for
systemic injection[142][141][371][372], and creating drug depots[305][7] and encapsulating
proteins in polymer particles or liposomes for local protein delivery [62][360][37]. Although
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these technologies have shown some progress in increasing protein half-life, all of them
reduce the protein bioactivity by at least 50%.
This work characterizes the in vitro behavior of the polymeric particle system created in
Aim 1. The protein tethering strategy allows IL-1ra protein to be tethered to the surface of
these particles. Once tethered, IL-1ra maintains its bioactivity and actively targets synovio-
cytes, cells crucial to the OA pathology. This binding happens in an IL-1receptor-dependent
manner. Furthermore, IL-1ra-tethered particles are able to inhibit IL-1β-induced NF-κB
activation. These studies show that this particle system has the potential to deliver IL-1ra
to arthritic joints and that it has potential for localizing/targeting drugs to inflammatory
cells of interest as a new way to target OA drug treatments.
4.3 Materials and Methods
4.3.1 Particle Preparation
Briefly, our block copolymer from Aim 1 was resuspended at a concentration of 40 mg/mL
in a 9:1 mixture of THF:DMF. 20 mg of polymer was added to a total volume of 2.5 mL
THF/DMF and was added to 50 mL of stirring PBS (0.01M, pH 6.0) at a rate of 20 mL/h
by syringe pump. Excess solvent was removed by rotary evaporation. The particles were
concentrated by centrifugation and were sonicated briefly to resuspend. The pH was raised
to 8.0 and protein (AF-488-IL1ra or AF-488-HD-BSA) was added. Particles were sized
using dynamic light scattering.
4.3.2 Fluorescent Protein Labeling
We labeled protein with Alexa Fluor 488 to visualize the particles during in vitro experi-
ments. Briefly, particles were made as described above. Protein (IL-1ra or Heat-Denatured
Bovine Serum Albumin (HD-BSA)) was reacted with Alexa Fluor 488 maleimide (Alexa
Fluor 488 C5-maleimide, #A10254, Invitrogen Corp., Carlsbad, CA) according to the man-
ufacturers instructions. There are 3 free solvent-accessible cysteines on IL-1ra that can
be fluorescently tagged[356], thereby avoiding the more prevalent primary amines (lysine
residues), allowing the protein to be fluorescently tagged before tethering it to particles, as
well as reducing the chance of altering the protein’s bioactivity. The resulting fluorescently
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tagged proteins are denoted AF-488-IL-1ra and AF-488-HD-BSA. For the confocal study,
AF-594 was used to fluorescently tag the IL-1ra (AF-594-IL-1ra). Protein-tethered particles
were stored in PBS solution at 4◦C until use.
4.3.3 IL-1ra-tethered Particles Bind To IL-1RI
350 ng of AF-488-IL-1ra (either soluble or tethered to particles) or an equivalent amount of
AF488-BSA-tethered particles (control) was incubated with 3 µL (1.5 µg) of recombinant
IL-1rI-Fc (#4101I, Symansis Cell Signaling Science, Auckland, NZ) for 2 h at room tem-
perature. Two µL of Protein A-conjugated magnetic beads (#21348, MagnaBind Protein
A Beads, Pierce, Rockford, IL) were then added and incubated at room temperature for 30
min. The particle solution was purified by magnetic column (MACS separation columns,
#130-042-901, Miltenyi Biotech, Bergisch Gladbach, Germany). The MACS column was
set on the magnetic stand and was prepared by washing with 2x 1 mL of MACS buffer (0.5%
BSA, 2 mM EDTA in PBS, pH 7.2). The particle solution was added to the column and
allowed to flow through. The column was washed with 5x 1 mL MACS buffer. The column
was then removed from the magnet and was placed over a flow cytometry tube. Three mL
of MACS buffer were used to elute the purified particles from the column. Binding was
analyzed by flow cytometry.
4.3.4 Synoviocyte Binding Experiments
The HIG-82 synoviocyte cell line was purchased from ATCC (CRL-1832, ATCC, Manassas,
VA). This cell line was originally derived from a female rabbit whose synoviocytes were
harvested and immortalized by Georgescu et al.[145][207]. Fibroblast-like synoviocytes play
a critical role in the pathology of OA by producing large amounts of inflammatory cytokines.
The cells were cultured in Ham’s F-12 supplemented with 10% heat-denatured fetal bovine
serum at 5% CO2, with a doubling time around 24 h. Cells were removed from culture
using 0.25% trypsin+0.5 mM EDTA. Cells were counted and plated at 2x105 cells/6-well.
After 6 hours of incubation, the media was replaced with serum-free media overnight. The
next day, particles were added to cells and incubated for 2 h at 37◦/5% CO2. Some samples
were incubated with 50 µg/mL IL-1β for 2 h to block available IL-1 receptors before adding
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particles.
HIG-82 synoviocyte cells were incubated with particles tethered with either AF-488-IL-
1ra or AF-488-HD-BSA. At 2 h post-addition of particles, we washed the cells with PBS
to remove unbound particles, and stained for cell nuclei with Hoechst dye. Samples were
analyzed by flow cytometry and confocal microscopy.
For the confocal samples, we plated HIG-82 cells on glass covers with 8-well divisions
(#155411, Lab-TekTMChambered Coverglass, Thermo Scientific, Rochester, NY) overnight.
The next morning, we added serum-free Ham’s F12 containing AF-594-IL-1ra-tethered par-
ticles or AF-488-HD-BSA-tethered particles. The cells were then incubated for 2 h at
37◦C/5% CO2. We washed the cells with PBS 3 times to remove unbound particles. We
then stained for cell nuclei using 1:10,000 dilution of Hoechst in PBS for 15 min. We imaged
the samples using confocal microscopy (particles: IL-1ra: AF594/red; BSA: AF488/green;
cell nuclei: Hoechst/blue).
For the flow cytometry samples, we plated HIG-82 cells on 12-well plates and serum
starved them overnight. We then blocked some of the cells with 50 µg/mL IL-1β for 2 h
prior to adding either IL-1ra or BSA-tethered particles to all wells. The cells were incubated
with the particles for an additional 2 h at 37◦C/5% CO2. We washed the cells with PBS 3
times to remove unbound particles and then removed the cells using 0.2 mL trypsin-EDTA
(0.25%), quenched with complete media. The cell suspensions were analyzed on an Accuri
C6 Flow Cytometer (BD Accuri Cytometers, Inc., Ann Arbor, MI).
4.3.5 Inhibition of IL-1β-Induced Inflammatory Signaling
We obtained NIH 3T3 cells stably transfected with an NF-κB-luciferase reporter con-
struct by Dr. van de Loo (Radboud University, Nijmegen, Netherlands)[315]. These IL-
1-responsive cells produce luciferase under control of an NF-κB-responsive promoter. The
produced luciferase will oxidize luciferin to produce oxyluciferin, producing luminescence
that can be measured by a plate reader.
NIH 3T3 NF-κB-luc cells were plated in 96-well plates at a density of 105 cells/mL (100
µL/well). Cells were allowed to adhere for 6 h before replacing the media with serum-free
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DMEM+1 mM sodium pyruvate overnight. The next morning, IL-1ra-tethered particles,
BSA-tethered particles, or soluble IL-1ra was added to each well (1 µg/mL IL-1ra or equiv-
alent amount of polymer for the BSA particles) and was incubated for 1 h. Then, 10 µL of
1 ng/mL IL-1β was added to each well to stimulate NF-κB activation (final concentration
of 0.1 ng/mL IL-1β). Cells were incubated with IL-1β for 6 h before washing 3 times with
PBS. Cells were then lysed with 20 µL of Passive Lysis Buffer (PLB, #E1941, Promega,
Madison, WI) for 20 min on a gentle vortexer. Lysate (20µL) was added to 100 µL of
Luciferase substrate in an opaque white 96-well plate. Luminescence was read using a plate
reader (HTS 7000 Plus, Perkin Elmer, Waltham, MA).
4.4 Results
We first tested whether IL-1ra retained its bioactivity when tethered to our particles. To
do this, we incubated labeled IL-1ra particles, BSA particles, or soluble IL-1ra with a
recombinant IL-1r-Fc. We then captured the IL-1rI using magnetic Protein A-conjugated
beads and evaluated the magnetic beads for labeled target protein (IL-1ra or BSA) by flow
cytometry. Our IL-1ra particles were bound significantly by the IL-1r, while BSA particles
had low levels of binding (Fig. 4.1). Similarly, IL-1ra particles that were not incubated
with IL-1rI-Fc showed minimal binding to the Protein A-magnetic beads.
67
                                
	 
      
      	         
                    
  
               !    " 	 #   
                 $         
  
            #    $    % 
 & "  
 '     (    
Figure 4.1: IL-1R binds to IL-1ra-tethered particles. Green fluorescent labeled IL-1ra-
tethered particles, BSA-tethered particles, or soluble IL-1ra were incubated with rhIL-1
receptor. IL-1 receptors were captured using Protein A-conjugated magnetic beads (n=3).
The beads were purified using a magnetic column system and were then analyzed by flow
cytometry (n=3). Blue, IL-1rI+IL-1ra-Particles (16.9%); Dark green, sol. IL-1ra (52.8%);
Orange, IL-1rI+BSA-particles (2.2%); Lime green, No IL-1rI+IL-1ra-Particles (2.6%); Red,
Magnetic Beads Only (0.9%).
We also showed that IL-1ra-tethered particles bind to synoviocytes, our target cell type,
by using a synoviocyte cell line (HIG-82). We incubated synoviocytes with IL-1ra particles
or BSA particles, and showed that the synoviocytes bound IL-1ra particles better than BSA
particles. We also demonstrated that the binding of our IL-1ra particles to synoviocytes was
IL-1r-mediated. Pre-incubating synoviocytes with IL-1β for 1 h abrogated the binding of IL-
1ra particles to the synoviocytes (Fig. 4.2). The ability to block IL-1ra-particle binding with
IL-1β confirms that the interaction between our particles and the synoviocytes is mediated
by IL-1 receptors. Furthermore, synoviocyte targeting in vitro shows proof of concept for
moving into an in vivo study of particle targeting and retention. Finally, although we
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have not tested the ability of our IL-1ra particles to regulate signaling in synoviocytes,
this result implies that IL-1ra-tethered particles have the potential to block IL-1β-induced
inflammatory signaling cascades.
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Figure 4.2: IL-1ra-Tethered Particles Are Bound by Synoviocytes: Flow Cytometry Anal-
ysis. A synoviocyte cell line (HIG-82) was incubated with fluorescently tagged IL-1ra-
tethered particles or fluorescently tagged BSA-tethered particles, with or without an IL-1β
pre-blocking step (n=1). Synoviocytes + IL-1ra-Particles (44.0%), Blue; Synoviocytes +
BSA-Particles (2.7%), Green; Synoviocytes + Pre-Block + IL-1ra-Particles, (2.8%), Orange;
Synoviocytes Only (0.1%), Red.
We also verified that our particles can bind cells of interest by confocal microscopy. HIG-
82 cells were incubated with IL-1ra particles or BSA particles for 1 h to allow binding. The
cells were then washed and counterstained with Hoechst before imaging them by confocal.
Samples incubated with IL-1ra particles had significantly higher colocalization of particles
(green) with cell nuclei (blue) than samples that received BSA particles (Fig. 4.3).
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Figure 4.3: IL-1ra-Tethered Particles Are Bound by Synoviocytes: Confocal Microscopy
Analysis (10 fields from 4 samples of each group were analyzed). Particles were incubated
with a synoviocyte cell line (HIG-82) for 2 h. Samples were rinsed three times with PBS
before imaging. IL-1ra-tethered particles, Red; BSA-tethered particles, Green; Nuclei, Blue.
To test whether our IL-1ra particles could inhibit IL-1β-mediated signaling cascades,
we used an IL-1-responsive fibroblast cell line, NIH3T3 stably expressing a construct for
luciferase driven by a NF-κB-responsive promoter. IL-1β is known to cause NF-κB acti-
vation as part of its signaling pathway[204]. We measured our IL-1ra-tethered particles’
effectiveness at blocking IL-1β-induced activation of NF-κB by pre-incubating NIH cells for
1 h with either soluble IL-1ra, IL-1ra-tethered particles, or BSA-tethered particles. When
these cells were then stimulated with IL-1β, only our IL-1ra-particles and the soluble IL-1ra
were able to inhibit NF-κB activation, whereas BSA-particles showed no effect on NF-κB
activity (Fig. 4.4). Remarkably, the IL-1ra-particles inhibited NF-κB activation to the same
levels as an equal amount of soluble IL-1ra, indicating that the tethered protein retains high




























Figure 4.4: IL-1ra-tethered particles reduce IL-1β-induced NF-κB activation as effectively
as soluble IL-1ra. NIH 3T3 fibroblasts with an NF-κB-responsive luciferase reporter con-
struct were pre-incubated for 1 h with 1 µg/mL IL-1ra-tethered particles, BSA-tethered
particles, or soluble IL-1ra before stimulating with 0.1 ng/mL IL-1β for 6 h. Both IL-1ra
particles and soluble IL-1ra inhibited NF-κB activation to comparable levels with unstim-
ulated controls (n=3). * = p<0.004
4.5 Discussion
Our IL-1ra-tethered polymer particles show retention of protein bioactivity and the ability
to target synoviocyte cells. The ability of these particles to modulate the activation of NF-
κB during IL-1β stimulation indicates that IL-1ra maintains its ability to block the IL-1
signaling pathway. By showing IL-1-mediated binding to synoviocytes, we posit that this
cell targeting strategy has potential to improve the effectiveness of drug delivery particles
for OA by localizing them via surface-tethered IL-1ra to important inflammatory mediator
cells. Although these IL-1ra-tethered particles bind to synoviocytes through IL-1ra, they
can also be internalized - either during or after initial interaction with the cells - and may
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cause inflammation or toxicity due to their size, although we do not forsee these effects
being prevalent at therapeutically relevant dosages. These IL-1ra-tethered particles also
have therapeutic benefit on their own, as shown by their ability to reduce NF-κB activation
in vitro. The modular nature of the particle’s protein tethering moiety suggests that this
system could harness the power of other important proteins in addition to IL-1ra for an
even more effective therapeutic strategy.
These results are superior to the elastin-like polypeptide-IL-1ra conjugate “depots (ELP-
IL1ra) from the Setton lab[305][36]. Although the retention rate of the ELP in vivo was
3.7 days, IL-1ra within the depot showed a 90% reduction in bioactivity in in vitro testing.
By presenting IL-1ra on the particle surface, we allow the synoviocytes easy access to the
protein and increase the potency of our particle system. Although effective protein delivery
from particles is still a challenge, this work adds to promising strategies, such as the phage-
panned peptide-targeted nanoparticles from the Hubbell lab[292] and hyaluronic acid-coated
PLGA particles[382] or chondroitin sulfate-coated gelatin particles[62]. These particles also
have additional benefit because they inhibit IL-1β-induced signaling in addition to their
targeting function.
4.6 Conclusions
This work assessed the in vitro bioactivity and targeting behavior of IL-1ra-tethered par-
ticles. We found that IL-1ra tethered to our polymer particles was still able to be bound
by the IL-1RI. Furthermore, IL-1ra-tethered particles effectively targeted a synoviocyte cell
line in vitro in an IL-1β-dependent manner. Finally, these IL-1ra-tethered particles can
modulate IL-1β-mediated NF-κB activation in a reporter cell line. These results show that
these IL-1ra-tethered particles have the potential to effectively deliver active IL-1ra to key
inflammatory cells in vivo and can target synoviocytes, a key mediator cell of osteoarthritis.
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CHAPTER V
IN VIVO EVALUATION OF IL-1RA-TETHERED PARTICLE
RETENTION IN THE HEALTHY RAT JOINT
5.1 Summary
Current intra-articular drug delivery technologies lack specific targeting strategies and suffer
from rapid clearance from the joint space. Specific targeting and localization of drug delivery
particles could improve the effectiveness of these drug-delivering particles. Our work used
in vivo near-IR imaging to show that IL-1ra-tethered polymeric particles have increased
retention in the intra-articular joint space in rats. We demonstrate that this new IL-1ra-
targeted particle system has the potential to improve retention of particles in the joint
space. Moreover, this new particle system has no adverse effect on the cartilage tissue. We
also demonstrate that in vivo imaging can be used for evaluating intra-articular protein
delivery. These results provide evidence that these particles prolong the retention time of
IL-1ra in the intra-articular space.
5.2 Introduction
Intra-articular drug delivery is the most direct route for administering drugs and proteins
for arthritis and other joint disorders and conditions. Localized delivery can avoid prob-
lems such as systemic toxicity, biological degradation, and biodistribution issues, and can
also reduce the total amount of drug used in each treatment. The synovial membrane sur-
rounding the intra-articular joint space creates a compartment that can retain biomolecules
larger than 100 kDa[271]. However, most small molecule drugs and proteins are under this
cut-off value and are thus cleared quickly from the joint space. Current technologies for
treating OA in vivo show limitations. Bolus injections of protein get cleared from the joint
within a few hours of delivery[129][74][83]. Most polymer particles are limited to delivering
hydrophobic small molecule drugs. Drug-delivering particles, made of such materials as
PLGA, could exacerbate inflammation by producing acidic degradation products. Acidic
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environments are known to stimulate inflammatory reactions in the body[96][161][164]. Par-
ticles that lack specific targeting moieties have also been cleared relatively quickly from the
joint, depending on the size of the particle itself[48][219][220]. Gene therapy-based protein
expression is promising for extended therapeutic delivery of proteins to an area; however,
protein expression declines over time and can be resistant to reinjection of the same deliv-
ery vehicle, essentially negating long-term benefits of this technology[158][21]. Gene therapy
also suffers from severe safety concerns, due to side effects, risk vs. benefit trade-offs, and
public perception.
Our technology created a non-toxic hydrated particle that retained bioactive protein
in vivo in a rat knee joint for up to 14 days. Tethering the protein to the particle car-
rier increases its retention half-life by three-fold compared to soluble protein, potentially
increasing its ability to effect changes in this disease state. The particles do not cause dam-
age to native healthy cartilage tissue. This strategy increases the retention time of IL-1ra
in the intra-articular space. By presenting multiple IL-1ra ligands on the particle surface,
we can significantly increase the local concentration of IL-1ra at the cell surface and can
take advantage of the “multi-valency effect of nanoscale ligand presentation.
5.3 Materials and Methods
5.3.1 Fluorescent Protein Labeling
We labeled IL-1ra with Alexa Fluor 750 prior to tethering it on the particles so we could
visualize the retention of IL-1ra-particles and soluble IL-1ra in the joint by IVIS imaging.
Briefly, particles were made as previously described (Chapter 3). IL-1ra was reacted with
Alexa Fluor 750 maleimide (Alexa Fluor 750 C5-maleimide, #A30459, Invitrogen Corp.,
Carlsbad, CA) or DyLight 650 maleimide (#62295, Pierce, Rockford, IL). There are 3 free
solvent-accessible cysteines on IL-1ra that can be fluorescently tagged, thereby avoiding the
more prevalent primary amines (lysine residues), allowing the protein to be fluorescently
tagged before tethering it to particles, as well as reducing the chance of altering the pro-
tein’s bioactivity[356]. The AF-650-IL-1ra-tethered particles were used to evaluate particle
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targeting and localization within the intra-articular joint space. Particles were made as dis-
cussed previously and were lyophilized prior to use. Particles were resuspended in distilled
water on the day of surgery.
5.3.2 Animal model
Male Lewis rats (10-12 week old) received 50 µL of either particles or soluble IL-1ra protein
(5 µg IL-1ra) via intra-articular injection to the right knee joint space, while the left knee re-
ceived the same volume of saline and served as contralateral controls. Lewis rats were chosen
for consistency with established models of OA in the Guldberg lab at Georgia Tech (medial
meniscal transection (MMT), medial colateral ligament transection (MCLT)). Transection
of the MCL and meniscus causes joint instability and is known to lead to osteoarthritis in
animal models.
Rats were deeply anesthetized with isofluorane. The hair was removed from the hind
limb surgical sites and the skin was cleaned with alcohol. Rats were positioned on their
back, and the leg was flexed to 90◦ at the knee. Particles were injected into the intra-
articular space by palpating the patellar ligament below the patella and injecting the particle
solution through the infrapatellar ligament using a sterile 27-gage 0.5” needle. Rats were
fully ambulatory following recovery and all injections were well tolerated. At the end point
of the study, rats were euthanized using CO2 asphyxiation.
5.3.3 IVIS Imaging for Particle Retention
Rats were anesthetized using isofluorane. Animals receiving IR-750-IL-1ra-tethered par-
ticles or soluble 750-labelled IL-1ra were scanned in an IVIS imaging system (700 Series,
Caliper Xenogen IVIS Lumina, Caliper Life Sciences, Hopkinton, MA). The excitation and
emission detectors were set at 745 nm and 780 nm. Both hind limbs were scanned to control
for background tissue fluorescence. The total photons within a fixed region centered on the
knee were measured and were analyzed with non-linear regression models. The data from
each animal were normalized to their individual day 0 values. The normalized data were
fitted using a one-phase exponential decay with the characteristic equation of:
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Y = (Yo - NS)*e
(−K∗X) - NS
, where Yo is the intersection of the best-fit line with the Y-axis, NS is the non-specific
binding value (i.e., the assymptotic y-value), X is time, and K is inversely proportional
to the half-life. The 95% confidence interval for the half-lives are [1.708 - 12.62] (IL-1ra
Particles) and [0.7856 - 1.244] (Soluble IL-1ra).
5.3.4 EPIC-µCT
EPIC-µCT has been established as an effective, non-destructive technique for imaging
cartilage[261][367][275]. EPIC-µCT uses charged contrast agents to quantify the GAGs
in the cartilage. Negatively charged dyes are excluded from healthy cartilage tissue due to
the presence of negatively charged GAG chains in the tissue. A lack of dye indicates healthy
cartilage tissue. Rat knees were evaluated by µ-CT for cartilage integrity and thickness.
Briefly, the explanted rat knee was immersed in 2 mL of 30% Hexabrix in PBS at 37◦C for
30 min. The knee was patted dry on a paper towel to remove excess Hexabrix and then
was placed in a 16 mm diameter CT tube and was inserted into the CT machine (µCT
40, Scanco Medical, Bassersdorf, Switzerland). Trabecular thickness and bone volume mea-
surement settings in the Scanco software were thresholded to include only cartilage tissue
and were used as the primary outcome measures for µ-CT evaluation (cartilage thickness
and total cartilage volume, respectively).
The knee tissue was evaluated using the following settings: 45 kVp, 176 µA, 200 ms inte-
gration time, a 1024x1024 pixel matrix (Medium resolution), and a 16 µm voxel size. Each
knee scan was first re-formatted to vertical slices, contoured by hand and then evaluated for
cartilage thickness and attenuation using the following program. Reconstructions were done
using sigma = 1, support = 1, lower = 75, upper = 220, and unit = 6. The evaluation script
was the uct evaluation v6.com; the IPL support script was IPLV6 Trabecular bone.com,
and the user script was uct evaluation v6 PRSUCT.com.
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5.4 Results
We have previously used near-IR dyes for in vivo imaging to track and quantify protein
retention or release[274][45]. These dyes allow for non-invasive, repeated imaging of ani-
mals without the expense and hazards of radiolabelling. Rats that received IL-1ra-particles
showed significant fluorescent signal for up to 14 days, compared to those receiving solu-
ble protein (Figs. 5.4, 5.5). For instance, IL-1ra-particles had 20% retention at 10 days,
whereas over 80% of the soluble IL-1ra had cleared by day 3. IL-1ra-particles had a half-life
in the joint of 3 days, while the soluble protein was retained for less than 1 day. The differ-
ence between the retention of IL-1ra-particles and soluble IL-1ra was statistically significant
(p<0.0001). These results show that IL-1ra-tethered particles have better intra-articular
retention compared to soluble IL-1ra and are compatible with the cartilage tissue environ-
ment.
EPIC-µCT did not detect any adverse effects from our IL-1ra-particle system on the
cartilage tissue compared to the contralateral controls; however, this technique may not
be sensitive enough to detect initial changes to the tissue (Fig. 5.1). We are processing
the tissue samples to confirm this finding by standard histological analysis. There was no
difference in the EPIC-µCT-measured cartilage thicknesses or the tissue attenuation among
all groups (IL-1ra-Particles, Sol. IL-1ra, Contralateral Controls) (Fig. 5.2, 5.3). The
attenuation value is a measure of the sulfated glyocsaminoglycans in the cartilage tissue
and provides an indirect assessment of the cartilage extracellular matrix composition.
IL-1ra-Particles Soluble IL-1ra Control
Medial Lateral Medial Lateral Medial Lateral
  
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Figure 5.1: Superior View of Tibial Articular Cartilage Surface. Reconstructions of Car-
tilage from EPIC-µCT Analysis. Visual comparisons confirm that there are no gross dif-
ferences between cartilage receiving IL-1ra-particles versus soluble IL-1ra or PBS. Medial
side, Left; Lateral side, Right.
We are currently processing the tissue for histological analysis to ensure that there are
no morphological or phenotypical changes to the cartilage tissue caused by our particles. We
also have tissue samples in preparation to look for particle localization within the synovial
joint space. However, these results may not be completed by the time of the thesis defense,










Figure 5.2: No differences in cartilage thickness were detected by EPIC-µCT between IL-
1ra-particles and soluble IL-1ra groups. X-axis, animal treatment groups; Y-axis, trabecular
thickness, as calculated from EPIC-µCT reconstructions. Sol. Ctrl, contralateral control
knees from rats receiving soluble IL-1ra; Sol. IL-1ra, knees receiving soluble IL-1ra; IL-
1ra particles, knees receiving IL-1ra-tethered particles; Particle Ctrl, contralateral control
knees from rats receiving IL-1ra-tethered particles. Control knees were injected with an






Figure 5.3: EPIC-µCT does not detect any differences in cartilage attenuation between
groups receiving IL-1ra particles or soluble IL-1ra. X-axis, animal treatment groups; Y-
axis, Bone Volume, as calculated from EPIC-µCT reconstructions. Sol. Ctrl, contralateral
control knees from rats receiving soluble IL-1ra; Sol. IL-1ra, knees receiving soluble IL-
1ra; IL-1ra particles, knees receiving IL-1ra-tethered particles; Particle Ctrl, contralateral
control knees from rats receiving IL-1ra-tethered particles. Control knees were injected with
an equal volume of PBS at the same time as the particles.
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IL-1ra-Particles


















Figure 5.4: IL-1ra-Particles are retained longer than soluble IL-1ra in the intra-articular
joint space. IL-1ra was tagged with a near infrared (IR) dye (AF750-maleimide) prior to
tethering IL-1ra to particles. IL-1ra-tethered particles or soluble IL-1ra was injected into
the right knee of 8-10 wk old rats. Left knees were injected with saline at the same time.
Total IR photon counts within a fixed area centered over the rat’s knee were measured by
IVIS imaging over 14 days.
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Figure 5.5: IL1ra-particles show attenuated signal compared to soluble IL1ra (IL-1ra-
Particles, n = 6; soluble IL-1ra, n = 5). Infrared (IR) photon counts were measured in each
rat over 14 days by an IVIS imaging system. All data were normalized by individual rat to
its Day 0 photon count. The photon’s signal decay was fit using a one-phase exponential
decay model. IC50 = 3.01 days for IL-1ra-Particles vs. 0.96 days for soluble IL-1ra.
5.5 Discussion
We interrogated whether tethering IL-1ra to particles could increase the residence time
in the intra-articular joint space. Healthy rat knee joints retained detectable amounts of
IL-1ra-tethered particles for up to 14 days. Previous work suggested that microparticles
generally stay longer in the joint than soluble proteins[23][179]. PLGA particles (300-
490 nm) with encapsulated betamethasone showed significant anti-inflammatory effect for
up to 21 days in Antigen-Induced Arthritic rabbit joints. The goal of this work was to
two-fold: one goal was to determine whether this new particle system could increase the
retention of IL-1ra compared to a bolus dose of soluble IL-1ra; secondly, we wanted to
ensure that this polymer particle system did not cause damage to the cartilage tissue. Part
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of the concern with current hydrophobic polymer particles is that their mechanical property
mismatch could act as wear particles in the soft cartilage tissue environment. Our material
incorporates an oligo(ethylene glycol) chain, which should provide a hydrated corona around
the particle. However, we wanted to ensure that this particle system had no adverse effects.
The cartilage tissue surface and thickness were the same across groups, regardless of the
treatment they received.
This technology is comparable in half-life to the fusion protein system developed by Set-
ton et al.[36][305]. Their elastin-like polypeptide gel had a half-life of 3.7 days in vivo, while
ours had a half-life of 3.01 days. However, a fusion protein of IL-1ra and the ELP showed
a 90% loss of IL-1ra bioactivity in vitro[305]. Further characterization of this system is
necessary to establish the effective bioactivity of tethered IL-1ra for better comparison with
the Setton technology; however, since we are not encapsulating IL-1ra within a hydrogel-like
system, the bioactivity of our IL-1ra particles should be much higher than the ELP-IL-1ra
system. Additionally, although our technology increased IL-1ra half-life in the joint, 3 days
may not be long enough to substantially affect OA disease progression. Allen et al. showed
that the IL-1ra-ELP technology, which has a 3 day half-life in the joint as well, reduced the
severity of cartilage destruction in an IL-1β-induced model of arthritis; however, this model
may not be fully representative of a diseased OA joint and may oversell the effectiveness of
their ELP-based system. By increasing the particle half-life by optimizing particle size, we
can maximize the therapeutic benefit of IL-1ra-tethered particles.
Other attempts to increase protein half-life, such as PEGylation, only moderately in-
creased the systemic residence time of the proteins but also negatively affected the proteins
bioactivity[371][141][142]. Other intra-articular drug delivery systems have shown a range
of retention times. Radiolabeled liposomes with Dex encapsulated were delivered to healthy
rabbit joints and showed 36% retention compared to 2% of free Dex remaining at 24 h[48].
However, other liposomal drug formulations have shown intra-articular half-lives up to 134
h[109]. PLGA microparticles effectively reduced joint swelling for up to 21 days in an
antigen-induced arthritic rabbit model[178], although no direct measurement of particle
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half-life was assessed. Using a nearIR dye-labeled protein rather than radiolabeled pro-
tein to assess the residence time and effectiveness of our therapy has several advantages.
First, nearIR dyes require no special handling or processing equipment, while radiolabeling
requires careful handling procedures to avoid contamination. Secondly, the nearIR dye is
stable over time; the radiolabeled signal decays over time and could affect the accurate
detection during the course of an experiment. Finally, biodistribution is easily assessed by
merely dissecting and imaging tissue in a nearIR imager. The same assessment is costly
and technically involved[107].
5.6 Conclusion
This work tested the in vivo behavior of our IL-1ra-tethered particle system compared with
soluble protein. Our particles increased the half-life of IL-1ra in a healthy rat knee joint
3-fold (3.08 days vs. 0.96 days) compared to a bolus injection of soluble IL-1ra. This
new polymer particle system showed no adverse effects on the cartilage tissue morphology
by EPIC-µCT analysis. This study shows that IL-1ra-tethered particles can increase the
retention of therapeutics in the intra-articular joint space. Further analysis is ongoing to
assess whether the IL-1ra-tethered particles are localizing to the synovial cells within the
joint space and to ensure that the particle-receiving joint tissue morphology is comparable




The field of biomaterials had made significant progress toward creating targeted drug de-
livery particles for a wide array of applications. However, current technologies still lack a
robust strategy for controlled delivery of proteins. In this thesis, we created a new way of
delivering protein for targeting OA treatment by taking advantage of the signaling mecha-
nism of IL-1ra, a key protein antagonist in OA. IL-1ra acts as an IL-1 antagonist by binding
to the IL-1 receptor without inducing receptor-protein internalization or cytoplasmic signal-
ing. We created a new polymer particle system that presents IL-1ra on the particle surface
to increase its retention time in the joint space. We characterized this protein-particle sys-
tem by chemical analysis, and in in vitro and in vivo settings. This work was divided into
three specific aims.
Our first goal was to engineer a block copolymer that could form submicron-scale parti-
cles to deliver IL-1ra in a controlled manner. We included a stable protein-tethering moiety,
4-nitrophenol, that remained accessible on the surface of the particles after assembly. In
chapter 3, we showed that we successfully designed a block copolymer with a hydrophilic
monomer (TEGM) segment paired with a hydrophobic monomer (CHM) segment. We
were then able to synthesize this copolymer and characterize its ability to form particles
and tether IL-1ra to the particle surface. This polymer system has built-in modularity to
allow for variation in particle size, choice of protein, and ability to deliver a drug and pro-
tein simultaneously. The size of each segment of the block copolymer can be increased or
decreased by varying the molar ratio of monomers to µRAFT agent. The overall molecular
weight of the polymer can also be increased in the same way. The size of the hydrophobic
segment of the block copolymer could be increased to adjust the drug-carrying capacity or
to increase the particle stability.
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We then characterized the in vitro behavior of our IL-1ra-tethered particles by show-
ing that IL-1ra maintains its bioactivity after tethering it to the particle surface, that it
binds to our cells of interest, synoviocytes, in an IL-1-dependent manner, and that IL-1ra-
tethered particles can inhibit NF-κB activation after an IL-1β insult. The first study took
IL-1ra-tethered particles and incubated them with a recombinant IL-1R-Fc protein. IL-
1ra-tethered particles were bound by the IL-1r in significantly higher number compared to
BSA-tethered particles (11.9% vs. 1.6% BSA-particles), showing that the IL-1ra maintains
its ability to bind the IL-1R and suggesting that its bioactivity is maintained. The sec-
ond study then looked for IL-1ra-particles to specifically bind to synoviocytes, our target
cell of interest in OA. When synoviocytes were incubated with IL-1ra-tethered particles,
they showed increased IL-1ra-particle binding (44.0% vs. 2.8%) compared to particles pre-
senting a non-targeting protein. Importantly, this binding was abrogated by pre-blocking
the cells with IL-1β (44.0% vs. 2.7%), demonstrating that the IL-1ra-particles target the
IL-1 receptor in synoviocytes. When we stimulated IL-1-responsive cells with IL-1β, our
IL-1ra-tethered particles reduced IL-1β-initiated NF-κB activation, measured by NF-κB-
induced luciferase expression, as much as the same dose of soluble IL-1ra did. Both of these
treatments reduced NF-κB activation to the same level as unstimulated controls.
Finally, we examined the retention and effect of IL-1ra-tethered particles in healthy
rat knee joints. Our IL-1ra-tethered particles extended the half-life of IR-labeled IL-1ra
by three-fold compared to soluble IL-1ra. Additionally, the particles did not cause any
detectable wear damage to the cartilage tissue. Full histological analysis of the tissue is
ongoing, as is analysis to look at particle targeting within the joint space. We expect that
the histology will show no differences between healthy control tissue and tissue that received
IL-1ra particles.
In summary, this thesis project engineered and characterized a new polymeric drug
delivery particle system for delivering IL-1ra, as outlined in the Specific Aims. The outcomes
of this project were as follows: First, we developed a new amphiphilic block copolymer using
RAFT polymerization and verified that it formed particles on our desired size scale. We
also verified that this polymer particle tethered proteins to its surface under mild reaction
85
conditions. The modular nature of this material’s chemistry allows for it to be used in
a range of different applications by varying the tethered surface protein. Secondly, we
characterized the behavior of IL-1ra-tethered particles in multiple in vitro tests. We ensured
that tethered IL-1ra retained its bioactivity, that IL-1ra-particles targeted a synoviocyte
cell line in an IL-1-dependent manner, and that IL-1ra-tethered particles inhibited IL-
1β-induced activation of NF-κB. Finally, we examined particle retention in healthy rat
knee joints over 14 days. IL-1ra-tethered particles had significantly longer half-life in the
intra-articular joint space than soluble IL-1ra protein. These particles did not cause any
detectable wear damage to the cartilage tissue, as assessed by EPIC-µCT.
Overall, this project created and characterized a new modular polymer particle system
that can deliver IL-1ra in a targeted fashion for treating osteoarthritis. This IL-1ra-based
technology shows promise for not only localizing particles to inflammatory cells, but also
for modulating the associated inflammatory cascades. This IL-1ra particle system shows
promise for treating OA-induced inflammation and should be evaluated in a representative
in vivo model of osteoarthritis, such as the ACLT or MMT/MCLT model. Because of the
particle size, only 2-3 cells can bind each particle simultaneously, reducing how much of the
tethered IL-1ra is actually available for binding to receptors on the cell surface. Optimizing
the size of the particle could increase the number of cells that can bind each particle for
more effective, long-lasting therapeutic effectiveness. Furthermore, the quantity of IL-1ra
that needs to be delivered to counteract chronic IL-1β during OA may require multiple
injections or greater quantities of particles than is safe or possible. Due to these limitations,
this technology would probably be most effective at slowing or preventing OA progression
if it is delivered within the first week after an acute joint injury. The rationale for this
timing is to avoid the immediate inflammation that happens after an injury (approximately
the first 48 h) but to start inhibiting the onset of chronic inflammation. Additionally, this
strategy would be best paired with encapsulated clodronate within the particles to reduce
the number of macrophages in the area and thus also reduce the amount of secreted IL-1β in
the joint space. Although soluble IL-1ra has been effective in the short term at slowing the
onset of OA damage, OA pathology involves more than just IL-1. Pairing this IL-1ra-based
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targeting/therapeutic particle strategy with other anti-cytokine proteins and drugs should
cooperatively enhance the action of IL-1ra and the other delivered agents.
As mentioned above, the particles should be evaluated for drug encapsulation and re-
lease of steroidal or other anti-inflammatory drugs together with surface-tethered IL-1ra.
The work here advances the use of block copolymer particles for protein delivery. Our am-
phiphilic block copolymer particles incorporate the hydrophobic drug-encapsulating prop-
erties of PLGA with the “stealth nature of PEG particles to form a hybrid system. Current
drug delivery systems generally lack a robust strategy to include targeting peptides or pro-
teins. By incorporating a stable protein-tethering moiety on the particle surface, we provide
an easy way to add targeting and/or therapeutic proteins to a basic drug delivery particle




The first step in extending this work is to test the effectiveness of IL-1ra-tethered particles
in a relevant OA model. We did preliminary studies using the MIA-induced OA model
in rats; however, we saw no improvement in joint phenotype or cartilage degradation in
rats receiving our IL-1ra-particles or soluble IL-1ra protein. We expected that at least the
soluble protein would show some improvements at 14 days post-treatment, which led us
to conclude that the MIA model of osteoarthritis does not create a cytokine environment
analogous to that of natural OA. These results are not entirely unexpected because we were
unable to find any mention in the literature of using IL-1ra to ameliorate MIA-induced OA
in rats. Only two studies used intra-articular injections of IL-1ra in rats, one in an IL-1β-
induced model [7] and the other in a collagen-induced arthritis model[29]. Taking these
facts and our results as a whole, we believe that using a different model of OA, such as the
ACLT or MMT/MCLT model, are more representative of natural OA and will produce a
cytokine environment in the joint that is similar to that found in human OA. The ACLT
and MMT/MCLT models do take longer to develop an arthritic phenotype, so they are at a
disadvantage compared with the near-immediate effects of MIA-induced arthritis. However,
when testing cytokine-based treatments, such as our IL-1ra-tethered particles, it is crucial
to have the most representative and accurate cytokine environment in the animal model to
replicate the disease and evaluate the potential effectiveness of the technology.
Another future strategy would be to test out other proteins, specifically cytokines, that
are relevant to OA. Our primary cytokine of interest for OA inflammation was IL-1β.
However other cytokines play crucial roles in this complex disease state. One of those,
TNF-α, exhibits signs of redundancy with IL-1. Researchers have tested soluble TNF-RI
for treating OA[350]. Although administering TNF-RI alone was not sufficient to improve
OA symptoms, IL-1ra and TNF-RI together reduced synovitis and decreased the cartilage
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damage in a rabbit model of OA. The modularity of our particle technology could allow
the delivery of TNF-RI and IL-1ra simultaneously. TGF-β also shows abnormal patterns
of receptor expression during OA and the aging process[342]. Adding exogenous TGF-β or
a TGF-β receptor antagonist could be an alternate strategy for modulating OA inflamma-
tion. However, the exact levels of TGF-β being delivered is crucial to its success because
overexpression of TGF-β also leads to negative effects, such as joint fibrosis and osteophyte
formation[18][342]. The final protein factor that warrants immediate consideration is IGF-
1[249]. Its role in upregulating levels of soluble IL-1RII could provide a natural method of
creating an IL-1β sink in the OA joint space.
This thesis work was limited to characterizing the particles’ ability to deliver proteins
on its surface. However, the polymer was originally conceptualized to include hydrophobic
drugs in its core. We believe that adding small hydrophobic drugs, such as dexametha-
sone or clodronate, to the core of our targeted particles could also improve its efficacy by
localizing the drug release to some of the most crucial cells in this disease etiology. Small
molecule drugs can inhibit and/or target pathways that may synergize with IL-1ra’s anti-
inflammatory effect but also can exert their own unique effects as well. Drugs would release
either by diffusion and/or by particle disaggregation to release its payload. These particles
could also incorporate MMP inhibitors, imaging agents for inflammation, and siRNA to
inhibit inflammatory pathways or to influence the macrophage/synoviocyte phenotype in
the joint. Combining drugs or small molecule biomolecules could act synergistically with
our IL-1ra and other surface-tethered proteins to better address the complex OA pathology.
The protein tethering chemistry could also be altered to address any effects on protein
bioactivity that are caused by tethering protein via primary amines. Finding more selective
protein tethering chemistries (e.g., maleimides/free cysteines) that interfere less with a
protein’s bioactivity could be used as an alternative strategy. Proteins could also be attached
using enzyme-cleavable sequences rather than covalent linkages to allow protein release and
internalization.
Although we chose a sub-micron-scale particle in this work, we could explore a variety
of particle sizes for optimal treatment. By increasing the particle size, we reduce the chance
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of fast clearance by the synovial fluid; however, increasing the particle size reduces the total
surface area available for protein tethering and can affect the particles’ diffusion through
the cartilage tissue and its mobility in the joint. The best compromise between particle
size, clearance rate, and deliverable protein quantity must be found by trial and error.
The block copolymer could also be altered to improve its “stealth” characteristics. Al-
though our polymer used an oligoethylene derivative, the fully carbon backbone of the
copolymer is hydrophobic and could cause issues, especially in vivo. We could use a larger
pendant poly(ethylene glycol) (PEG) chain to help mask the backbone or we could find a
way to use a PEG chain as the main chain of the hydrophilic block copolymer. Both of
these could improve the protein-resistant particle shell.
Particle stability in serum and in vivo were not characterized in this work. If the stability
of the polymer particles is an issue in its effectiveness, we could increase the particles’
stability by adding functionalities to cross-link the core. Previous work has shown that
cross-linking increases particle residence time and half-life[376].
In addition to its application in OA, our IL-1ra-tethered particles have possible appli-
cations for other diseases, such as cancer and heart disease. IL-1 and macrophages play
a crucial role in the neovascularization process in tumors. Targeting macrophages via IL-
1ra could interfere with the pro-angiogenic signaling and could also deliver drugs to cause
the macrophages to apoptose (clodronate, others), thus eliminating the tumors support
network[213]. IL-1ra-tethered particles could also be used to deliver pro-angiogenic or anti-
inflammatory drugs to the heart after myocardial infarction (MI) (heart attack). IL-1 is
known to play a key role in the overwhelming inflammatory/fibrotic response after MIs.
IL-1ra could help push the macrophages toward a more M2-like (wound healing) pheno-
type and could help improve patient outcomes by reducing inflammation and increasing
the hearts contractility. Finally, IL-1ra is known to support islet survival in vitro. These
particles could be co-injected during an islet transplant via hepatic portal vein injection
or could serve as a support system within an encapsulated islet system, such as the PEG
hydrogel system established in the Garćıa laboratory.
This particle system has an enormous breadth of possible applications when you consider
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varying the targeting/therapeutic proteins on the particle surface. Although IL-1ra is widely
applicable and useful, there is a host of applications that would benefit from targeted
drug/protein/siRNA/DNA delivery. This polymer particle technology could be developed
for cancer therapy and cardiac drug delivery, as well as for in vitro applications, like localized





We obtained the original plasmid containing the human IL-1ra sequence[111] from Dr.
Michael Smith (University of Virginia) (Fig. A.1). We grew up the bacteria and sequenced
its DNA to verify its fidelity. We then designed PCR primers to amplify the gene sequence
(see Table A.1), while adding HindIII restriction enzyme sequences on both ends of the
PCR product (Table A.1). After digesting the PCR product and the backbone vector
Xa-3 biotinylation vector (PinPoint Xa-3 Vector, #V206A, Promega Corp., Madison, WI)
with HindIII and/or CIP treatment (1 h) for 3 h at 37◦C, we ran the digested products
on a 1.2% agarose gel in TAE buffer, extracted the products using a gel extraction kit
(QIAquick, #28704, Qiagen, Valencia, CA), and ligated the reaction mixtures at room
temperature overnight. We then transduced chemically competent BL21 E. coli bacteria
with the various reaction mixtures and plated the transformed bacteria on Amp-LB agar
plates overnight. We selected 6 colonies from each successful reaction and grew them up
overnight in 5 mL cultures with ampicillin. We extracted and digested the cultures’ DNA
with HindIII (or KpnI as a directional control). We found at least 5 clones that had
the IL-1ra sequence in the correct orientation (Fig. A.2). We sent those 5 sets of DNA for
sequencing and chose one of the confirmed positive clones as our IL-1ra-expressing construct
(see subsection: sequencing results). We then transduced chemically competent JM109 E.
coli cells with the IL-1ra construct in order to efficiently produce recombinant protein and
made a glycerol stock of the JM109/IL-1ra bacteria for future use.
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Figure A.1: Original IL-1ra construct from Dr. M. Smith (Eisenberg+ 1990)
A.1.1 Digestion Products
IL-1ra has a KpnI site that cleaves at #149 out of #475 bp in the IL-1ra sequence. There
is also a KpnI cleavage site on the Xa-3 backbone, 12 bp past the HindIII terminus of the
IL-1ra sequence. Cutting the construct with HindIII should result in the Xa-3 backbone
(3284 bp) and the IL-1ra insert (475 bp). Digesting with KpnI in the correct orientation
should result in a “backbone” of 3433 bp and an IL-1ra insert of 338 bp. However, if the
IL1ra insert is inserted backward, the digest products will be 3610 bp and 149 bp.
HindIII: 475 bp/3284 bp KpnI: Correct Orientation: 338 bp/3433 bp KpnI: Incorrect
Orientation: 149 bp/3610 bp
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Table A.1: Cloning Primers
Verification Primers*
Primer Name Primer Location Primer Sequence
pRSET5a fwd1 #2824 -#14 on pRSET back-
bone
5-TAA TGC AGG ATC TCG ATC
CCG C-3
pRSET5a fwd2 #179-#205 5-CAA CCA ACT AGT TGC TGG
ATA CTT GCA 3
pRSET5a fwd3 #281-#302 5-TGG AGG GAA GAT GTG CCT
GTC C-3
pRSET5a rev Reverse complement of #314-
#335
5-GCT GGA GTC TGG TCT CAT
CAC C-3
Amplification Primers**
Primer Name Primer Location Primer Sequence
IL-1ra HindIII
fwd 9907
#394-#426 5-CAA GAG AAG CTT(Hind)




Reverse complement of #849-
#879
5-GGA CTA AAG CTT(Hind)
TTA TCC CTA CTA CTC GTC
CTC CTG G-3
Sequencing Primers**
Primer Name Primer Location Primer Sequence
XA3 backbone
seq fwd
#196-#211 5-GTC TCC AAG ATC CTC GTG
AAG G-3
Reverse IL-1ra Reverse complement of #604-
#619
5-CAC CAG ACT TGA CAC AGG
ACA G-3
pRSET5a fwd2 IL-1ra #492-#512 5-CAA CCA ACT AGT TGC TGG
ATA CTT GCA 3
pRSET5a fwd3 IL-1ra #594-#609 5-TGG AGG GAA GAT GTG CCT
GTC C-3
pRSET5A rev Reverse complement of #622-
#637
5-GCT GGA GTC TGG TCT CAT
CAC C-3
* numbers refer to original sequence published by Eisenberg+ 1990.
** numbers refer to placement within XaIII+IL-1ra construct, with 1 as the start of the
XaIII backbone sequence.
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Figure A.2: HindIII and KpnI digest of potential IL-1ra clones
A.1.2 Theoretical Plasmid Map Sequence
DNA sequence: #1 (Beginning of the PinPoint XaIII vector):
5’-ATGAAACTGA AGGTAACAGT CAACGGCACT GCGTATGACG TTGACGTTGA
CGTCGACAAG TCACACGAAA ACCCGATGGG CACCATCCTG TTCGGCGGCG
GCACCGGCGG CGCGCCGGCA CCGGCAGCAG GTGGCGCAGG CGCCGGTAAG
GCCGGAGAGG GCGAGATTCC CGCTCCGCTG GCCGGCACCG TCTCCAAGAT
CTCGTGAAG GAGGGTGACA CGGTCAAGGC TGGTCAGACC GTGCTCGTTC
TCGAGGCCAT G [biotinylated lysine codon][AAG*]ATGGAG ACCGAGATCA
ACGCTCCCAC CGACGGCAAG GTCGAGAAGG TCCTGGTCAA GGAGCGTGAC
GCGGTGCAGG GCGGTCAGGG TCTCATCAAG ATCGGGGATC TCGAGCTCAT
CGAAGGTCGC GAA [start][IL-1ra insert][HindIII][AAG CTT] ACC ATG
GGA CCC TCT GGG AGA AAA TCC AGC AAG ATG CAA GCC TTC AGA
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ATC TGG GAT GTT AAC CAG AAG ACC TTC TAT CTG AGG AAC AAC
CAA CTA GTT GCT GGA TAC TTG CAA GGA CCA AAT GTC AAT TTA
GAA GAA AAG ATA GAT GTG GTA CCC ATT GAG CCT CAT GCT CTG
TTC TTG GGA ATC CAT GGA GGG AAG ATG TGc CTG TCC TGT GTC
AAG TCT GGT GAT GAG ACC AGA CTC CAG CTG GAG GCA GTT AAC
ATC ACT GAC CTG AGC GAG AAC AGA AAG CAG GAC AAG CGC TTC
GCC TTC ATC CGC TCA GAC AGT GGC CCC ACC ACC AGT TTT GAG
TCT GCC GCC TGC CCC GGT TGG TTC CTC TGC ACA GCG ATG GAA
GCT GAC CAG CCC GTC AGC CTC ACC AAT ATC CCT GAC GAA GGC
GTC ATG GTC ACC AAA TTC TAC TTC CAG GAG GAC GAG TAG TAG
GGA TAA [HindIII][AAG CTT] CAGCTGGGATC CGGTACCGAT ATCAGATCTC
CCGGGGCGGC CGCGATCTGG TTCTATAGTG TCACCTAAAT CGTATGTGTA
TGATACATAA GGTTATGTAT TAATTGTAGC CGCGTTCTAA CGACAATATG
TCCATATGGT GCACTCTCAG TACAATCTGC TCTGATGCCG CATAGTTAAG
CCAGCCCCGA CACCCGCCAA CACCCGCTGA CGCGCCCTGA CGGGCTTGTC
TGCTCCCGGC ATCCGCTTAC AGACAAGCTG TGACCGTCTC CGGGAGCTGC
ATGTGTCAGA GGTTTTCACC GTCATCACCG AAACGCGCGA GACGAAAGGG
CCTCGTGATA CGCCTATTTT TATAGGTTAA TGTCATGATA ATAATGGTTT
CTTAGACGTC AGGTGGCACT TTTCGGGGAA ATGTGCGCGG AACCCCTATT
TGTTTATTTT TCTAAATACA TTCAAATATG TATCCGCTCA TGAGACAATA
ACCCTGATAA ATGCTTCAAT AATATTGAAA AAGGAAGAGT ATGAGTATTC
AACATTTCCG TGTCGCCCTT ATTCCCTTTT TTGCGGCATT TTGCCTTCCT
GTTTTTGCTC ACCCAGAAAC GCTGGTGAAA GTAAAAGATG CTGAAGATCA
GTTGGGTGCA CGAGTGGGTT ACATCGAACT GGATCTCAAC AGCGGTAAGA
TCCTTGAGAG TTTTCGCCCC GAAGAACGTT TTCCAATGAT GAGCACTTTT
AAAGTTCTGC TATGTGGCGC GGTATTATCC CGTATTGACG CCGGGCAAGA
GCAACTCGGT CGCCGCATAC ACTATTCTCA GAATGACTTG GTTGAGTACT
CACCAGTCAC AGAAAAGCAT CTTACGGATG GCATGACAGT AAGAGAATTA
TGCAGTGCTG CCATAACCAT GAGTGATAAC ACTGCGGCCA ACTTACTTCT
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GACAACGATC GGAGGACCGA AGGAGCTAAC CGCTTTTTTG CACAACATGG
GGGATCATGT AACTCGCCTT GATCGTTGGG AACCGGAGCT GAATGAAGCC
ATACCAAACG ACGAGCGTGA CACCACGATG CCTGTAGCAA TGGCAACAAC
GTTGCGCAAA CTATTAACTG GCGAACTACT TACTCTAGCT TCCCGGCAAC
AATTAATAGA CTGGATGGAG GCGGATAAAG TTGCAGGACC ACTTCTGCGC
TCGGCCCTTC CGGCTGGCTG GTTTATTGCT GATAAATCTG GAGCCGGTGA
GCGTGGGTCT CGCGGTATCA TTGCAGCACT GGGGCCAGAT GGTAAGCCCT
CCCGTATCGT AGTTATCTAC ACGACGGGGA GTCAGGCAAC TATGGATGAA
CGAAATAGAC AGATCGCTGA GATAGGTGCC TCACTGATTA AGCATTGGTA
ACTGTCAGAC CAAGTTTACT CATATATACT TTAGATTGAT TTAAAACTTC
ATTTTTAATT TAAAAGGATC TAGGTGAAGA TCCTTTTTGA TAATCTCATG
ACCAAAATCC CTTAACGTGA GTTTTCGTTC CACTGAGCGT CAGACCCCGT
AGAAAAGATC AAAGGATCTT CTTGAGATCC TTTTTTTCTG CGCGTAATCT
GCTGCTTGCA AACAAAAAAA CCACCGCTAC CAGCGGTGGT TTGTTTGCCG
GATCAAGAGC TACCAACTCT TTTTCCGAAG GTAACTGGCT TCAGCAGAGC
GCAGATACCA AATACTGTTC TTCTAGTGTA GCCGTAGTTA GGCCACCACT
TCAAGAACTC TGTAGCACCG CCTACATACC TCGCTCTGCT AATCCTGTTA
CCAGTGGCTG CTGCCAGTGG CGATAAGTCG TGTCTTACCG GGTTGGACTC
AAGACGATAG TTACCGGATA AGGCGCAGCG GTCGGGCTGA ACGGGGGGTT
CGTGCACACA GCCCAGCTTG GAGCGAACGA CCTACACCGA ACTGAGATAC
CTACAGCGTG AGCTATGAGA AAGCGCCACG CTTCCCGAAG GGAGAAAGGC
GGACAGGTAT CCGGTAAGCG GCAGGGTCGG AACAGGAGAG CGCACGAGGG
AGCTTCCAGG GGGAAACGCC TGGTATCTTT ATAGTCCTGT CGGGTTTCGC
CACCTCTGAC TTGAGCGTCG ATTTTTGTGA TGCTCGTCAG GGGGGCGGAG
CCTATGGAAA AACGCCAGCA ACGCGGCCTT TTTACGGTTC CTGGCCTTTT
GCTGGCCTTT TGCTCACATG TTCTTTCCTG CGTTATCCCC TGATTCTGTG
GATAACCGTA TTACCGCCTT TGAGTGAGCT GATACCGCTC GCCGCAGCCG
AACGACCGAG CGCAGCGAGT CAGTGAGCGA GGAAGCGGAA GAGCGCCCAA
TACGCAAACC GCCTCTCCCC GCGCGTTGGC CGATTCATTA ATGCAGGTTA
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ACCTGGCTTA TCGAAATTAA TACGACTCAC TATAGGGAGA CCGGCCTCGA
GCAGCAAGGA GATGGCGCCC AACAGTCCCC CGGCCACGGG GCCTGCCACC
ATACCCACGC CGAAACAAGC GCTCATGAGC CCGAAGTGGC GAGCCCGATC
TTCCCCATCG GTGATGTCGG CGATATAGGC GCCAGCAACC GCACCTGTGG
CGCCGGTGAT GCCGGCCACG ATGCGTCCGG CGTAGAGGAT CGATCCGGGC
TTATCGACTG CACGGTGCAC CAATGCTTCT GGCGTCAGGC AGCCATCGGA
AGCTGTGGTA TGGCTGTGCA GGTCGTAAAT CACTGCATAA TTCGTGTCGC
TCAAGGCGCA CTCCCGTTCT GGATAATGTT TTTTGCGCCG ACATCATAAC
GGTTCTGGCA AATATTCTGA AATGAGCTGT TGACAATTAA TCATCGGCTC
GTATAATGTG TGGAATTGTG AGCGGATAAC AATTTCACAC AGGAAACAGA
ATTCCCAGCT TGGCTGCAGA ACCATTCCAT TCGTTGATCC GGGAGTAACT
CAC - 3’
Amino acid sequence of the whole protein: (Extinction Coeff: 16,980 cm−1 M−1) (MW:












5’ - ATGAAACTGA AGGTAACAGT CAACGGCACT GCGTATGACG TTGACGTTGA
CGTCGACAAG TCACACGAAA ACCCGATGGG CACCATCCTG TTCGGCGGCG
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GCACCGGCGG CGCGCCGGCA CCGGCAGCAG GTGGCGCAGG CGCCGGTAAG
GCCGGAGAGG GCGAGATTCC CGCTCCGCTG GCCGGCACCG TCTCCAAGAT
CTCGTGAAGTCGAGGCCATG[AAG*]ATGGAGACCGAGATCAACGCTCCCAC CGACG-
GCAAG
GTCGAGAAGG TCCTGGTCAA GGAGCGTGAC GCGGTGCAGG GCGGTCAGGG
TCTCATCAAGATCGGGGATC TCGAGCTCAT CGAAGGTCGCGAAAAGCTT ACC
ATG GGA CCC TCT GGG AGA AAA TCC AGC AAG ATG CAA GCC TTC AGA ATC
TGG GAT GTT AAC CAG AAG ACC TTC TAT CTG AGG AAC AAC CAA CTA GTT
GCT GGA TAC TTG CAA GGA CCA AAT GTC AAT TTA GAA GAA AAG ATA GAT
GTG GTA CCC ATT GAG CCT CAT GCT CTG TTC TTG GGA ATC CAT GGA GGG
AAG ATG TGc CTG TCC TGT GTC AAG TCT GGT GAT GAG ACC AGA CTC CAG
CTG GAG GCA GTT AAC ATC ACT GAC CTG AGC GAG AAC AGA AAG CAG GAC
AAG CGC TTC GCC TTC ATC CGC TCA GAC AGT GGC CCC ACC ACC AGT TTT
GAG TCT GCC GCC TGC CCC GGT TGG TTC CTC TGC ACA GCG ATG GAA GCT
GAC CAG CCC GTC AGC CTC ACC AAT ATC CCT GAC GAA GGC GTC ATG GTC
ACC AAA TTC TAC TTC CAG GAG GAC GAG TAG TAG GGA TAA AAG CTT
CAGCTGGGATC CGGTACCGAT ATCAGATCTC CCGGGGCGGC CGCGATCTGG
TTCTATAGTG TCACCTAAAT CGTATGTGTA TGATACATAA GGTTATGTAT
TAATTGTAGC CGCGTTCTAA CGACAATATG TCCATATGGT GCACTCTCAG
TACAATCTGC TCTGATGCCG CATAGTTAAG CCAGCCCCGA CACCCGCCAA
CACCCGCTGA CGCGCCCTGA CGGGCTTGTC TGCTCCCGGC ATCCGCTTAC
AGACAAGCTG TGACCGTCTC CGGGAGCTGC ATGTGTCAGA GGTTTTCACC
GTCATCACCG AAACGCGCGA GACGAAAGGG CCTCGTGATA CGCCTATTTT
TATAGGTTAA TGTCATGATA ATAATGGTTT CTTAGACGTC AGGTGGCACT
TTTCGGGGAA ATGTGCGCGG AACCCCTATT TGTTTATTTT TCTAAATACA
TTCAAATATG TATCCGCTCA TGAGACAATA ACCCTGATAA ATGCTTCAAT
AATATTGAAA AAGGAAGAGT ATGAGTATTC AACATTTCCG TGTCGCCCTT
ATTCCCTTTT TTGCGGCATT TTGCCTTCCT GTTTTTGCTC ACCCAGAAAC
GCTGGTGAAA GTAAAAGATG CTGAAGATCA GTTGGGTGCA CGAGTGGGTT
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ACATCGAACT GGATCTCAAC AGCGGTAAGA TCCTTGAGAG TTTTCGCCCC
GAAGAACGTT TTCCAATGAT GAGCACTTTT AAAGTTCTGC TATGTGGCGC
GGTATTATCC CGTATTGACG CCGGGCAAGA GCAACTCGGT CGCCGCATAC
ACTATTCTCA GAATGACTTG GTTGAGTACT CACCAGTCAC AGAAAAGCAT
CTTACGGATG GCATGACAGT AAGAGAATTA TGCAGTGCTG CCATAACCAT
GAGTGATAAC ACTGCGGCCA ACTTACTTCT GACAACGATC GGAGGACCGA
AGGAGCTAAC CGCTTTTTTG CACAACATGG GGGATCATGT AACTCGCCTT
GATCGTTGGG AACCGGAGCT GAATGAAGCC ATACCAAACG ACGAGCGTGA
CACCACGATG CCTGTAGCAA TGGCAACAAC GTTGCGCAAA CTATTAACTG
GCGAACTACT TACTCTAGCT TCCCGGCAAC AATTAATAGA CTGGATGGAG
GCGGATAAAG TTGCAGGACC ACTTCTGCGC TCGGCCCTTC CGGCTGGCTG
GTTTATTGCT GATAAATCTG GAGCCGGTGA GCGTGGGTCT CGCGGTATCA
TTGCAGCACT GGGGCCAGAT GGTAAGCCCT CCCGTATCGT AGTTATCTAC
ACGACGGGGA GTCAGGCAAC TATGGATGAA CGAAATAGAC AGATCGCTGA
GATAGGTGCC TCACTGATTA AGCATTGGTA ACTGTCAGAC CAAGTTTACT
CATATATACT TTAGATTGAT TTAAAACTTC ATTTTTAATT TAAAAGGATC
TAGGTGAAGA TCCTTTTTGA TAATCTCATG ACCAAAATCC CTTAACGTGA
GTTTTCGTTC CACTGAGCGT CAGACCCCGT AGAAAAGATC AAAGGATCTT
CTTGAGATCC TTTTTTTCTG CGCGTAATCT GCTGCTTGCA AACAAAAAAA
CCACCGCTAC CAGCGGTGGT TTGTTTGCCG GATCAAGAGC TACCAACTCT
TTTTCCGAAG GTAACTGGCT TCAGCAGAGC GCAGATACCA AATACTGTTC
TTCTAGTGTA GCCGTAGTTA GGCCACCACT TCAAGAACTC TGTAGCACCG
CCTACATACC TCGCTCTGCT AATCCTGTTA CCAGTGGCTG CTGCCAGTGG
CGATAAGTCG TGTCTTACCG GGTTGGACTC AAGACGATAG TTACCGGATA
AGGCGCAGCG GTCGGGCTGA ACGGGGGGTT CGTGCACACA GCCCAGCTTG
GAGCGAACGA CCTACACCGA ACTGAGATAC CTACAGCGTG AGCTATGAGA
AAGCGCCACG CTTCCCGAAG GGAGAAAGGC GGACAGGTAT CCGGTAAGCG
GCAGGGTCGG AACAGGAGAG CGCACGAGGG AGCTTCCAGG GGGAAACGCC
TGGTATCTTT ATAGTCCTGT CGGGTTTCGC CACCTCTGAC TTGAGCGTCG
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ATTTTTGTGA TGCTCGTCAG GGGGGCGGAG CCTATGGAAA AACGCCAGCA
ACGCGGCCTT TTTACGGTTC CTGGCCTTTT GCTGGCCTTT TGCTCACATG
TTCTTTCCTG CGTTATCCCC TGATTCTGTG GATAACCGTA TTACCGCCTT
TGAGTGAGCT GATACCGCTC GCCGCAGCCG AACGACCGAG CGCAGCGAG
TCAGTGAGCGA GGAAGCGGAA GAGCGCCCAA TACGCAAACC GCCTCTCCCC
GCGCGTTGGC CGATTCATTA ATGCAGGTTA ACCTGGCTTA TCGAAATTAA
TACGACTCAC TATAGGGAGA CCGGCCTCGA GCAGCAAGGA GATGGCGCCC
AACAGTCCCC CGGCCACGGG GCCTGCCACC ATACCCACGC CGAAACAAGC
GCTCATGAGC CCGAAGTGGC GAGCCCGATC TTCCCCATCG GTGATGTCGG
CGATATAGGC GCCAGCAACC GCACCTGTGG CGCCGGTGAT GCCGGCCACG
ATGCGTCCGG CGTAGAGGAT CGATCCGGGC TTATCGACTG CACGGTGCAC
CAATGCTTCT GGCGTCAGGC AGCCATCGGA AGCTGTGGTA TGGCTGTGCA
GGTCGTAAAT CACTGCATAA TTCGTGTCGC TCAAGGCGCA CTCCCGTTCT
GGATAATGTT TTTTGCGCCG ACATCATAAC GGTTCTGGCA AATATTCTGA
AATGAGCTGT TGACAATTAA TCATCGGCTC GTATAATGTG TGGAATTGTG
AGCGGATAAC AATTTCACAC AGGAAACAGA ATTCCCAGCT TGGCTGCAGA
ACCATTCCAT TCGTTGATCC GGGAGTAACT CAC - 3’
A.1.4 Recombinant IL-1ra protein expression
IL-1ra+JM109 E. coli were grown at 37◦C and 225 rpm in 500 mL LB broth containing
1 mg biotin (#29129, Thermo Scientific, Rockford, IL) and Ampicillin. The bacteria were
considered to be in log growth phase at an OD between 0.03 and 0.05 (1 mm path length,
using Nanodrop Cell Cultures setting) and were induced with 50 µL of 1 M IPTG. The
cultures then shook overnight at 37◦C/225 rpm. The cultures were spun down at 10,000
rpm/4◦C for 20 min, and the bacterial pellets were frozen for later use.
The bacterial pellets were thawed in cell lysis buffer (10 mL/1 g bacteria; 50 mM Tris-
HCl, pH 7.4, 50 mM NaCl, 5% Glycerol in water) at 4◦C while stirring. 1 mL protease
inhibitor cocktail (#P8465, Sigma-Aldrich, St. Louis, MO) was added per 4 g bacteria.
When the pellet was fully thawed, lysozyme was added to a final concentration of 1 mg/mL
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and was stirred for 20 min. Sodium deoxycholate (DOC) was added to the cell lysate at a
final concentration of 1 mg/mL and the mixture was stirred for 5 min. 2000 U DNAseI per
gram bacteria was added and the lysate was stirred for 30 min at 4◦C. The bacterial lysate
was centrifuged for 30 min at 10,000 rpm/4◦C. The supernatant was then filtered through
a 0.45 µm sterile filter, and sodium azide was added at a final concentration of 0.01%. The
lysate was stored at 4◦C overnight for purification the next day.
Avidin resin (#53146, UltraLink Immobilized Monomeric Avidin Resin, Pierce, Rock-
ford, IL) was packed in a column to purify the biotinylated IL-1ra protein. The pump
system (BioRad Econo Gradient Pump, BioRad, Hercules, CA) was prepared by running
PBS through for 5 min at 2 mL/min. The column was then attached to the system and
more PBS was run through for 10 min at 1.5 mL/min. Elution buffer (50 mg d-biotin
(#29129, Thermo Scientific, Rockford, IL) in 100 mL PBS) was run through the column at
1.5 mL/min for 10 min. Regeneration buffer (750 mg glycine in 100 mL dI H2O, pH 2.8)
was run through the column for 15 min at 1.5 mL/min. PBS was run through at 2 mL/min
for 10 min. Bacterial lysate was applied to the column at 0.5 mL/min for 2 h. PBS wash
for 30 min at 2.5 mL/min. Elution buffer applied at 1.2 mL/min for 18 min (equivalent
of 9 fractions of 2 min) and eluate was collected. Regeneration buffer was run through the
column for 10 min at 1.5 mL/min. PBS+0.01% azide was run through the column for 15
min at 2 mL/min. The column was wrapped on both ends with parafilm and stored at
4◦C until further use. For multiple runs in the same day, after the regeneration buffer step,
PBS was run through the column for 15 min at 2 mL/min, and protein solution was then
applied to the column again.
To remove the excess biotin, the protein eluate was centrifuged in filter conicals (10
kDa MWCO) (Amicon Ultra-15, Millipore, Billerica, MA) at 3,750 x rpm for 20 min. Cold
PBS was added to the filtrate and the conicals were spun again. This was repeated twice.
The filtrate was removed and run through an endotoxin removal column (EndoTrap Red,
Hyglos, Regensburg, Germany) and the eluate was then nanodropped and stored at -80◦C
until use.
Alternatively, streptavidin resin (#53117, UltraLink Immobilized Streptavidin Plus,
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Pierce, Rockford, IL) was packed into the column and used in the following manner: The
pump system was prepared by running PBS-/- through for 10 min at 2 mL/min. The
column was then attached to the system and flushed for another 10 min at 2 mL/min. Bac-
terial lysate was then applied to the column at 0.5 mL/min. The column was then rinsed
for 30 min with 0.01% Triton-X-100 in PBS at 2.5 mL/min, followed by 30 min of PBS
alone at 2.5 mL/min. The attached protein was then eluted using 8 M Guanadine-HCl, pH
1.5 and the eluate was immediately put into a dialysis cassette and immersed in fresh PBS
to dialyze the denaturing guanidine out of the solution. Buffer was changed 3 times over
18 h of dialysis (1 h, 2 h, 12 h).
The protein was analyzed by Western blot and Coomassie gel (Fig. A.3).
Figure A.3: Western Blot and Coomassie Stain for recombinantly produced IL-1ra
We verified that the biotin tag could be cleaved without affecting the protein by digesting
it with factor Xa. The digestion produced the expected size of protein bands without
showing signs of further protein cleavage (Figure A.4).
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Figure A.4: IL-1ra maintains its expected weight after Xa-mediated cleavage of the biotin
tag
The biotinylated IL-1ra was assessed for bioactivity by SPR. A gold-coated coverslip was
incubated overnight in hexadecanethiol to set up a hydrophobic self-assembled monolayer.
The coverslip was rinsed in 100% ethanol and was equilibrated in PBS before using in the
SPR. The SPR run was injected as follows:
1. Protein A (50 µg/mL) at 5 µL/min
2. IL-1RI-Fc (5 µg/mL) at 5 µL/min
3. Lysozyme (25 µg/mL) at 20 µL/min
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4. IL-1ra (25 µg/mL) at 20 µL/min
Figure A.5: SPR analysis of bioactivity of recombinant IL-1ra
A.1.5 Endotoxin Removal
The following endotoxin removal protocols were used in attempts to reduce endotoxin con-
tamination of our recombinant IL-1ra:
1. Running protein solution through EndoTrap Red columns (Hyglos)
2. On-column washes with 0.1% Triton-X-100 (50 column volumes, about 250 mL)
followed by overnight dialysis against 25 mM Tris-HCl/150 mM NaCl, pH 7.8, followed by
Endotoxin Removal Solution (1:10) (Sigma).
3. Denaturation and refolding of protein (8 M guanidine HCl, pH 2.8 or 8 M guanidine
HCl, pH 1.5)
4. Washing the protein purification column with Triton-X-114 followed by running the
eluted protein throug Endotrap Red columns (p. 62 of Book #4)
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5. Running protein solution through Endotoxin Removal columns (Pierce) (p. 87, book
#4)
A.2 Results
All endotoxin removal protocols were unsuccessful at reducing endotoxin levels in our re-
combinant protein without detrimentally affecting the protein itself (Fig. A.#). The only
protocol that was able to significantly reduce endotoxin was elution by 8 M guanidine HCl,
pH 1.5; however, this elution also denatured the protein irreversibly, thereby eliminating its
detection by antibody probing (Fig. A.#). Even using 8 M guanidine HCl at a higher pH
(2.8) was unable to significantly affect the levels of endotoxin bound to IL-1ra. The Pierce
Endotoxin Removal columns removed both the protein and the endotoxin simultaneously
(Fig. A.#).
A.3 Discussion and Conclusions
We successfully cloned the IL-1ra cDNA into a biotinylation vector for expression in E.
coli. We sequenced the new construct and verified its accuracy with the predicted sequence.
Biotinylated IL-1ra maintained its ability to bind to the IL-1R, as shown by SPR analysis
(Fig. A.5). However, we were unable to reduce endotoxin contamination to acceptable
levels, preventing us from using this protein in further studies. Endotoxin contamination
activates pattern recognition receptors, called TLRs, on inflammatory cells and results
in upregulation of inflammatory signaling cascades, which would be counterproductive to
our goal of reducing inflammatory signaling in immune cells. The biotinylation tag itself
may be causing the endotoxin “stickiness” because of the size of the tag sequence itself
(approximately 13 kDa). The biotin tag was initially added to aid in efficienct purification
of the protein. Alternative approaches include adding IL-1ra into a His-6 construct or
using the original untagged protein and purifying it by affinity purification. These methods
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ABSTRACT: Inflammatory responses to implanted biomedical devices elicit a foreign
body fibrotic reaction that limits device integration and performance in various biomedical
applications. We examined chronic inflammatory responses to microgel conformal coatings
consisting of thin films of poly(N-isopropylacrylamide) hydrogel microparticles cross-linked
with poly(ethylene glycol) diacrylate deposited on poly(ethylene terephthalate) (PET). Un-
modified and microgel-coated PET disks were implanted subcutaneously in rats for 4 weeks
and explants were analyzed by histology and immunohistochemistry. Microgel coatings
reduced chronic inflammation and resulted in a more mature/organized fibrous capsule.
Microgel-coated samples exhibited 22% thinner fibrous capsules that contained 40% fewer
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cells compared to unmodified PET disks. Furthermore, microgel-coated samples contained
significantly higher levels of macrophages (40%) than unmodified PET controls. These
results demonstrate that microgel coatings reduce chronic inflammation to implanted bio-
materials.
Keywords: foreign body response, macrophage, hydrogel, polyethylene terephthalate,
fibrous capsule
INTRODUCTION: Biomaterials and implantable devices elicit a host foreign body re-
sponse that often impairs wound healing and tissue remodeling.1 Implantation of these syn-
thetic materials triggers dynamic, multi-component responses involving protein adsorption,
leukocyte recruitment, adhesion and activation, cytokine expression/release, macrophage
fusion into multi-nucleated foreign body giant cells (FBGCs), tissue remodeling and fi-
brous encapsulation of the implant.2 These inflammatory responses significantly interfere
with the biological performance of these devices, often resulting in inadequate performance
and failures that may require secondary interventions. Examples of chronic inflamma-
tory responses to biomedical devices include thrombogenic responses on vascular grafts,3,4
degradation and stress cracking of pacemaker leads,5,6 tissue fibrosis surrounding mam-
mary prostheses,7 reactive gliosis around neural probes,8 degradation in glucose biosensor
function,9 and generation of wear debris around orthopedic joint prostheses.10
Fibrous capsule formation around the implant and the presence of macrophages and
FBGCs at the tissue-material interface are the hallmarks of a chronic inflammatory re-
sponse. The αMβ2 integrin and macrophage mannose receptor have been identified as
critical components for FBGC formation.11 Although the molecular mechanisms leading to
macrophage fusion have not been fully elucidated, soluble molecules, signal transducers,
and numerous receptors are likely involved.2 FBGCs have been implicated in biodegrada-
tion of polymeric implants through surface oxidation and enzymatic degradation.12,13 Multi-
nucleated giant cells have been observed in chronically inflamed tissues induced by a foreign
stimulus, yet the physiological significance and precise role of FBGCs at the tissue-material
interface remains poorly understood. The cell-cell interactions of the foreign body response
are quite complex, and the overall biological response to implanted materials is likely a
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composite of macrophages, fibroblasts, lymphocytes, and FBGCs. Further elucidation of
the molecular events governing inflammation will aid in the development of implantable
materials with more appropriate host responses.
Significant research efforts have focused on modifying material properties to generate im-
plants that appropriately integrate with the host tissue while eliciting minimal undesirable
effects. A common approach to reduce inflammatory responses is the use of non-fouling (pro-
tein adsorption-resistant) polymeric coatings, which have been developed in various forms
including polymer brushes and thin or bulk hydrogels. Although many of these methods
have been effective when tested in vitro, these coatings usually exhibit high levels of ad-
herent leukocytes, persistent inflammation, and fibrous encapsulation of the implant.14−16
Long-term tissue fibrosis is particularly limiting for interactive implants such as biosensors,
biomedical leads and electrodes, encapsulated cells, and drug delivery systems, because it
impedes analyte transport and exchange of nutrients and cellular byproducts with the sur-
rounding medium.9,17−21 By controlling capsule thickness, implant coatings may have the
ability to maintain an open exchange of key biomolecules and extend the in vivo lifetime of
these constructs.
We recently engineered a hydrogel-based coating composed of pNIPAm-co-AA micro-
gel particles cross-linked with PEG diacrylate tethered onto a poly(ethylene terephthalate)
(PET) substrate.22 PET was chosen as the base material because this polymer is used in
many biomedical devices including sutures, vascular grafts, sewing cuffs for heart valves,
and components for percutaneous access devices. PET elicits acute and chronic inflamma-
tory responses, characterized by leukocyte adhesion and fibrous encapsulation.23,24 We have
shown that these microgel coatings modulate events associated with acute inflammation (i.e.
protein adsorption and cell adhesion) and significantly reduce leukocyte recruitment and
cytokine expression in vivo at early time points.22 In the present study, we evaluated chronic
host responses to these microgel coatings. We demonstrate that these conformal microgel




Thin sheets of poly(ethylene terephthalate) (AIN Plastics/ThyssenKrupp Materials NA,
Madison Heights, MI) were cut into disks (8 mm diameter) using a sterile biopsy punch
(Miltex Inc., York, PA) and extensively rinsed in 70% ethanol to remove contaminants
introduced during the manufacturing process. Microgel particles were synthesized with 10
mol% acrylic acid as a co-monomer to incorporate functional groups for future modification.
pNIPAm-co-AA microgel particles (100 mM total monomer concentration) were synthesized
with 2 mol% PEG diacrylate (M.W. 575) by a free radical precipitation polymerization
method.25 Particle composition and size (hydrodynamic radius 334± 30 nm) were confirmed
by NMR and dynamic light scattering, respectively. Microgel particles were deposited on
both sides of PET disks using a spin coating and photo-crosslinking process as previously
described.22,25 AFM and XPS analyses demonstrated uniform conformal microgel coatings,
in excellent agreement with previous analyses.22,25 Unmodified PET disks were used as
controls.
After surface functionalization, all samples were rinsed in 70% ethanol on a rocker plate
for 4 days, changing the solution daily to remove endotoxin contaminants, and were stored
in 70% ethanol until use. Samples contained 10-fold lower levels of endotoxin than the
United States Food and Drug Administrations recommended 0.5 EU/mL, as determined by
the LAL chromogenic assay (Cambrex, East Rutherford, NJ). Prior to use, samples were
rinsed three times in sterile phosphate buffered saline (PBS) and allowed to rehydrate in
PBS for at least 1 hour.
Subcutaneous implantation
NIH guidelines for the care and use of laboratory animals (NIH publication #85-23 Rev.
1985) have been observed. Samples (unmodified PET, microgel-coated PET; n = 8 sam-
ples/group) were implanted subcutaneously following IACUC-approved procedures to eval-
uate the chronic phase foreign body response. Male 5 to 6 wk old Wistar rats (Charles
River Laboratories, Wilmington, MA) were anesthetized by isofluorane. A single 1-cm in-
cision was made on the dorsum proximal to the spine, and a subcutaneous pocket laterally
spanning the dorsum was created. Sterile samples (two per subject, one on either side of
the spine) were implanted, and the incision was closed using sterile wound clips. After four
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weeks, rats were sacrificed using a CO2 chamber and samples were explanted, rinsed in
sterile PBS, and fixed in formalin. Samples were carefully explanted with the surrounding
tissue intact to avoid disrupting the cell-material interface. Explants were bisected in order
to avoid edge effects and to standardize the sectioning location for analysis, and they were
paraffin-embedded for histological processing.
Histological staining of explants
Histological sections (5 µm thick) were stained for various markers. A Verhoeff-van Gieson
kit (Accustain R©Elastic Stain kit from Sigma-Aldrich, St. Louis, MO) was used to stain
collagen (pink), elastin fibers (black), and nuclei (dark blue). Sixteen total fields per sam-
ple (eight fields on both the muscle and skin sides of the implant) were acquired using a
high magnification 60X Plan Apo Nikon objective (1.40 NA). ImagePro software (Media
Cybernetics, Silver Spring, MD) was used to quantify fibrous capsule thickness.
Sections were also stained using immunohistochemical methods to determine the inflam-
matory cellular profile at the cell-material interface. Following proteolytic antigen retrieval
with pronase (1 mg/mL solution for 10 min), sections were incubated in a mouse monoclonal
antibody against the CD68 antigen of macrophages (clone ED1, AbD Serotec, Raleigh, NC),
a biotinylated secondary antibody, and an avidin-linked alkaline phosphatase-based develop-
ing reagent (Vectastain R©ABC-AP Kit, Vector Labs, Burlingame, CA), and counterstained
with hematoxylin. Control sections (secondary antibody-only controls and tissue-specific
controls) confirmed specificity of the primary antibody for this marker. Sixteen total fields
per sample (eight fields on both the muscle and skin sides of the implant) were acquired using
a high magnification 60X Plan Apo Nikon objective (1.40 NA). Images were blindly scored
for total nuclei, CD68+ cells with one nucleus (macrophages), and CD68+ multi-nucleated
cells (foreign body giant cells).
Statistical analysis
Data are presented as mean ± standard error. Statistical analysis (t-tests, 95% confidence
level considered significant) was performed by ANOVA using Systat 11.0 (Systat Software
Inc., San Jose, CA).
RESULTS
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Fibrous capsule formation surrounding implants
PET disks were functionalized with p(NIPAM-co-AAc-co-PEGDA) microgel particles via a
spin coating and photo-crosslinking method to generate uniform, conformal coatings. XPS
and AFM analyses confirmed the chemical composition and the uniformity of microgel
coating, in excellent agreement with previous studies.22 Tissue responses to these materials
were evaluated using an established subcutaneous rat model to determine the extent of
chronic inflammation.1 Unmodified PET and microgel-coated PET disks were implanted
for 4 weeks. Explants were processed histologically, and sections were analyzed for fibrous
capsule development using a Verhoeff van Gieson kit to stain collagen and elastin fibers;
all nuclei were counterstained for reference (Figure 1). The capsule was defined as the
dense tissue adjacent to the implant, and image analysis of high magnification images was
used to measure capsule thickness as the perpendicular distance starting at the capsule-
implant interface and moving outward. Measurement of fibrous capsule thickness following
subcutaneous implantation is a standard measure of chronic inflammation to synthetic
materials.1
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Figure B.1: Figure 1. Microgel coatings reduce chronic inflammation associated with
materials implanted subcutaneously in the rat dorsum for 4 wk. Explants were evaluated
for fibrous encapsulation by staining collagen (pink), elastin (black), and nuclei (black).
Representative images for unmodified PET (a) and microgel-coated PET (b) disks, and
the original implant location is designated. Black arrows indicate capsule measurements.
Microgel coatings reduced fibrous capsule thickness by 22% compared to unmodified PET
controls as quantified in (c), * p <0.04. The density of capsule-associated cells was also
significantly reduced in microgel-coated samples (* p <5.6x10−3) compared to unmodified
PET controls as quantified in (d). Data is represented as the average value ± standard
error of the mean using n = 4-7 samples per treatment group. Scale bar is 50 µm.
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Unmodified PET controls exhibited a tissue reaction characteristic of chronic inflamma-
tion with a thick collagenous capsule containing high numbers of cells (Figure 1a). Microgel-
coated samples exhibited thinner and more compact capsules with more organized collagen
fibrils (Figure 1b). Image analysis demonstrated significantly thinner capsules (22%) for
microgel-coated PET compared to unmodified PET controls (p<0.04, Figure 1c). The av-
erage capsule thickness was 112.3 ± 5.1 and 87.3 ± 2.9 µm for PET controls and microgel-
coated samples, respectively.
The density of total cells present in the tissue capsules was scored using counterstained
nuclei, and sections were quantified in 100 µm increments along the implant interface (Figure
1d). Microgel-coated samples contained approximately 40% fewer capsule-associated cells
than their unmodified PET control counterparts (p<0.01). The average cell density was
51.2 ± 2.2 and 31.1 ± 1.2 cells per 100 µm length of implant for PET controls and microgel-
coated samples, respectively. These results demonstrate that microgel coatings reduce the
thickness and cell density of tissue capsules surrounding implanted biomaterials.
Inflammatory cell profile at the implant interface Explant sections were processed to
evaluate the composition of cells at the implant-tissue interface (Figure 2). Immuno-
histochemistry was used stain for the CD68 antigen, a marker of monocytes and tissue
macrophages, and all nuclei were counterstained for reference. Images were scored for total
CD68+ cells containing one nucleus (macrophages) and CD68+ cells fused to form multi-
nucleated FBGCs.
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Figure B.2: Figure 2. Inflammatory cell profiles associated with biomaterials implanted
subcutaneously in the rat dorsum for 4 wk. Explant sections were stained via immunohis-
tochemical methods for macrophage marker CD68 (pink) and counter-stained with hema-
toxylin to label nuclei (blue). Representative images for unmodified PET (a) and microgel-
coated PET (b) disks, and the original implant location is designated. Total CD68+ cells
were quantified in (c), but no statistical differences were found between treatment groups.
(d) When normalized to total capsule-associated cells (from Fig. 1d), unmodified PET con-
trols contained proportionately fewer CD68+ cells than microgel-coated PET (* p <0.02).
Multinucleated CD68+ cells (FBGCs) at the cell-implant interface were also quantified (e),
but no statistical differences were found between treatment groups. FBGCs are designated
by black arrows. Data is represented as the average value ± standard error of the mean
using n = 47 samples per treatment group. Scale bar is 50 µm.
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High magnification images of unmodified PET controls (Figure 2a) and microgel-coated
disks (Figure 2b) revealed that CD68 staining was localized to the capsule, primarily along
the capsule-implant interface. All implanted samples, regardless of coating, contained sim-
ilar levels of CD68+ cells as quantified in Figure 2c (no differences between groups). The
average number was 19.5 ± 1.8 and 20.4 ± 1.1 CD68+ cells per 100 µm of implant length
for PET controls and microgel-coated samples, respectively. CD68+ cell counts were then
normalized to total cells in the fibrous capsule (as quantified in Figure 1d) to determine
the relative numbers of macrophages in the capsule. Microgel-coated samples contained
significantly higher relative levels of macrophages than unmodified PET controls (Figure
2d, p<0.02). The average values were 37.8 ± 10.4 and 68.1 ± 5.8% CD68+ cells for PET
controls and microgel-coated samples, respectively. We note that this antibody can poten-
tially stain CD68 antigens in both adipose tissue26 and fibroblasts,27 the latter of which are
also localized in the fibrous capsule and participate in collagen deposition.
Sections were also scored for multi-nucleated FBGC, designated by black arrows (Figure
2). Few samples contained extensive development of multi-nucleated FBGC. The average
values were 4.1 ± 1.3 and 5.9 ± 0.8 FBGCs per mm of implant length for PET controls
and microgel-coated samples, respectively. Numbers of FBGC per sample ranged from
1.4-11.1 and 3.0-11.8 cells/mm implant length for PET controls and microgel-coated disks,
respectively. No statistical differences were found between groups.
DISCUSSION
We have engineered a hydrogel-based polymeric coating composed of PEG-crosslinked
pNIPAm-co-AA microparticles, which are applied to PET substrates using a spin coating
and photo-crosslinking method to generate a conformal monolayer.25 This coating strat-
egy offers many advantages over traditional surface modification methods, including precise
control over particle synthesis, the ability to generate complex architectures including mo-
saic coatings containing variations in particle composition or spatial arrangement, and de-
position onto biomedically-relevant materials. We previously demonstrated these coatings
reduce protein adsorption and cell adhesion.25,28 In addition, these microgel coatings reduce
leukocyte adhesion and activation, as well as expression of pro-inflammatory cytokines, to
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biomedical polymer implants in vivo at acute time points.22 The results of the present study
demonstrate that the microgel coatings also modulate chronic inflammatory events, such as
reductions in fibrous capsule thickness and cell density within the capsule.
Microgel coatings reduced chronic inflammation compared to uncoated PET controls
as determined by the organization and thickness of the tissue capsule. The more com-
pact and organized structure of the fibrous capsule associated with microgel-coated sam-
ples suggests that these coatings lead to faster resolution of the tissue reaction and more
mature and thinner capsules. This reduced chronic inflammation is likely related to the re-
duced monocyte/macrophage adhesion and pro-inflammatory cytokine expression observed
at acute time points.22 Furthermore, tissue associated with microgel-coated samples con-
tained less total cells but proportionately more macrophages than unmodified PET con-
trols. The reduction in total number of cells is consistent with a reduced chronic inflamma-
tory response for microgel-coated samples. The relevance of the relative increase in mono-
cytes/macrophages for the microgel-coated implants compared to the PET controls is not
clear at this point. An intriguing possibility is that microgel coatings modulate macrophage
profiles towards an “alternatively activated”/anti-inflammatory phenotype29 that results in
reduced chronic inflammation and a faster resolution of the tissue response. Further studies
are necessary to characterize macrophage phenotypes and cytokines associated with these
biomaterials. Moreover, it will be important to conduct more extensive studies in order
to determine inflammatory responses at longer, clinically-relevant implantation times as
well as the in vivo stability of these coatings. Previous efforts have focused on hydrogel
coatings that exhibit in vitro resistance to protein adsorption and leukocyte adhesion to re-
duce biomaterial-mediated related inflammation.14,15,30−35 Although these coatings reduce
biofouling in vitro, some of these materials still exhibit high levels of adherent leukocytes
and continued inflammation in vivo with significant fibrous encapsulation of the implant.
For instance, in vitro protein adsorption was significantly suppressed by photochemically
immobilized polymer coatings on silicone rubber substrates and by polyethylene oxide-like
tetraglyme coatings, yet neither treatment significantly reduced fibrous capsule thickness
when implanted subcutaneously.14,34 In contrast, other coatings, such as dihydroxypropyl
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methacrylate, PEG, and phosphorylcholine-based polymers, have shown reductions in fi-
brous encapsulation compared to the base substrates.30−33,35 The reductions in fibrous
capsule thickness elicited by these coatings are comparable to those observed in the present
study. Taken together, these studies do not reveal a clear correlation between in vitro
fouling behavior and in vivo leukocyte adhesion and tissue response. However, it is pos-
sible that differences in the surface density, composition, and structure of the non-fouling
polymer, material stability, and implantation time point, site and species complicate this
relationship. In the present study, microgel coatings reduced fibrous capsule thickness by
22% compared to unmodified control samples. Whether such a reduction in fibrous capsule
thickness translates into improved biological performance remains to be determined. Func-
tional testing in specific applications (e.g. glucose sensors, pacing leads, neural electrodes)
is required to evaluate the potential of these microgel coatings to ameliorate chronic in-
flammatory responses to implanted devices. Fibrous capsules on the order of 85 µm thick
(as in our current study) may still pose a significant barrier to certain implanted devices
or therapeutics by blocking the exchange of nutrients or impeding signal transduction to
an external medium. For example, Moussy and colleagues recently demonstrated a cor-
relation between increased collagen deposition surrounding implanted glucose sensors and
decreased sensor sensitivity; natural angiogenesis failed to overcome the barrier to glucose
diffusion caused by the associated fibrous capsule.36 The present work provides the founda-
tion for developing a microgel-based coating system incorporating various signaling agents
and bioactive therapeutics within a low-fouling background. These biotherapeutic delivery
systems offer several advantages over approaches relying on passive non-fouling behavior,
including highly controlled presentation/release of immunomodulatory agents, control over
reaction kinetics, and versatility through hybrid designs. Biomaterial-associated inflamma-
tion/fibrosis and/or implant integration could be further improved by using such complex
coatings with mechanisms to deliver immunomodulatory agents, such as IL-1ra, angiostatin,
or dexamethasone, which have improved biological responses to implanted materials.15,37−40
CONCLUSION
Using a model of chronic biomaterial-mediated inflammation, we demonstrate that surface
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coatings comprised of pNIPAm-co-PEG hydrogel microparticles reduce chronic inflamma-
tion. Microgel coatings elicited thinner and more compact capsules with more organized
collagen fibrils and fewer total cells within the capsule compared to uncoated PET. Our
current results demonstrate that microgel particles can be applied as implant coatings to
modulate inflammation and achieve more desirable chronic host responses in vivo, with the
potential to extend implant performance and lifetime.
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APPENDIX C
CENTRIFUGAL DEPOSITION OF MICROGELS FOR RAPID
ASSEMBLY OF NON-FOULING THIN FILMS
South et al. ACS Appl Mater Interfaces 2009[319].
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ABSTRACT Thin films assembled from microgel building blocks have been constructed
using a simple, high-throughput, and reproducible centrifugation (or “active”) deposition
technique. When compared to a common passive adsorption method (e.g. dip-coating),
microgels that are actively deposited onto a surface have smaller footprints and are more
closely packed. Under both active and passive deposition conditions, the microgel footprint
areas progressively decrease until a uniform monolayer film is achieved. However, under
active deposition, the microgels continue to reduce in size even after a uniform monolayer
has been assembled, forming a tightly packed, highly homogenous film. Taking advantage of
the rapid and uniform assembly of these films, we demonstrate the use of active deposition
towards the fabrication of polyelectrolyte multi-layers containing anionic microgels and a
cationic linear polymer. Microgel multi-layers successfully demonstrated effective blocking
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of the underlying substrate towards macrophage adhesion, which is a highly sought-after
property for modulating the inflammatory response to an implanted biomaterial.
KEYWORDS Hydrogel particles, centrifugation, film interfaces, layer by layer, cellular
adhesion
INTRODUCTION The construction of polymeric thin films is a subject of significant
industrial importance (e.g. for drug delivery,1 wettability control,2 corrosion3 or cellular
adhesion inhibition4) and fundamental interest. Over the past few decades, a variety of
fabrication techniques have been employed to form films from a variety of building blocks,
and their versatility has been demonstrated. Whereas extensive research has been con-
ducted in the use of linear polymers5−8 and continuous hydrogel networks9−12 as polymeric
film interfaces, recent investigations into the use of solvent-swollen polymer colloids, or
microgels, have illustrated the utility of colloidal gels as building blocks.13−18 When the
solvent is water, microgels are composed of a water-soluble polymer cross-linked into a
contiguous network, with the diameters of the particles typically ranging from 100 nm to
many microns.19−21 When stimulus-sensitive polymers are used (such as pH sensitive22 or
thermoresponsive23) to form microgels, those particles can then exhibit responsive behav-
ior by undergoing a volume phase transition as a function of that stimulus.13 Given their
growing importance in film formation, microgels have been used as building blocks in the
construction of films with potential utility in drug release,24,25 tunable microlenses,26,27 col-
loidal crystals,28−30 and non-fouling films.31−33 These interfaces have been assembled using
a variety of deposition techniques such as dip-coating,34−40 spin-coating,24,25,31−33,41,42 or
solvent-evaporation.16,29,30 In addition, different hierarchical structures have been accom-
plished by layer-by-layer assembly,24,25,34,41 binary particle mixtures,39 or phase-separation
induced deposition.16
One particularly important aspect of film formation is control over the deposited mate-
rial. For biomedical coatings, for example, the hydrophobicity, morphology, elasticity, and
chemistry of a synthetic materials surface can have a dramatic effect on cell phenotype and
behavior.43 Furthermore, complete coverage of the underlying substrate is typically desired
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in order to ensure total control of cell adhesion, spreading, and proliferation. Hydrogel-
based materials can be fabricated to possess characteristics that make them suitable as a
biomaterial because their volume consists mostly of water when in an aqueous environment
and they are highly tunable in terms of their mechanical properties and chemical composi-
tion. Additionally, in a particulate form, microgels enable further complexity by enabling
the assembly of multi-functional interfaces, due to a mixture of various types of microgels
that can simultaneously assemble on the same surface, along with additional interesting
morphologies. It is this ability to easily tune and adjust an interface that makes microgels
an appealing material for controlling and studying how proteins, cells, and tissues interact
with a synthetic interface.
In this contribution we report a film fabrication approach that employs centrifugation to
assemble a microgel film in a fast, efficient, and reproducible manner. Whereas centrifuga-
tion has been used beyond the traditional use of purification, such as in the preparation of
liposomes,44 rapid patterning of cells,45 or high-speed fabrication of photonic microfluidics,46
to our knowledge little has been explored in using centrifugation as a polymer film deposi-
tion technique. In this work we have demonstrated for the first time the use of centrifugation
to fabricate microgel-based films, and explore what effect this additional parameter or force
may have on the assembly of microgel monolayers. Our initial hypothesis was that centrifu-
gation would simply decrease the amount of time it would take to create a continuous and
uniform monolayercompared to a passive process. However, upon further investigation, it
was evident that using centrifugation (referred to herein as “active” deposition) to force soft
particles onto a hard substrate resulted in an assembly that had smaller and more closely
packed particles than what could be ultimately obtained with simple microgel adsorption
(“passive” deposition). To evaluate the generality of this phenomenon, a model system
consisting of two microgel particles of different sizes was studied. In addition, possible
mechanisms for the observed results were briefly explored in this study. Lastly, we illus-
trate the techniques ability to construct rapid multi-layered polyelectrolyte layer-by-layer
films for fabricating effective uniform non-fouling coatings to prevent macrophage adhesion.
MATERIALS AND METHODS
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Materials. All reagents were purchased from Sigma-Aldrich unless otherwise specified.
The monomer N-isopropylacrylamide (NIPAm) was recrystallized from hexanes (J.T. Baker)
and dried under vacuum prior to use. The cross-linkers N,N-methylenebis(acrylamide)
(BIS) and poly(ethylene glycol) diacrylate with average Mw = 575 (PEGDA575), co-
monomer acrylic acid (AAc), and initiator ammonium persulfate (APS) were used as re-
ceived. Buffer chemicals sodium dihydrogen phosphate monohydrate (Fisher Scientific), 2-
(N-morpholino)ethanesulfonic acid (MES), sodium chloride (Mallinckrodt), and sodium hy-
droxide were used as received. The surface modification reagent 3-aminopropyltrimethoxysilane
(APTMS, TCI America) was used as received. Covalent attachment chemicals N-hydroxysuccinimide
(NHS), N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC), and hydrox-
ylamine hydrochloride were used as received. Poly(diallyldimethylammonium chloride) high
molecular weight 400,000-500,000 (PDADMAC) was used as received. Glass disks of 12-
mm diameter were purchased from Bellco Glass. Absolute (200 proof) ethanol was used
as received from EMD Chemicals Inc. All water used throughout this investigation was
house distilled, deionized to a resistance of at least 18 Mω (Barnstead Thermolyne E-Pure
system). IC-21 murine macrophage cell line was obtained from ATCC (Manassasa, VA) and
cultured as directed. RPMI-1640 media was purchased from Gibco (Invitrogen Corporation,
Carlsbad, CA) and/or ATCC (Manassas, VA), supplemented with 10% Fetal Bovine Serum
(Invitrogen) and 1% penicillin streptomycin (Gibco) and used to culture the IC-21 cell line.
100 mm and 150 mm tissue culture polystyrene dishes (Corning Inc., Corning, NY) were
used to culture cells. PBS (with and without Calcium and Magnesium) were obtained from
Gibco. Versene (Gibco) was used to dissociate the cells from the dishes. 12-well plates from
Corning (Corning, NY) were bought via Sigma-Aldrich (St. Louis, MO) and used for the
cell culture experiments. Calcein and Ethidium homodimer were bought from Invitrogen
Corporation (Carlsbad, CA) and used at final concentrations of 4 µM to stain for live and
dead cells.
Microgel Synthesis. Microgels were synthesized using aqueous free radical precipitation
polymerization. Microgel (1) was synthesized using a total monomer concentration of 70
mM. The molar composition consisted of 85% NIPAm, 5% BIS, and 10% AAc. Surfactant
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SDS was used at a concentration of 1 mM. All of these components were dissolved in 49
mL of deionized water and filtered through Whatman #2 filter paper in a vacuum filtration
system. The aqueous solution was then transferred to a three-neck round bottom flask
and purged with N2 for approximately 1 hour while the solution was heated to 70
◦C. The
initiator APS (0.0114 g), used in a total final concentration of 1 mM, was dissolved in 1 mL
of deionized water and added to initiate the polymerization. The reaction was allowed to
proceed for 4 hours at 70◦C under a blanket of N2.
Microgel (2) was synthesized using a total monomer concentration of 100 mM, along with
molar compositions of 88% NIPAm, 2% BIS, and 10% AAc. Surfactant SDS and initiator
APS were used in concentrations of 0.17 mM and 1 mM, respectively. The remaining
conditions of the synthesis were carried out in the same fashion as described for (1).
Non-fouling microgels were synthesized using a total monomer concentration of 100 mM
with molar compositions of 88% NIPAm, 2% PEGDA575, and 10% AAc. Surfactant SDS
and initiator APS were used in concentrations of 0.17 mM and 1 mM, respectively. The
remaining conditions of the synthesis were carried out in the same fashion as described for
(1).
Microgel Characterization. Dynamic light scattering (DLS) was used as previously
described,28,47 to measure the hydrodynamic radius and diffusion coefficient of synthesized
particles. A Protein Solutions DynaPro equipped with a temperature controlled microsam-
pler was used. Light scattering data was collected at an interval of 10 seconds per reading
with a photodiode detector fixed at 90◦ relative to the incident the laser light (783.9 nm).
Dynamics Software was used to calculate the autocorrelation decay from the random fluc-
tuations in scattered light intensity. This information was then used to determine the
diffusion coefficient of the sample in solution, which correlates with the hydrodynamic ra-
dius of the particles using the Stokes-Einstein equation. Electrophoretic measurements were
performed with a Malvern Instruments Zetasizer. All measurements were conducted using
a dilute solution of microgels in pH 7.4 phosphate buffer containing 100 mM ionic strength
(PBS).
Film Preparation. The 12-mm diameter glass coverslip disks were placed in a ceramic
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glass slide holder and cleaned using a sequential solvent sonication method. A sequential
solvent sonication method proceeded with the following solvent sequence using a Bransonic
2510 Ultrasonicator (42 kHz +/- 6% output): 30 minutes in dilute soapy (Alconox) water,
15 minutes in deionized water, 15 minutes in acetone, 15 minutes in absolute ethanol, and
15 minutes in isopropyl alcohol. Afterwards, the glass was immediately equilibrated for 30
minutes in absolute ethanol and 1% by volume APTMS was added. The glass was incubated
with the APTMS-ethanol solution for 2 hours under gentle agitation. The glass was then
rinsed with a 70% aqueous ethanol solution and deionized water, and then dried under a
gentle stream of N2.
Cleaned and dried glass disks were individually placed at the bottom of 24-well plates
and PBS was immediately added. The glass was allowed to equilibrate for 30 minutes, and
the buffer was then replaced with a 0.1 mg/mL solution of microgels in pH 7.4 phosphate
buffer containing 100 mM ionic strength (PBS). For centrifuged films, the well plates were
placed immediately across a counter-weighted well plate in an Eppendorf 5804R centrifuge
equipped with a plate-holding rotor. Films were centrifugally deposited at a maximum rotor
speed of 2,250 x g for a specific amount of time. Passively adsorbed microgel films were
made by simply controlling the exposure time of the functionalized glass to the microgel
solution. After deposition, the films were rinsed with deionized water and dried under a
gentle stream of N2. All films were deposited at room temperature.
Samples prepared using non-fouling microgels were deposited using a 0.8 mg/mL micro-
gel solution in PBS. Centrifugation was carried out at 2,250 x g for 5 minutes at room tem-
perature. Afterwards, the monolayers were covalently attached to the amine-functionalized
glass by activating the acids on the particles. To accomplish this, EDC/NHS bioconjugation
chemistry was employed. A solution containing 2 mM EDC and 5 mM NHS was prepared
in 10 mM MES buffer (pH 6) and allowed to react with the non-fouling microgel film for
2 hours at room temperature. After rinsing the films with water, they were exposed to a
10 mM solution of hydroxylamine in MES buffer for 10 minutes to quench the EDC/NHS
reaction. The films were then rinsed with water to remove excess reagents.
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Multilayer formation. In the past, our group has amply demonstrated the use of micro-
gels in the fabrication of multi-layered thin films.24,25,34,41 In this study, microgel monolayer
films were constructed using active deposition in the same fashion as described above. To
add an additional layer, a 0.14 monoM (molar concentration of monomer) solution of PDAD-
MAC was added to the film and allowed to adsorb to the microgel film for 30 minutes. The
films were then washed five times with deionized water. Another layer of microgels was then
added to the well and centrifuged onto the surface, as described above. This process was
repeated until four microgel layers were deposited. The thickness of the microgel multilayer
film was determined by using a razor blade to scratch the surface of the film to expose the
underlying substrate, and AFM was used to determine the height of the film compared to
the substrate.
Atomic Force Microscopy Imaging and Analysis. Microgel films were imaged using
an Asylum Research MFP-3D Instrument (Santa Barbara, CA). Imaging was performed
and processed using the MFP-3D software under the IgorPro (WaveMetrics Inc., Lake
Oswego, OR) environment. Non-contact mode aluminum-coated silicon nitride cantilevers
were purchased from NanoWorld (force constant = 42 N/m, resonance frequency = 320
kHz). All images were taken in air under ambient conditions.
Quantitative image analysis was performed to calculate the average particle footprint
area on the glass surface. Briefly, an iterative inverse mask was created to highlight the
particles and the image was flattened to the 2nd order. A histogram was then generated
to evaluate the bimodal distribution of surface height and particle height. Three times the
standard deviation of the surface height was added to the average height of the surface
to account for variations in the surface around the particles. A new inverted mask was
generated based on this calculation, and the percentage of the image that was masked was
calculated. This percentage was divided by the number of particles (counted manually) to
give an average particle footprint area. The radial distribution function for the images was
calculated using code written in-house in the IDL v. 6.1 programming environment.
In Vitro Cellular Adhesion Studies. Microgel multi-layer films were sterilized after as-
sembly in 70% ethanol aqueous solution. Before use with cells, films were washed three times
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in sterile PBS, and then equilibrated in fresh PBS for at least 1 hour before use. A murine
peritoneal macrophage cell line, IC-21, was employed to test for adhesion to the multi-layer
films in vitro. Macrophages are one of the primary mediators of the inflammatory response,
and can fuse to form the foreign body giant cells that make up a significant portion of
the fibrous capsule around an implanted biomaterial. The use of a macrophage cell line
is standard for examining non-fouling behavior in vitro due to this cell type’s extremely
adhesive nature and role in the body’s response to a biomaterial. The IC-21 cell line is a
virally transformed murine peritoneal macrophage line that expresses many of the standard
macrophage surface proteins and maintains the phagocytic and cytolytic behaviors char-
acteristic of untransformed macrophages. IC-21 cells were cultured in RPMI-1640 media
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin streptomycin (PS). The
cultures were grown at 37◦C with 5% CO2. The cells were removed using Versene, counted
by hemacytometer, then diluted to a concentration of 200,000 cells/1.5 mL media. The
microgel films were placed in a sterile 12-well culture dish, and 1.5 mL of cells/media were
added. The films were incubated at 37◦C for 4 hours, after which the excess media/cells
were aspirated and samples were transferred to new wells and fresh media. Samples were
incubated overnight and stained the next day with 4 µM calcein and ethidium homodimer
in PBS. Samples were imaged at 20x magnification with a Nikon Eclipse E400 upright mi-
croscope (Nikon Instruments, Inc., Melville, NY). Images were taken with Spot Advanced
software (Diagnostic Instruments, Sterling Heights, MI). Eight representative images were
taken per sample, with three samples per group. Cells were counted using the public domain
NIH ImageJ program (developed at the U.S. National Institutes of Health and available on
the Internet at
http://rsb.info.nih.gov/nih-image/
). The cell count was averaged over all representative images of the same sample type, and
the error bars shown represent the standard error for the group of three samples.
RESULTS AND DISCUSSION To study assembled microgel monolayers using the active
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centrifugation deposition technique, two different anionic microgel particles composed of N-
isopropylacrylamide (NIPAm), acrylic acid (AAc), and the cross-linker N,N-methylenebis(acrylamide)
(BIS) were synthesized; these particles were used in the Coulombically-driven assembly of
microgel films onto cationic silane-modified glass substrates. The particles were character-
ized using dynamic and static light scattering, and atomic force microscopy; the results of
these characterizations are summarized in Table 1. The hydrodynamic radius of particle
(1) is roughly half the size of particle (2), due to differences in cross-linker density, total
monomer concentration in the reaction, and amount of surfactant used in the synthesis.
Accordingly, the diffusion coefficient for (1) is twice as large as (2). Additionally, (2) has
an approximately 6 times larger footprint area when passively adsorbed onto a surface, and
is slightly softer than (1), as evidenced by the higher Rs/Rh (radius on the surface/radius
in solution) ratio. However, both particles types have similar electrophoretic mobilities.
Therefore, any differences seen under centrifugal deposition will be due to differences in
sedimentation velocity, not the surface accessibility of anionic charges on the particle for
attachment to the cationic substrate.
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Figure C.1: Table 1. Microgel Characteristics. [a] Determined by dynamic light scattering
in pH 7.4 phosphate buffer containing 100 mM ionic strength (PBS) at room temperature.
[b] Determined by atomic force microscopy on 30 minute passively deposited samples. [c]
Determined by atomic force microscopy at time point of active deposition where the particle
footprint area was smallest. [d] Determined by electrophoretic light scattering in PBS at
room temperature.
Centrifugal, or active, deposition is performed by placing the substrates of interest at
the bottom of each well in a multiwell-plate (e.g. a cell culture plate), followed by the
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addition of a microgel dispersion into the well above the substrate. The plates are then
placed in a swinging bucket, well-plate rotor. When the rotor spins, the well-plates swing
out so as to align the centrifugal force (g), perpendicular to the plane of each substrate,
thereby forcing the colloidal particles onto the substrate. For all experiments described
in this study, the maximum centrifugal force of the rotor (2,250x g) was used. Because
of its utility in the deposition of films on multiple samples simultaneously, centrifugal film
deposition is fast, reproducible, and many samples can be made in parallel with a high
degree of quality control.
Microgels (1) and (2) were both subject to active film deposition, with passive deposition
being used as a comparison throughout this entire study. Atomic force microscopy has been
used previously to study passively adsorbed microgel particle monolayers.40 It is important
to point out that the microgels were dispersed and deposited in a phosphate buffered saline
solution of high ionic strength (100 mM); these conditions have previously been shown to
be appropriate for reducing anionic repulsion between microgels during film formation.39
Microgels that are actively deposited form films that are fundamentally different than those
deposited passively. As can be seen in Figure 1, when active deposition is used (Figure 1b
and 1d), the microgels appear to be smaller and more closely packed than those deposited
passively (Figure 1a and 1c). This difference in particle size is perhaps more clearly seen
when smaller scan sizes are used (Figure 1 insets). It is also worth noting that regardless
of the deposition method, the particles all have heights of only 10-15 nm in the dehydrated
state, illustrating the extremely low polymer density of the particles, as we have described
previously.39,41 The calculated radial distribution functions for these images, also shown in
Figure 1, quantitatively illustrate the differences in particle spacing and nearest neighbor
probability. Both particle (1) and particle (2) show nearest neighbor distances that are closer
under active deposition, thus confirming that these films are more tightly packed when
actively deposited as compared to passive adsorption. One might expect that microgels
would flatten under centrifugal force and therefore result in particles with larger footprint
areas and a film that has decreased particle density. However, the opposite is apparent in
these experiments, which must mean the particles have some mobility to slide along the
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substrates surface (most likely from the contribution of buffer salts reducing the Coulombic
attraction between particle and surface).
Figure C.2: Figure 1. Height traces, using atomic force microscopy, of microgels (1) (a and
b) and (2) (c and d) under passive deposition (a and c) and active centrifugal deposition (b
and d). Microgels (1) and (2) were passively deposited for 16 hours. Microgels (1) and (2)
were actively deposited for 10 min and 5 min respectively. Inset scale bars are 0.5 µm (a
and b) and 1 µm (c and d). On the right, radial distribution functions are shown for each
particle type and deposition condition, illustrating the quantitative differences in particle
spacing between active and passive deposition.
The evolution of the microgel films was monitored as a function of deposition time under
both active and passive conditions (Figure 2). The larger microgels (2) obtained uniform
coverage faster than the smaller microgels (1) when centrifuged onto a surface. This is
expected due to larger or more massive particles having a higher sedimentation velocity.
The opposite was true for the passively adsorbed microgels, as the smaller particles have
a higher diffusion coefficient and therefore reach the surface faster, assuming an equivalent
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sticking probability. In addition, the particle footprint area was monitored as a function of
time. Under both deposition conditions and for both microgel types, the microgel footprints
appeared to decrease until the film reached a uniform monolayer. However, under active
deposition, the microgels continued to shrink even after apparently forming a uniform mono-
layer. The deswelling ratio of these particles in solution is approximately 0.96 and 0.76 for
microgels (1) and (2) respectively. The ratio of particle radius on a film of active to passive
deposition is approximately 0.76 and 0.71 for microgels (1) and (2) respectively. Therefore
it appears that active deposition shrinks microgels to a greater or at least similar extent
as deswelling the microgels in solution. There are a few possible mechanisms by which
active deposition might result in smaller microgels that pack more tightly. For example,
centrifugation could cause the microgels to concentrate in the solution above the substrate,
and thus deswell due to an increase in the local osmotic pressure.48−50 Alternatively, the
use of a high ionic strength buffer (100 mM) during deposition could permit the particles
to desorb or rearrange on the surface, thereby dynamically reconfiguring the interface as
microgels continue to strike the interface at a high velocity. Finally, it may be the case that
actively deposited microgels have somewhat different adsorption/adhesion characteristics
than those of passively deposited microgels.
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Figure C.3: Figure 2. Microgel footprint area as a function of deposition time for centrifu-
gation (active) and passive deposition techniques. (a) Microgel (1) and (b) microgel (2).
*Denotes formation of a uniform monolayer without patchy particle coverage. Error bars
represent the standard error of the mean particle footprint area taken from three 10 µm x
10 µm (a) or 20 µm x 20 µm for (b) atomic force microscopy images.
Considering these possibilities, it is unlikely that microgel pre-concentration during cen-
trifugation is exclusively responsible for these observations, as small particle footprints might
be expected early in the deposition, as well. However, Figure 2 clearly shows the microgels
are initially larger and grow smaller over time during film assembly. Therefore, a dynamic
rearrangement at the interface must be occurring during the formation of the film, both
under active and passive deposition conditions, with the effect persisting even after forma-
tion of a uniform monolayer under active conditions. To further explore this phenomenon,
we used a two-step deposition method, the results of which are shown in Figure 3. In this
experiment, microgels were first adsorbed passively to obtain partial coverage, and then
without replacing microgels or removing the film from solution, samples were subjected to
active microgel deposition conditions. The results illustrate that under these conditions,
the average particle footprint area does still decrease upon active deposition, but not to the
same extent as that observed during active deposition alone. Additionally, if particles are
first passively adsorbed until a uniform monolayer is generated, additional centrifugation
does not induce a statistically meaningful change in the adsorbed microgel size. These data
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suggest that the passively adsorbed microgels do not rearrange dramatically or desorb from
the surface during further active deposition. When space is available for microgels to de-
posit (Figure 3a), it appears that lateral repulsion between microgels might result in some
decrease in microgel footprint. However, when microgels centrifuged on top of the passively
deposited particles are unable to make their way onto the substrate (Figure 3b), significant
restructuring of the interface is not observed. These results are in agreement with a previ-
ous study using similar pNIPAm-co-AAc microgels adsorbed on an amine-modified surface,
where the authors illustrated that even with increasing NaCl concentrations there was no
evidence of particle desorption from the surface.35
Considering these results, it is therefore likely that particle adsorption is fundamentally
different between the two cases. Passive adsorption likely results in a polymer chain confor-
mation that is closer to the thermodynamic minimum, whereas the active approach results
in a polymer conformation that is higher in energy (kinetically determined) and is therefore
more likely to evolve and age during centrifugation. This theory is further reiterated by
observing the impact of ionic strength of the dispersion buffer on film assembly. When
microgels are dispersed in a lower ionic strength buffer (2 mM), there is also a noticeable
difference in microgel size and spacing (see Supporting Information). Though the parti-
cles are not as small and highly packed as under high ionic strength (100 mM) conditions,
due to reduced shielding of repulsive side chains, active deposition once again results in a
smaller size and spacing of microgels on the surface compared to passive deposition. This
observation suggests that even when shielding of the anionic side chains is significantly re-
duced, centrifugation can still overcome particle-particle repulsion to a greater extent than
a dip-coating method, presumably due to the higher energy used in deposition.
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Figure C.4: Figure 3. Height traces, using atomic force microscopy characterization, of
the two-step deposition process for microgel (2). (a) A sub-monolayer, exhibiting patchy
coverage, was passively deposited first and then subjected to centrifugal deposition. (b)
A uniform monolayer was first deposited passively and then subjected to centrifugal depo-
sition. (c) Shows a uniform monolayer deposited actively for comparison. Scale bar is 1
µm. (d) Bar graph showing the average particle footprint area for all samples. Error bars
represent the standard error of the mean particle footprint area taken from three 20 µm x
20 µm AFM images.
The recent work of FitzGerald et al. (40) seems to support the hypothesis that particles
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can reorganize laterally because of interparticle repulsion. These investigators studied the
passive adsorption of pH-sensitive microgel particles using liquid AFM imaging. Their
results demonstrate the dynamic nature of such particles at the particlesurface interface.
When these particles are in their nondeformable latex form at higher pH, they observe a
significant deviation from what is expected from the random sequential adsorption model
of hard spheres, where the diameter of the particles at the interface is almost twice the size
of that in solution. Furthermore, when the pH was adjusted to more acidic conditions, thus
inducing a latex-to-swollen microgel transition, this swelling pressure caused neighboring
particles to desorb from the surface. Even though coulombic interactions exist between the
particle and substrate, the particleparticle interactions dominate in their example. These
results illustrate an extreme case of dynamic microgel adsorption where lateral particle
interactions can dictate particle coverage. Similarly, our results illustrate that polymeric
particles can undergo size changes and film rearrangement as a function of coverage, albeit
in the limit of strong microgelsurface interactions.
Multi-layered polyelectrolyte microgel interfaces, which we have demonstrated previously,24,25,34,41
were fabricated using rapid centrifugal film deposition to illustrate the utility of the tech-
nique. The progression of layers of a multi-layered microgel film is shown in Figure 4. Atop
a glass substrate that was rendered cationic by amine functionalization, anionic microgels
(microgel 2) were alternatively layered with poly(diallyldimethylammonium chloride), or
PDADMAC, as a cationic polymer. As more layers are added, up to four layers of mi-
crogels (with a resulting height of approximately 60 nm, thus illustrating the deposition
of additional layers), less of the underlying glass substrate appears to be exposed and the
resulting film is quite uniform. In light of this observation, we constructed multilayers of
non-fouling microgels to aid in preventing cellular adhesion to a surface. In the past we have
used spin-coating to fabricate a monolayer of non-fouling microgels containing the cross-
linker poly(ethylene glycol) diacrylate or PEG-DA.31−33 PEG is a polymer widely known to
resist protein and cellular adhesion due to its high degree of hydration and comformational
flexibility,4,51−53 Previously we have shown that spin-coating of non-fouling microgels onto
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a substrate provided the high coverage needed to block the background substrate from pro-
tein and cellular adhesion. However, spin coating is an intrinsically serial process that can
be quite wasteful of material. However, as shown below, centrifugation-based assembly can
be parallelized and also provides the required high coverages using a rapid multi-layering
approach in a non-wasteful manner.
Figure C.5: Figure 4. AFM images of microgel thin films constructed in a multi-layered
fashion (using microgel 2). Each image has a 20 µm x 20 µm scan size (5 µm scale bar)
with a 5 µm x 5µm (2 µm scale bar) inset. Images were obtained from 1, 2, 3, and 4 layer
films (left to right) formed by active deposition.
The results in Figure 5 demonstrate the effectiveness of actively deposited non-fouling
microgel multi-layers towards blocking macrophage adhesion. Macrophages adhere and
spread well on the positive control tissue culture polystyrene (TCPS). Glass that was ex-
tensively cleaned also shows cellular adhesion and spreading with an approximately five-fold
reduction in number of cells adhering compared to TCPS. However, four-layer microgel films,
which were generated quickly using centrifugation deposition, showed significant blockage of
macrophage adhesion with an over 200-fold and over 30-fold reduction in number of adher-
ent cells compared to TCPS and cleaned glass respectively. Furthermore, the few cells that
adhere to the surface of the microgel multi-layer films do not appear to be able to spread,
and therefore it is speculated that these cells have found small defects in the film, which
presumably could be blocked with additional layers. Optimization of the film properties in
the context of non-fouling biomaterial coatings will be the subject of later studies.
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Figure C.6: Figure 5. Fluorescence microscopy of fluorescently stained macrophages adher-
ing on (a) tissue culture polystyrene (TCPS), (b) cleaned glass, and (c) 4 actively deposited
layers of PEG cross-linked pNIPAm microgels. Scale bar represents 100 µm. (d) Quantita-
tive cellular adhesion from fluorescence microscopy images with error bars representing the
standard error.
CONCLUSION Centrifugation has been demonstrated to be a rapid and robust method
for generating colloidal films. When using soft anionic microgel particles to construct an
interface, centrifugation deposition results in particles that are smaller and more closely
packed compared to a more common dip-coating, or passive adsorption, technique. The
footprint area of centrifuged particles actively shrinks during assembly, even after they
have formed a uniform monolayer. Passively deposited microgels stop decreasing in foot-
print size once they have reached a uniform film, and when these films are subjected to
centrifugally forced microgels afterwards, the centrifugation approach does not force sig-
nificant morphological changes in the deposited particles. The impact of this phenomenon
on particle adhesion, modulus, and film stability is currently being explored in our labs.
In addition, it has been demonstrated that the centrifugal deposition approach enables a
functional multi-layered microgel interface with a high degree of uniformity and substrate
coverage. These interfaces can be used in the development of microstructured hydrogel
coatings for controlling biological and cellular adhesions, and exploited for various other
applications in which complexity, tunability, and uniformity is desired.
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APPENDIX D
APPLICATION OF IL-1RA-TETHERED PARTICLES IN AN
OSTEOARTHRITIC RAT MODEL
The technology developed in this thesis work was tested in two different experiments using
an MIA model of osteoarthritis in rats. In both experiments, rats were injected in the
right knee with MIA and were allowed to ambulate freely for 7 days prior to beginning any
treatment. The first experiment used a low dose of MIA (0.3 mg/knee) and allowed OA
to progress up to 3 weeks after MIA injection. The second experiment used a high dose of
MIA (1 mg/knee) and the rats were allowed to progress for 3 weeks.
In the low-dose experiment, we saw no significant cartilage damage in any group, in-
cluding the group that received MIA and no further treatment (Fig. D.1). We concluded
that the MIA dose was too low to allow noticeable macroscopic changes at 3 weeks. For the
following experiment, we increased the dose and kept the evaluation period the same. How-
ever, in this case, we saw severe cartilage damage in all groups, including those that received
a bolus dose of soluble IL-1ra. Although there is no published evidence that soluble IL-1ra
can attenuate OA damage in MIA models, other models of OA have shown improvements
after bolus IL-1ra injections[][]. We expected that rats that were treated with soluble IL-1ra
would show improvement in phenotype and would act as our positive controls. However,
even the bolus IL-1ra group showed severe cartilage damage (Fig. D.2). We conclude from
this set of experiments that the MIA model of OA most likely does not create a represen-
tative inflammatory environment in the joint. Other models of OA, specifically those that
are induced by mechanical changes (ACL transection, MCL transection, medial meniscal
transection) better represent the clinical, physiological changes seen during OA. Testing out
this IL-1ra particle system in these models should allow us to better assess the effectiveness
of our technology for treating OA in both acute and chronic disease models.
[Low Dose MIA Animal Experiment]
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Figure D.1: Tibial cartilage reconstructions of rats receiving 0.3 mg MIA. Left to Right:
small particles, low dose; large particles, high dose; large particles, low dose; MIA only;
saline only.
[High Dose MIA Animal Experiment]
Figure D.2: EPIC-µCT reconstructions of the tibial plateau cartilage in rats with MIA-
induced osteoarthritis (1 mg MIA/40 µL). Only right knees were injected with MIA. Left
knees were injected with an equal volume of saline and served as healthy contralateral
controls. 7 days post-MIA injection, the right knees were re-injected with IL-1ra-tethered
particles, soluble IL-1ra, or saline; left knees were again injected with equal volume of saline.
Left to right: MIA-only left knee; MIA-only right knee; IL-1ra bolus left knee; IL-1ra bolus





Figure D.3: Comparison of tibial cartilage thicknesses among groups from the low-dose
MIA study. All animals received 0.3 mg MIA in the right knee only. Left knees received
equal amounts of injected saline. No significant differences were detected among contralat-
eral knees or among MIA-treated knees, regardless of treatment group. Differences in
cartilage thickness were not statistically significant among groups except for between the
contralateral control knees and the small particle/low dose group (p = 0.0243). All other
comparisons, including between the MIA-treated knees and the contralateral controls, were
not statistically significant (p >0.05). Lg/lo = large particles, low dose; Lg/hi = large
particles, high dose; Sm/lo = small particles, low dose; Sm/hi = small particles, high dose;







Figure D.4: Comparison of cartilage thicknesses among groups from the high-dose MIA
study. All animals received 1 mg MIA in the right knee only. Left knees received equal
amounts of injected saline. No significant differences were detected among contralateral
knees or among MIA-treated knees, regardless of treatment group. Differences in cartilage
thickness were statistically significant between the contralateral controls and MIA-treated
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